PCIDB

KNApSAcK Metabolite C00002365

Metabolite

KNApSAcK Entry

id C00002365
Name Taxol / Paclitaxel / (-)-Paclitaxel
CAS RN 33069-62-4
Standard InChI InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35+,36+,37+,38-,40-,45+,46-,47+/m0/s1
Standard InChI (Main Layer) InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)

Cluster

Phytochemical cluster No. 49
KCF-S cluster No. 238

Link

ChEMBL

By standard InChI
By standard InChI Main Layer CHEMBL48 CHEMBL428647 CHEMBL418410 CHEMBL44384 CHEMBL70362 CHEMBL304291 CHEMBL317544 CHEMBL325387 CHEMBL137050 CHEMBL341418 CHEMBL352705 CHEMBL372351 CHEMBL503883 CHEMBL533732 CHEMBL601767 CHEMBL1368986 CHEMBL1394061 CHEMBL1394818 CHEMBL1429740 CHEMBL1436401

KEGG

By LinkDB C07394

CTD

By CAS RN D017239

Human Protein / Gene in interaction

156 ChEMBL Protein in interactions

accession description class description compound assay ID (# of activities) # of diseases
(OMIM / KEGG)
P10635 Cytochrome P450 2D6 Cytochrome P450 2D6 CHEMBL428647 CHEMBL1368986 CHEMBL1436401 CHEMBL1741321 (2) CHEMBL1909136 (2)
1 / 0
P42345 Serine/threonine-protein kinase mTOR Enzyme CHEMBL48 CHEMBL1613805 (1) CHEMBL1614293 (1)
0 / 0
P33527 Multidrug resistance-associated protein 1 drugs CHEMBL428647 CHEMBL2076443 (1)
0 / 0
P04637 Cellular tumor antigen p53 Transcription Factor CHEMBL428647 CHEMBL1436401 CHEMBL1613992 (1) CHEMBL1826890 (1)
7 / 44
Q16637 Survival motor neuron protein Unclassified protein CHEMBL317544 CHEMBL1613842 (1)
4 / 2
Q9Y6L6 Solute carrier organic anion transporter family member 1B1 Electrochemical transporter CHEMBL428647 CHEMBL2169429 (1)
1 / 0
O94956 Solute carrier organic anion transporter family member 2B1 Unclassified protein CHEMBL428647 CHEMBL2169431 (1)
0 / 0
Q99700 Ataxin-2 Unclassified protein CHEMBL48 CHEMBL428647 CHEMBL418410 CHEMBL304291 CHEMBL1368986 CHEMBL1429740 CHEMBL1794367 (1) CHEMBL2114784 (6)
1 / 1
P49798 Regulator of G-protein signaling 4 Unclassified protein CHEMBL317544 CHEMBL1794499 (1)
2 / 0
O95342 Bile salt export pump drug CHEMBL428647 CHEMBL2076226 (1) CHEMBL2076242 (1)
2 / 1
P21728 D(1A) dopamine receptor Dopamine receptor CHEMBL428647 CHEMBL1909139 (2)
0 / 0
P35354 Prostaglandin G/H synthase 2 Oxidoreductase CHEMBL428647 CHEMBL1909131 (2)
0 / 3
Q12809 Potassium voltage-gated channel subfamily H member 2 KCNH, Kv10-12.x (Ether-a-go-go) CHEMBL428647 CHEMBL1909190 (2)
2 / 2
P08246 Neutrophil elastase S1A CHEMBL428647 CHEMBL1909195 (2)
2 / 1
P33765 Adenosine receptor A3 Adenosine receptor CHEMBL428647 CHEMBL1909215 (2)
0 / 0
P10632 Cytochrome P450 2C8 Cytochrome P450 2C8 CHEMBL428647 CHEMBL1743268 (1)
0 / 0
Q16539 Mitogen-activated protein kinase 14 p38 CHEMBL428647 CHEMBL1909201 (2)
0 / 0
P49146 Neuropeptide Y receptor type 2 Neuropeptide Y receptor CHEMBL428647 CHEMBL1909176 (2)
0 / 0
P29466 Caspase-1 C14 CHEMBL428647 CHEMBL1909193 (2)
0 / 0
P17252 Protein kinase C alpha type Alpha CHEMBL428647 CHEMBL1909198 (2)
0 / 0
P27361 Mitogen-activated protein kinase 3 Erk CHEMBL428647 CHEMBL1909199 (2)
0 / 0
Q9H4B7 Tubulin beta-1 chain Structural CHEMBL428647 CHEMBL70362 CHEMBL372351 CHEMBL728403 (3) CHEMBL729968 (2)
CHEMBL812703 (1) CHEMBL864668 (2)
CHEMBL864667 (1) CHEMBL864670 (1)
CHEMBL870002 (1) CHEMBL867154 (1)
CHEMBL867157 (1)
1 / 0
Q03181 Peroxisome proliferator-activated receptor delta NR1C2 CHEMBL48 CHEMBL1794552 (1)
0 / 0
P14780 Matrix metalloproteinase-9 M10A CHEMBL428647 CHEMBL1909197 (2)
2 / 2
Q13526 Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 Enzyme CHEMBL48 CHEMBL304291 CHEMBL1738600 (1) CHEMBL1794585 (1)
0 / 0
O15245 Solute carrier family 22 member 1 Drug uniporter CHEMBL428647 CHEMBL993349 (1)
0 / 0
O75604 Ubiquitin carboxyl-terminal hydrolase 2 Enzyme CHEMBL1368986 CHEMBL1394061 CHEMBL1614331 (2)
0 / 0
P02545 Prelamin-A/C Unclassified protein CHEMBL48 CHEMBL418410 CHEMBL317544 CHEMBL1368986 CHEMBL1614310 (1) CHEMBL1614544 (4)
11 / 10
P37840 Alpha-synuclein Unclassified protein CHEMBL418410 CHEMBL2354282 (1)
4 / 2
P10828 Thyroid hormone receptor beta NR1A2 CHEMBL317544 CHEMBL1613776 (1)
3 / 1
P19793 Retinoic acid receptor RXR-alpha NR2B1 CHEMBL48 CHEMBL1794471 (1)
0 / 0
P00918 Carbonic anhydrase 2 Lyase CHEMBL428647 CHEMBL1909123 (2)
1 / 2
P07550 Beta-2 adrenergic receptor Adrenergic receptor CHEMBL428647 CHEMBL1909092 (2)
0 / 1
P21397 Amine oxidase [flavin-containing] A Oxidoreductase CHEMBL428647 CHEMBL1909169 (2)
1 / 1
P25021 Histamine H2 receptor Histamine receptor CHEMBL428647 CHEMBL1909157 (2)
0 / 0
P35367 Histamine H1 receptor Histamine receptor CHEMBL428647 CHEMBL1909156 (2)
0 / 0
Q01959 Sodium-dependent dopamine transporter Dopamine CHEMBL428647 CHEMBL1909143 (2)
1 / 0
P08912 Muscarinic acetylcholine receptor M5 Acetylcholine receptor CHEMBL428647 CHEMBL1909174 (2)
0 / 0
P18825 Alpha-2C adrenergic receptor Adrenergic receptor CHEMBL428647 CHEMBL1909090 (2)
0 / 0
P13945 Beta-3 adrenergic receptor Adrenergic receptor CHEMBL428647 CHEMBL1909093 (2)
0 / 0
P04183 Thymidine kinase, cytosolic Enzyme CHEMBL428647 CHEMBL910877 (1)
0 / 1
P08183 Multidrug resistance protein 1 drug CHEMBL428647 CHEMBL372351 CHEMBL827234 (1) CHEMBL828626 (1)
CHEMBL829287 (1) CHEMBL864672 (2)
CHEMBL1743157 (1) CHEMBL1908285 (1)
CHEMBL1908286 (1) CHEMBL1908289 (1)
CHEMBL1908291 (1) CHEMBL1908292 (1)
CHEMBL2076068 (1) CHEMBL2076069 (1)
CHEMBL2076285 (1) CHEMBL2076286 (1)
CHEMBL2076698 (1) CHEMBL2076861 (1)
CHEMBL2077348 (1) CHEMBL2075696 (1)
CHEMBL2076208 (1) CHEMBL2076213 (1)
CHEMBL2076214 (1) CHEMBL2076218 (1)
CHEMBL2076219 (1) CHEMBL2076044 (1)
CHEMBL2078581 (1) CHEMBL2078582 (1)
CHEMBL2077843 (1)
1 / 0
P25024 C-X-C chemokine receptor type 1 CXC chemokine receptor CHEMBL428647 CHEMBL1909127 (2)
0 / 0
P06241 Tyrosine-protein kinase Fyn Src CHEMBL428647 CHEMBL1909204 (2)
0 / 0
Q08209 Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform Ser_Thr CHEMBL428647 CHEMBL1909202 (2)
0 / 0
P11712 Cytochrome P450 2C9 Cytochrome P450 2C9 CHEMBL428647 CHEMBL1368986 CHEMBL1436401 CHEMBL1614027 (1) CHEMBL1741325 (2)
CHEMBL1909135 (2)
0 / 1
P05106 Integrin beta-3 Membrane receptor CHEMBL428647 CHEMBL833127 (1)
2 / 2
P06756 Integrin alpha-V Membrane receptor CHEMBL428647 CHEMBL833127 (1)
0 / 0
P54132 Bloom syndrome protein Enzyme CHEMBL317544 CHEMBL1614522 (1) CHEMBL1614067 (1)
1 / 2
P00533 Epidermal growth factor receptor TK tyrosine-protein kinase EGFR subfamily CHEMBL428647 CHEMBL1909203 (2)
1 / 11
P11473 Vitamin D3 receptor NR1I1 CHEMBL48 CHEMBL1794376 (1)
2 / 3
P14416 D(2) dopamine receptor Dopamine receptor CHEMBL428647 CHEMBL1909140 (2)
2 / 0
P23219 Prostaglandin G/H synthase 1 Oxidoreductase CHEMBL428647 CHEMBL1909130 (2)
0 / 0
P37288 Vasopressin V1a receptor Vasopressin and oxytocin receptor CHEMBL428647 CHEMBL1909120 (2)
0 / 0
P41145 Kappa-type opioid receptor Opioid receptor CHEMBL428647 CHEMBL1909181 (2)
0 / 0
Q9Y271 Cysteinyl leukotriene receptor 1 Leukotriene receptor CHEMBL428647 CHEMBL1909164 (2)
0 / 0
P29274 Adenosine receptor A2a Adenosine receptor CHEMBL428647 CHEMBL1909214 (2)
0 / 0
P25929 Neuropeptide Y receptor type 1 Neuropeptide Y receptor CHEMBL428647 CHEMBL1909175 (2)
0 / 0
P50052 Type-2 angiotensin II receptor Angiotensin receptor CHEMBL428647 CHEMBL1909096 (2)
1 / 1
P17948 Vascular endothelial growth factor receptor 1 Vegfr CHEMBL428647 CHEMBL1909118 (2)
0 / 0
P41968 Melanocortin receptor 3 Melanocortin receptor CHEMBL428647 CHEMBL1909166 (2)
1 / 0
P11509 Cytochrome P450 2A6 Cytochrome P450 2A6 CHEMBL428647 CHEMBL1909133 (2)
0 / 0
Q16665 Hypoxia-inducible factor 1-alpha Transcription Factor CHEMBL1368986 CHEMBL1429740 CHEMBL1614456 (2) CHEMBL1613803 (2)
0 / 0
P84022 Mothers against decapentaplegic homolog 3 Unclassified protein CHEMBL418410 CHEMBL304291 CHEMBL1429740 CHEMBL1794584 (3)
2 / 0
O75496 Geminin Unclassified protein CHEMBL48 CHEMBL428647 CHEMBL418410 CHEMBL304291 CHEMBL317544 CHEMBL1429740 CHEMBL1613941 (1) CHEMBL1738370 (1)
CHEMBL1738636 (1) CHEMBL1737957 (1)
CHEMBL2114843 (4) CHEMBL2114780 (5)
0 / 0
P51151 Ras-related protein Rab-9A Unclassified protein CHEMBL418410 CHEMBL1613838 (1)
0 / 0
P04035 3-hydroxy-3-methylglutaryl-coenzyme A reductase Oxidoreductase CHEMBL428647 CHEMBL1909158 (2)
0 / 0
P08913 Alpha-2A adrenergic receptor Adrenergic receptor CHEMBL428647 CHEMBL1909088 (2)
0 / 0
P21917 D(4) dopamine receptor Dopamine receptor CHEMBL428647 CHEMBL1909142 (2)
0 / 0
P30988 Calcitonin receptor Calcitonin receptor CHEMBL428647 CHEMBL1909101 (2)
0 / 0
P35462 D(3) dopamine receptor Dopamine receptor CHEMBL428647 CHEMBL1909141 (2)
1 / 0
P41143 Delta-type opioid receptor Opioid receptor CHEMBL428647 CHEMBL1909180 (2)
0 / 0
Q92731 Estrogen receptor beta NR3A2 CHEMBL428647 CHEMBL1909146 (2)
0 / 1
P41595 5-hydroxytryptamine receptor 2B Serotonin receptor CHEMBL428647 CHEMBL1909104 (2)
0 / 0
P25101 Endothelin-1 receptor Endothelin receptor CHEMBL428647 CHEMBL1909144 (2)
0 / 0
P30411 B2 bradykinin receptor Bradykinin receptor CHEMBL428647 CHEMBL1909100 (2)
0 / 0
P32245 Melanocortin receptor 4 Melanocortin receptor CHEMBL428647 CHEMBL1909167 (2)
1 / 0
P32238 Cholecystokinin receptor type A Cholecystokinin receptor CHEMBL428647 CHEMBL1909129 (2)
0 / 0
P08311 Cathepsin G S1A CHEMBL428647 CHEMBL1909194 (2)
0 / 0
Q99720 Sigma non-opioid intracellular receptor 1 Membrane receptor CHEMBL428647 CHEMBL1909110 (2)
1 / 0
P03956 Interstitial collagenase M10A CHEMBL428647 CHEMBL1909196 (2)
0 / 1
P32241 Vasoactive intestinal polypeptide receptor 1 Vasoactive intestinal peptide receptor CHEMBL428647 CHEMBL1909119 (2)
0 / 0
P83916 Chromobox protein homolog 1 Unclassified protein CHEMBL418410 CHEMBL1794401 (1)
0 / 0
Q9NPD5 Solute carrier organic anion transporter family member 1B3 Electrochemical transporter CHEMBL428647 CHEMBL2169430 (1)
1 / 0
O94782 Ubiquitin carboxyl-terminal hydrolase 1 Enzyme CHEMBL1368986 CHEMBL1436401 CHEMBL1794467 (2)
0 / 0
P04150 Glucocorticoid receptor NR3C1 CHEMBL48 CHEMBL428647 CHEMBL1794382 (1) CHEMBL1909150 (2)
0 / 1
P08172 Muscarinic acetylcholine receptor M2 Acetylcholine receptor CHEMBL428647 CHEMBL1909171 (2)
2 / 0
P11229 Muscarinic acetylcholine receptor M1 Acetylcholine receptor CHEMBL428647 CHEMBL1909170 (2)
0 / 0
P21554 Cannabinoid receptor 1 Cannabinoid receptor CHEMBL428647 CHEMBL1909122 (2)
0 / 0
P31645 Sodium-dependent serotonin transporter Serotonin CHEMBL428647 CHEMBL1909109 (2)
2 / 0
P37231 Peroxisome proliferator-activated receptor gamma NR1C3 CHEMBL48 CHEMBL1794293 (1)
5 / 3
P04626 Receptor tyrosine-protein kinase erbB-2 TK tyrosine-protein kinase EGFR subfamily CHEMBL428647 CHEMBL1909205 (2)
5 / 10
P20309 Muscarinic acetylcholine receptor M3 Acetylcholine receptor CHEMBL428647 CHEMBL1909172 (2)
1 / 0
P21452 Substance-K receptor Neurokinin receptor CHEMBL428647 CHEMBL1909114 (2)
0 / 0
P51679 C-C chemokine receptor type 4 CC chemokine receptor CHEMBL428647 CHEMBL1909125 (2)
0 / 0
P51681 C-C chemokine receptor type 5 CC chemokine receptor CHEMBL428647 CHEMBL1909126 (2)
3 / 0
P50406 5-hydroxytryptamine receptor 6 Serotonin receptor CHEMBL428647 CHEMBL1909108 (2)
0 / 0
P41597 C-C chemokine receptor type 2 CC chemokine receptor CHEMBL428647 CHEMBL1909124 (2)
1 / 0
P28482 Mitogen-activated protein kinase 1 Erk CHEMBL428647 CHEMBL1909200 (2)
0 / 0
P08575 Receptor-type tyrosine-protein phosphatase C Enzyme CHEMBL428647 CHEMBL1909207 (2)
2 / 1
P05177 Cytochrome P450 1A2 Cytochrome P450 1A2 CHEMBL428647 CHEMBL1368986 CHEMBL1436401 CHEMBL1741322 (2) CHEMBL1909132 (2)
0 / 0
Q99714 3-hydroxyacyl-CoA dehydrogenase type-2 Enzyme CHEMBL1436401 CHEMBL1614227 (1)
3 / 3
O15118 Niemann-Pick C1 protein Unclassified protein CHEMBL428647 CHEMBL418410 CHEMBL1614342 (2)
1 / 1
Q01453 Peripheral myelin protein 22 Unclassified protein CHEMBL317544 CHEMBL1614171 (1)
5 / 2
Q96QE3 ATPase family AAA domain-containing protein 5 Unclassified protein CHEMBL48 CHEMBL418410 CHEMBL1738588 (1) CHEMBL1738675 (1)
0 / 0
P21439 Multidrug resistance protein 3 Enzyme CHEMBL428647 CHEMBL1743163 (1)
3 / 2
O76074 cGMP-specific 3',5'-cyclic phosphodiesterase PDE_5A CHEMBL428647 CHEMBL1909186 (2)
0 / 0
P03372 Estrogen receptor NR3A1 CHEMBL48 CHEMBL428647 CHEMBL1794542 (1) CHEMBL1909145 (2)
1 / 1
P08588 Beta-1 adrenergic receptor Adrenergic receptor CHEMBL428647 CHEMBL1909091 (2)
1 / 0
P22303 Acetylcholinesterase Hydrolase CHEMBL428647 CHEMBL1909212 (2)
1 / 0
P28223 5-hydroxytryptamine receptor 2A Serotonin receptor CHEMBL428647 CHEMBL1909211 (2)
0 / 0
P28335 5-hydroxytryptamine receptor 2C Serotonin receptor CHEMBL428647 CHEMBL1909105 (2)
0 / 0
P35372 Mu-type opioid receptor Opioid receptor CHEMBL428647 CHEMBL1909182 (2)
0 / 0
P08173 Muscarinic acetylcholine receptor M4 Acetylcholine receptor CHEMBL428647 CHEMBL1909173 (2)
0 / 0
P25103 Substance-P receptor Neurokinin receptor CHEMBL428647 CHEMBL1909113 (2)
0 / 0
P25105 Platelet-activating factor receptor PAF receptor CHEMBL428647 CHEMBL1909187 (2)
0 / 0
P33032 Melanocortin receptor 5 Melanocortin receptor CHEMBL428647 CHEMBL1909168 (2)
0 / 0
P33261 Cytochrome P450 2C19 Cytochrome P450 2C19 CHEMBL428647 CHEMBL1368986 CHEMBL1436401 CHEMBL1741323 (2) CHEMBL1909134 (2)
1 / 1
P08684 Cytochrome P450 3A4 Cytochrome P450 3A4 CHEMBL428647 CHEMBL1368986 CHEMBL1436401 CHEMBL836230 (1) CHEMBL1614108 (1)
CHEMBL1613886 (1) CHEMBL1741324 (2)
CHEMBL1743290 (1) CHEMBL1909138 (2)
0 / 1
P05181 Cytochrome P450 2E1 Cytochrome P450 2E1 CHEMBL428647 CHEMBL1909137 (2)
0 / 0
Q9UNA4 DNA polymerase iota Enzyme CHEMBL304291 CHEMBL1794483 (1)
0 / 0
Q6W5P4 Neuropeptide S receptor Neuropeptide receptor CHEMBL317544 CHEMBL1614052 (1)
1 / 0
P10636 Microtubule-associated protein tau Unclassified protein CHEMBL418410 CHEMBL1436401 CHEMBL1614421 (2)
4 / 3
Q16236 Nuclear factor erythroid 2-related factor 2 Unclassified protein CHEMBL48 CHEMBL418410 CHEMBL1737980 (1) CHEMBL1738184 (1)
0 / 0
P10275 Androgen receptor NR3C4 CHEMBL48 CHEMBL1794560 (1)
3 / 4
P23975 Sodium-dependent noradrenaline transporter Norepinephrine CHEMBL428647 CHEMBL1909094 (2)
1 / 1
P25100 Alpha-1D adrenergic receptor Adrenergic receptor CHEMBL428647 CHEMBL1909087 (2)
0 / 0
P30542 Adenosine receptor A1 Adenosine receptor CHEMBL428647 CHEMBL1909213 (2)
0 / 0
P18089 Alpha-2B adrenergic receptor Adrenergic receptor CHEMBL428647 CHEMBL1909089 (2)
0 / 0
P24557 Thromboxane-A synthase Cytochrome P450 5A1 CHEMBL428647 CHEMBL1909116 (2)
1 / 1
P06239 Tyrosine-protein kinase Lck Src CHEMBL428647 CHEMBL1909206 (2)
0 / 1
P25025 C-X-C chemokine receptor type 2 CXC chemokine receptor CHEMBL428647 CHEMBL1909128 (2)
0 / 0
Q07817 Bcl-2-like protein 1 Other cytosolic protein CHEMBL428647 CHEMBL854833 (1)
0 / 0
P10415 Apoptosis regulator Bcl-2 Other cytosolic protein CHEMBL428647 CHEMBL854832 (1)
0 / 7
P46063 ATP-dependent DNA helicase Q1 Enzyme CHEMBL418410 CHEMBL1613829 (1)
0 / 0
P40225 Thrombopoietin Unclassified protein CHEMBL1436401 CHEMBL1614086 (1) CHEMBL1614034 (1)
1 / 1
Q96KQ7 Histone-lysine N-methyltransferase EHMT2 Enzyme CHEMBL304291 CHEMBL1738442 (1)
0 / 0
Q9NUW8 Tyrosyl-DNA phosphodiesterase 1 Enzyme CHEMBL1394061 CHEMBL1614364 (1)
1 / 1
O75874 Isocitrate dehydrogenase [NADP] cytoplasmic Enzyme CHEMBL428647 CHEMBL418410 CHEMBL304291 CHEMBL1429740 CHEMBL2354311 (4)
1 / 0
O00255 Menin Unclassified protein CHEMBL317544 CHEMBL1436401 CHEMBL1614257 (1) CHEMBL1614531 (1)
2 / 5
Q03164 Histone-lysine N-methyltransferase 2A Enzyme CHEMBL317544 CHEMBL1436401 CHEMBL1614257 (1) CHEMBL1614531 (1)
1 / 3
Q5T3U5 Multidrug resistance-associated protein 7 Unclassified protein CHEMBL428647 CHEMBL2076671 (1)
0 / 0
Q13748 Tubulin alpha-3C/D chain Structural CHEMBL428647 CHEMBL70362 CHEMBL372351 CHEMBL728403 (3) CHEMBL729968 (2)
CHEMBL864668 (2) CHEMBL864667 (1)
CHEMBL864670 (1) CHEMBL870002 (1)
CHEMBL867154 (1) CHEMBL867157 (1)
0 / 0
P68366 Tubulin alpha-4A chain Structural CHEMBL428647 CHEMBL70362 CHEMBL372351 CHEMBL728403 (3) CHEMBL729968 (2)
CHEMBL864668 (2) CHEMBL864667 (1)
CHEMBL864670 (1) CHEMBL870002 (1)
CHEMBL867154 (1) CHEMBL867157 (1)
0 / 0
P04350 Tubulin beta-4A chain Structural CHEMBL428647 CHEMBL70362 CHEMBL372351 CHEMBL728403 (3) CHEMBL729968 (2)
CHEMBL864668 (2) CHEMBL864667 (1)
CHEMBL864670 (1) CHEMBL870002 (1)
CHEMBL867154 (1) CHEMBL867157 (1)
2 / 0
Q3ZCM7 Tubulin beta-8 chain Structural CHEMBL428647 CHEMBL70362 CHEMBL372351 CHEMBL728403 (3) CHEMBL729968 (2)
CHEMBL864668 (2) CHEMBL864667 (1)
CHEMBL864670 (1) CHEMBL870002 (1)
CHEMBL867154 (1) CHEMBL867157 (1)
0 / 0
P07437 Tubulin beta chain Structural CHEMBL428647 CHEMBL70362 CHEMBL372351 CHEMBL728403 (3) CHEMBL729968 (2)
CHEMBL864668 (2) CHEMBL864667 (1)
CHEMBL864670 (1) CHEMBL870002 (1)
CHEMBL867154 (1) CHEMBL867157 (1)
0 / 0
Q71U36 Tubulin alpha-1A chain Structural CHEMBL428647 CHEMBL70362 CHEMBL372351 CHEMBL728403 (3) CHEMBL729968 (2)
CHEMBL864668 (2) CHEMBL864667 (1)
CHEMBL864670 (1) CHEMBL870002 (1)
CHEMBL867154 (1) CHEMBL867157 (1)
1 / 1
P68371 Tubulin beta-4B chain Structural CHEMBL428647 CHEMBL70362 CHEMBL372351 CHEMBL728403 (3) CHEMBL729968 (2)
CHEMBL864668 (2) CHEMBL864667 (1)
CHEMBL864670 (1) CHEMBL870002 (1)
CHEMBL867154 (1) CHEMBL867157 (1)
0 / 0
Q13509 Tubulin beta-3 chain Structural CHEMBL428647 CHEMBL70362 CHEMBL372351 CHEMBL728403 (3) CHEMBL729968 (2)
CHEMBL864668 (2) CHEMBL864667 (1)
CHEMBL864670 (1) CHEMBL870002 (1)
CHEMBL867154 (1) CHEMBL867157 (1)
2 / 1
P68363 Tubulin alpha-1B chain Unclassified protein CHEMBL428647 CHEMBL70362 CHEMBL372351 CHEMBL728403 (3) CHEMBL729968 (2)
CHEMBL864668 (2) CHEMBL864667 (1)
CHEMBL864670 (1) CHEMBL870002 (1)
CHEMBL867154 (1) CHEMBL867157 (1)
0 / 0
Q13885 Tubulin beta-2A chain Structural CHEMBL428647 CHEMBL70362 CHEMBL372351 CHEMBL728403 (3) CHEMBL729968 (2)
CHEMBL864668 (2) CHEMBL864667 (1)
CHEMBL864670 (1) CHEMBL870002 (1)
CHEMBL867154 (1) CHEMBL867157 (1)
0 / 0
Q6PEY2 Tubulin alpha-3E chain Unclassified protein CHEMBL428647 CHEMBL70362 CHEMBL372351 CHEMBL728403 (3) CHEMBL729968 (2)
CHEMBL864668 (2) CHEMBL864667 (1)
CHEMBL864670 (1) CHEMBL870002 (1)
CHEMBL867154 (1) CHEMBL867157 (1)
0 / 0
Q9BQE3 Tubulin alpha-1C chain Unclassified protein CHEMBL428647 CHEMBL70362 CHEMBL372351 CHEMBL728403 (3) CHEMBL729968 (2)
CHEMBL864668 (2) CHEMBL864667 (1)
CHEMBL864670 (1) CHEMBL870002 (1)
CHEMBL867154 (1) CHEMBL867157 (1)
0 / 0
Q9BUF5 Tubulin beta-6 chain Structural CHEMBL428647 CHEMBL70362 CHEMBL372351 CHEMBL728403 (3) CHEMBL729968 (2)
CHEMBL864668 (2) CHEMBL864667 (1)
CHEMBL864670 (1) CHEMBL870002 (1)
CHEMBL867154 (1) CHEMBL867157 (1)
0 / 0
Q9BVA1 Tubulin beta-2B chain Structural CHEMBL428647 CHEMBL70362 CHEMBL372351 CHEMBL728403 (3) CHEMBL729968 (2)
CHEMBL864668 (2) CHEMBL864667 (1)
CHEMBL864670 (1) CHEMBL870002 (1)
CHEMBL867154 (1) CHEMBL867157 (1)
1 / 0

CTD interaction (975)

compound gene gene name gene description interaction interaction type form reference
pmid
D017239 23461 ABCA5
ABC13
EST90625
ATP-binding cassette, sub-family A (ABC1), member 5 Paclitaxel results in increased expression of ABCA5 mRNA increases expression
mRNA 20737486
D017239 10347 ABCA7
ABCA-SSN
ABCX
ATP-binding cassette, sub-family A (ABC1), member 7 Paclitaxel results in increased expression of ABCA7 mRNA increases expression
mRNA 20737486
D017239 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) ABCB1 gene polymorphism affects the metabolism of Paclitaxel affects metabolic processing
gene 15901749
D017239 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) ABCB1 gene SNP affects the susceptibility to Paclitaxel affects response to substance
gene 16950614
D017239 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) ABCB1 mRNA results in decreased susceptibility to Paclitaxel decreases response to substance
mRNA 16322897
D017239 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) ABCB1 mRNA results in increased susceptibility to Paclitaxel increases response to substance
mRNA 15239142
D017239 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) ABCB1 protein affects the reaction [acetochlor results in increased susceptibility to Paclitaxel] affects reaction
/ increases response to substance
protein 18433974
D017239 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) ABCB1 protein affects the reaction [alachlor results in increased susceptibility to Paclitaxel] affects reaction
/ increases response to substance
protein 18433974
D017239 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) ABCB1 protein affects the reaction [metolachlor results in increased susceptibility to Paclitaxel] affects reaction
/ increases response to substance
protein 18433974
D017239 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) ABCB1 protein results in decreased susceptibility to Paclitaxel decreases response to substance
protein 15252144
15990222
16831368
17284363
17697605
20196146
22233293
D017239 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) ABCB1 protein results in decreased uptake of Paclitaxel decreases uptake
protein 10617675
D017239 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) ABCB1 protein results in increased export of and affects the susceptibility to Paclitaxel affects response to substance
/ increases export
protein 18433974
D017239 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) ABCB1 protein results in increased transport of Paclitaxel increases transport
protein 12708479
D017239 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) carvedilol inhibits the reaction [ABCB1 protein results in increased transport of Paclitaxel] decreases reaction
/ increases transport
protein 12708479
D017239 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) [carvedilol inhibits the reaction [ABCB1 protein results in increased transport of Paclitaxel]] which results in decreased susceptibility to Paclitaxel decreases reaction
/ decreases response to substance
/ increases transport
protein 12708479
D017239 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) cinchonine analog inhibits the reaction [ABCB1 protein results in decreased susceptibility to Paclitaxel] decreases reaction
/ decreases response to substance
protein 20196146
D017239 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) cinchonine inhibits the reaction [ABCB1 protein results in decreased susceptibility to Paclitaxel] decreases reaction
/ decreases response to substance
protein 20196146
D017239 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) crizotinib inhibits the reaction [ABCB1 protein results in decreased susceptibility to Paclitaxel] decreases reaction
/ decreases response to substance
protein 22233293
D017239 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) [Cyclosporine results in decreased activity of ABCB1 protein] which results in increased susceptibility to Paclitaxel decreases activity
/ increases response to substance
protein 18673531
D017239 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) [IL8 results in increased expression of ABCB1 mRNA] which results in decreased susceptibility to Paclitaxel decreases response to substance
/ increases expression
mRNA 21742513
D017239 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) [IL8 results in increased expression of ABCB1 protein] which results in decreased susceptibility to Paclitaxel decreases response to substance
/ increases expression
protein 21742513
D017239 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) NR1I2 protein promotes the reaction [Paclitaxel results in increased expression of and results in increased activity of ABCB1 protein] increases activity
/ increases expression
/ increases reaction
protein 20041327
D017239 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) [Paclitaxel results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 mRNA increases activity
/ increases expression
mRNA 20041327
D017239 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) Paclitaxel results in increased expression of ABCB1 mRNA increases expression
mRNA 15650019
17284363
21833476
D017239 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) Paclitaxel results in increased expression of ABCB1 protein increases expression
protein 15650019
15990222
17284363
20041327
21833476
D017239 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) [Paclitaxel results in increased expression of ABCB1] which results in decreased susceptibility to Cisplatin decreases response to substance
/ increases expression
21833476
D017239 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) [Paclitaxel results in increased expression of ABCB1] which results in decreased susceptibility to Doxorubicin decreases response to substance
/ increases expression
21833476
D017239 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) [Paclitaxel results in increased expression of ABCB1] which results in decreased susceptibility to Fluorouracil decreases response to substance
/ increases expression
21833476
D017239 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) [Paclitaxel results in increased expression of ABCB1] which results in decreased susceptibility to Vincristine decreases response to substance
/ increases expression
21833476
D017239 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) Quinidine inhibits the reaction [ABCB1 protein results in decreased susceptibility to Paclitaxel] decreases reaction
/ decreases response to substance
protein 20196146
D017239 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) [valspodar results in decreased activity of ABCB1 protein] which results in increased susceptibility to Paclitaxel decreases activity
/ increases response to substance
protein 18673531
D017239 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) Verapamil inhibits the reaction [ABCB1 protein results in decreased susceptibility to Paclitaxel] decreases reaction
/ decreases response to substance
protein 22233293
D017239 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) Verapamil inhibits the reaction [ABCB1 protein results in increased transport of Paclitaxel] decreases reaction
/ increases transport
protein 12708479
D017239 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) [Verapamil results in decreased activity of ABCB1 protein] which results in increased susceptibility to Paclitaxel decreases activity
/ increases response to substance
protein 18673531
D017239 8647 ABCB11
ABC16
BRIC2
BSEP
PFIC-2
PFIC2
PGY4
SPGP
ATP-binding cassette, sub-family B (MDR/TAP), member 11 Paclitaxel results in decreased activity of ABCB11 protein decreases activity
protein 20829430
D017239 5244 ABCB4
ABC21
GBD1
ICP3
MDR2
MDR2/3
MDR3
PFIC-3
PGY3
ATP-binding cassette, sub-family B (MDR/TAP), member 4 (EC:3.6.3.44) ABCB4 protein results in decreased susceptibility to Paclitaxel decreases response to substance
protein 17697605
D017239 10058 ABCB6
ABC
ABC14
DUH3
LAN
MCOPCB7
MTABC3
PRP
umat
ATP-binding cassette, sub-family B (MDR/TAP), member 6 Paclitaxel results in decreased expression of ABCB6 mRNA decreases expression
mRNA 20737486
D017239 4363 ABCC1
ABC29
ABCC
GS-X
MRP
MRP1
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 ABCC1 results in decreased susceptibility to Paclitaxel decreases response to substance
15548710
D017239 89845 ABCC10
EST182763
MRP7
SIMRP7
ATP-binding cassette, sub-family C (CFTR/MRP), member 10 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [ABCC10 protein results in decreased abundance of and results in increased secretion of Paclitaxel] decreases abundance
/ decreases reaction
/ increases secretion
protein 19841739
D017239 89845 ABCC10
EST182763
MRP7
SIMRP7
ATP-binding cassette, sub-family C (CFTR/MRP), member 10 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [ABCC10 protein results in decreased susceptibility to Paclitaxel] decreases reaction
/ decreases response to substance
protein 19841739
D017239 89845 ABCC10
EST182763
MRP7
SIMRP7
ATP-binding cassette, sub-family C (CFTR/MRP), member 10 ABCC10 protein results in decreased abundance of and results in increased secretion of Paclitaxel decreases abundance
/ increases secretion
protein 19841739
D017239 89845 ABCC10
EST182763
MRP7
SIMRP7
ATP-binding cassette, sub-family C (CFTR/MRP), member 10 ABCC10 protein results in decreased susceptibility to Paclitaxel decreases response to substance
protein 19841739
D017239 89845 ABCC10
EST182763
MRP7
SIMRP7
ATP-binding cassette, sub-family C (CFTR/MRP), member 10 imatinib inhibits the reaction [ABCC10 protein results in decreased abundance of and results in increased secretion of Paclitaxel] decreases abundance
/ decreases reaction
/ increases secretion
protein 19841739
D017239 89845 ABCC10
EST182763
MRP7
SIMRP7
ATP-binding cassette, sub-family C (CFTR/MRP), member 10 imatinib inhibits the reaction [ABCC10 protein results in decreased susceptibility to Paclitaxel] decreases reaction
/ decreases response to substance
protein 19841739
D017239 89845 ABCC10
EST182763
MRP7
SIMRP7
ATP-binding cassette, sub-family C (CFTR/MRP), member 10 Paclitaxel results in increased expression of ABCC10 mRNA increases expression
mRNA 20737486
D017239 1244 ABCC2
ABC30
CMOAT
DJS
MRP2
cMRP
ATP-binding cassette, sub-family C (CFTR/MRP), member 2 ABCC2 protein affects the susceptibility to Paclitaxel affects response to substance
protein 15645438
D017239 1244 ABCC2
ABC30
CMOAT
DJS
MRP2
cMRP
ATP-binding cassette, sub-family C (CFTR/MRP), member 2 ABCC2 protein affects the transport of Paclitaxel affects transport
protein 15849751
D017239 1244 ABCC2
ABC30
CMOAT
DJS
MRP2
cMRP
ATP-binding cassette, sub-family C (CFTR/MRP), member 2 ABCC2 protein results in decreased susceptibility to Paclitaxel decreases response to substance
protein 15849751
D017239 1244 ABCC2
ABC30
CMOAT
DJS
MRP2
cMRP
ATP-binding cassette, sub-family C (CFTR/MRP), member 2 ABCC2 protein results in increased export of Paclitaxel increases export
protein 19952419
D017239 1244 ABCC2
ABC30
CMOAT
DJS
MRP2
cMRP
ATP-binding cassette, sub-family C (CFTR/MRP), member 2 montelukast inhibits the reaction [ABCC2 protein results in increased export of Paclitaxel] decreases reaction
/ increases export
protein 19952419
D017239 1244 ABCC2
ABC30
CMOAT
DJS
MRP2
cMRP
ATP-binding cassette, sub-family C (CFTR/MRP), member 2 Paclitaxel affects the expression of ABCC2 mRNA affects expression
mRNA 20737486
D017239 1244 ABCC2
ABC30
CMOAT
DJS
MRP2
cMRP
ATP-binding cassette, sub-family C (CFTR/MRP), member 2 Probenecid promotes the reaction [ABCC2 protein affects the transport of Paclitaxel] affects transport
/ increases reaction
protein 15849751
D017239 1244 ABCC2
ABC30
CMOAT
DJS
MRP2
cMRP
ATP-binding cassette, sub-family C (CFTR/MRP), member 2 Probenecid promotes the reaction [ABCC2 protein results in decreased susceptibility to Paclitaxel] decreases response to substance
/ increases reaction
protein 15849751
D017239 1244 ABCC2
ABC30
CMOAT
DJS
MRP2
cMRP
ATP-binding cassette, sub-family C (CFTR/MRP), member 2 verlukast inhibits the reaction [ABCC2 protein results in increased export of Paclitaxel] decreases reaction
/ increases export
protein 19952419
D017239 8714 ABCC3
ABC31
EST90757
MLP2
MOAT-D
MRP3
cMOAT2
ATP-binding cassette, sub-family C (CFTR/MRP), member 3 Paclitaxel results in increased expression of ABCC3 mRNA increases expression
mRNA 20737486
D017239 10057 ABCC5
ABC33
EST277145
MOAT-C
MOATC
MRP5
SMRP
pABC11
ATP-binding cassette, sub-family C (CFTR/MRP), member 5 Paclitaxel results in increased expression of ABCC5 mRNA increases expression
mRNA 20737486
D017239 9429 ABCG2
ABC15
ABCP
BCRP
BCRP1
BMDP
CD338
CDw338
EST157481
GOUT1
MRX
MXR
MXR1
UAQTL1
ATP-binding cassette, sub-family G (WHITE), member 2 [ERBB2 results in increased expression of ABCG2] which results in decreased susceptibility to Paclitaxel decreases response to substance
/ increases expression
21712253
D017239 9429 ABCG2
ABC15
ABCP
BCRP
BCRP1
BMDP
CD338
CDw338
EST157481
GOUT1
MRX
MXR
MXR1
UAQTL1
ATP-binding cassette, sub-family G (WHITE), member 2 Paclitaxel results in decreased expression of ABCG2 mRNA decreases expression
mRNA 21833476
D017239 9429 ABCG2
ABC15
ABCP
BCRP
BCRP1
BMDP
CD338
CDw338
EST157481
GOUT1
MRX
MXR
MXR1
UAQTL1
ATP-binding cassette, sub-family G (WHITE), member 2 Paclitaxel results in decreased expression of ABCG2 protein decreases expression
protein 21833476
D017239 9429 ABCG2
ABC15
ABCP
BCRP
BCRP1
BMDP
CD338
CDw338
EST157481
GOUT1
MRX
MXR
MXR1
UAQTL1
ATP-binding cassette, sub-family G (WHITE), member 2 [Paclitaxel results in decreased expression of ABCG2] which results in decreased susceptibility to Cisplatin decreases expression
/ decreases response to substance
21833476
D017239 9429 ABCG2
ABC15
ABCP
BCRP
BCRP1
BMDP
CD338
CDw338
EST157481
GOUT1
MRX
MXR
MXR1
UAQTL1
ATP-binding cassette, sub-family G (WHITE), member 2 [Paclitaxel results in decreased expression of ABCG2] which results in decreased susceptibility to Doxorubicin decreases expression
/ decreases response to substance
21833476
D017239 9429 ABCG2
ABC15
ABCP
BCRP
BCRP1
BMDP
CD338
CDw338
EST157481
GOUT1
MRX
MXR
MXR1
UAQTL1
ATP-binding cassette, sub-family G (WHITE), member 2 [Paclitaxel results in decreased expression of ABCG2] which results in decreased susceptibility to Fluorouracil decreases expression
/ decreases response to substance
21833476
D017239 9429 ABCG2
ABC15
ABCP
BCRP
BCRP1
BMDP
CD338
CDw338
EST157481
GOUT1
MRX
MXR
MXR1
UAQTL1
ATP-binding cassette, sub-family G (WHITE), member 2 [Paclitaxel results in decreased expression of ABCG2] which results in decreased susceptibility to Vincristine decreases expression
/ decreases response to substance
21833476
D017239 33 ACADL
ACAD4
LCAD
acyl-CoA dehydrogenase, long chain (EC:1.3.8.8) Paclitaxel results in decreased expression of ACADL protein decreases expression
protein 15907983
D017239 57007 ACKR3
CMKOR1
CXC-R7
CXCR-7
CXCR7
GPR159
RDC-1
RDC1
atypical chemokine receptor 3 ACKR3 mRNA results in decreased susceptibility to Paclitaxel decreases response to substance
mRNA 16322897
D017239 112 ADCY6
AC6
adenylate cyclase 6 (EC:4.6.1.1) Paclitaxel results in decreased expression of ADCY6 mRNA decreases expression
mRNA 15000894
D017239 120 ADD3
ADDL
adducin 3 (gamma) ADD3 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 159 ADSS
ADEH
ADSS_2
adenylosuccinate synthase (EC:6.3.4.4) Paclitaxel results in decreased expression of ADSS protein decreases expression
protein 15907983
D017239 9131 AIFM1
AIF
CMTX4
COWCK
COXPD6
PDCD8
apoptosis-inducing factor, mitochondrion-associated, 1 [Doxorubicin co-treated with Paclitaxel co-treated with Fluorouracil] results in increased expression of AIFM1 protein affects cotreatment
/ increases expression
protein 16168113
D017239 9131 AIFM1
AIF
CMTX4
COWCK
COXPD6
PDCD8
apoptosis-inducing factor, mitochondrion-associated, 1 [Doxorubicin co-treated with Paclitaxel] results in increased expression of AIFM1 protein affects cotreatment
/ increases expression
protein 16168113
D017239 9131 AIFM1
AIF
CMTX4
COWCK
COXPD6
PDCD8
apoptosis-inducing factor, mitochondrion-associated, 1 Paclitaxel results in increased expression of AIFM1 mRNA increases expression
mRNA 18058816
D017239 9131 AIFM1
AIF
CMTX4
COWCK
COXPD6
PDCD8
apoptosis-inducing factor, mitochondrion-associated, 1 [Tretinoin co-treated with Paclitaxel] affects the localization of AIFM1 protein affects cotreatment
/ affects localization
protein 17701358
D017239 9131 AIFM1
AIF
CMTX4
COWCK
COXPD6
PDCD8
apoptosis-inducing factor, mitochondrion-associated, 1 [Tretinoin co-treated with Paclitaxel] results in increased expression of AIFM1 protein affects cotreatment
/ increases expression
protein 17701358
D017239 231 AKR1B1
ADR
ALDR1
ALR2
AR
aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) AKR1B1 protein results in increased susceptibility to Paclitaxel increases response to substance
protein 16734730
D017239 1646 AKR1C2
AKR1C-pseudo
BABP
DD
DD2
DDH2
HAKRD
HBAB
MCDR2
SRXY8
aldo-keto reductase family 1, member C2 (EC:1.3.1.20 1.1.1.357) AKR1C2 mRNA results in increased susceptibility to Paclitaxel increases response to substance
mRNA 16322897
D017239 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Paclitaxel results in increased activity of AKT1 protein] decreases reaction
/ increases activity
protein 16211241
D017239 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Paclitaxel results in increased activity of AKT1 protein] decreases reaction
/ increases activity
protein 16211241
D017239 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) AKT1 protein affects the reaction [Paclitaxel results in increased activity of CASP3 protein] affects reaction
/ increases activity
protein 10075725
D017239 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) AKT1 protein affects the reaction [Paclitaxel results in increased cleavage of PARP1 protein] affects reaction
/ increases cleavage
protein 10075725
D017239 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) AKT1 protein affects the susceptibility to Paclitaxel affects response to substance
protein 18071906
D017239 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) AKT1 protein results in decreased susceptibility to Paclitaxel decreases response to substance
protein 16782806
D017239 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) Paclitaxel results in decreased phosphorylation of AKT1 protein decreases phosphorylation
protein 17404021
D017239 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) Paclitaxel results in increased activity of AKT1 protein increases activity
protein 16211241
D017239 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) [PDK1 protein binds to AKT1 protein] results in decreased susceptibility to [Paclitaxel co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] affects binding
/ affects cotreatment
/ decreases response to substance
protein 20361045
D017239 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) [PDK1 protein binds to AKT1 protein] which results in decreased susceptibility to Paclitaxel affects binding
/ decreases response to substance
protein 20361045
D017239 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) [pifithrin co-treated with Paclitaxel] results in decreased phosphorylation of AKT1 protein affects cotreatment
/ decreases phosphorylation
protein 18516295
D017239 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) U 0126 inhibits the reaction [Paclitaxel results in increased activity of AKT1 protein] decreases reaction
/ increases activity
protein 16211241
D017239 208 AKT2
HIHGHH
PKBB
PKBBETA
PRKBB
RAC-BETA
v-akt murine thymoma viral oncogene homolog 2 (EC:2.7.11.1) AKT2 protein affects the susceptibility to Paclitaxel affects response to substance
protein 18071906
D017239 208 AKT2
HIHGHH
PKBB
PKBBETA
PRKBB
RAC-BETA
v-akt murine thymoma viral oncogene homolog 2 (EC:2.7.11.1) Paclitaxel results in increased phosphorylation of AKT2 protein increases phosphorylation
protein 18071906
D017239 10000 AKT3
MPPH
PKB-GAMMA
PKBG
PRKBG
RAC-PK-gamma
RAC-gamma
STK-2
v-akt murine thymoma viral oncogene homolog 3 (EC:2.7.11.1) AKT3 protein affects the susceptibility to Paclitaxel affects response to substance
protein 18071906
D017239 223 ALDH9A1
ALDH4
ALDH7
ALDH9
E3
TMABADH
aldehyde dehydrogenase 9 family, member A1 (EC:1.2.1.3 1.2.1.19 1.2.1.47) Paclitaxel results in increased expression of ALDH9A1 protein increases expression
protein 15907983
D017239 79053 ALG8
CDG1H
ALG8, alpha-1,3-glucosyltransferase (EC:2.4.1.265) ALG8 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 267 AMFR
GP78
RNF45
autocrine motility factor receptor, E3 ubiquitin protein ligase (EC:6.3.2.19) AMFR mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] affects cotreatment
/ affects response to substance
mRNA 16896004
D017239 8125 ANP32A
C15orf1
HPPCn
I1PP2A
LANP
MAPM
PHAP1
PHAPI
PP32
acidic (leucine-rich) nuclear phosphoprotein 32 family, member A ANP32A protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 301 ANXA1
ANX1
LPC1
annexin A1 ANXA1 protein results in increased susceptibility to Paclitaxel increases response to substance
protein 16734730
D017239 307 ANXA4
ANX4
PIG28
ZAP36
annexin A4 ANXA4 results in decreased susceptibility to Paclitaxel decreases response to substance
21636539
D017239 653145 ANXA8
ANX8
annexin A8 ANXA8 protein results in increased susceptibility to Paclitaxel increases response to substance
protein 16734730
D017239 316 AOX1
AO
AOH1
aldehyde oxidase 1 (EC:1.2.3.1) AOX1 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 317 APAF1
APAF-1
CED4
apoptotic peptidase activating factor 1 Paclitaxel results in increased expression of APAF1 protein increases expression
protein 14749477
D017239 378708 APITD1
CENP-S
CENPS
FAAP16
MHF1
apoptosis-inducing, TAF9-like domain 1 Paclitaxel results in increased expression of APITD1 mRNA increases expression
mRNA 18058816
D017239 334 APLP2
APLP-2
APPH
APPL2
CDEBP
amyloid beta (A4) precursor-like protein 2 APLP2 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 27350 APOBEC3C
A3C
APOBEC1L
ARDC2
ARDC4
ARP5
PBI
bK150C2.3
apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3C APOBEC3C protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 347 APOD
apolipoprotein D Paclitaxel results in increased expression of APOD mRNA increases expression
mRNA 19682730
D017239 367 AR
AIS
DHTR
HUMARA
HYSP1
KD
NR3C4
SBMA
SMAX1
TFM
androgen receptor Paclitaxel inhibits the reaction [Dihydrotestosterone results in increased localization of AR protein] decreases reaction
/ increases localization
protein 20807808
D017239 367 AR
AIS
DHTR
HUMARA
HYSP1
KD
NR3C4
SBMA
SMAX1
TFM
androgen receptor Paclitaxel results in decreased localization of AR protein decreases localization
protein 20807808
D017239 374 AREG
AR
CRDGF
SDGF
amphiregulin Paclitaxel results in increased expression of AREG protein increases expression
protein 20726858
D017239 377 ARF3
ADP-ribosylation factor 3 ARF3 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 396 ARHGDIA
GDIA1
NPHS8
RHOGDI
RHOGDI-1
Rho GDP dissociation inhibitor (GDI) alpha ARHGDIA mRNA affects the reaction [Paclitaxel results in increased activity of CASP3 protein] affects reaction
/ increases activity
mRNA 17264767
D017239 396 ARHGDIA
GDIA1
NPHS8
RHOGDI
RHOGDI-1
Rho GDP dissociation inhibitor (GDI) alpha ARHGDIA mRNA affects the susceptibility to Paclitaxel affects response to substance
mRNA 17264767
D017239 407 ARR3
ARRX
arrestin 3, retinal (X-arrestin) ARR3 mRNA results in decreased susceptibility to Paclitaxel decreases response to substance
mRNA 16322897
D017239 259266 ASPM
ASP
Calmbp1
MCPH5
asp (abnormal spindle) homolog, microcephaly associated (Drosophila) Paclitaxel results in increased expression of ASPM mRNA increases expression
mRNA 17374387
D017239 22809 ATF5
ATFX
HMFN0395
activating transcription factor 5 Paclitaxel results in decreased expression of ATF5 mRNA decreases expression
mRNA 15000894
D017239 523 ATP6V1A
ATP6A1
ATP6V1A1
HO68
VA68
VPP2
Vma1
ATPase, H+ transporting, lysosomal 70kDa, V1 subunit A (EC:3.6.3.14) ATP6V1A protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 538 ATP7A
DSMAX
MK
MNK
SMAX3
ATPase, Cu++ transporting, alpha polypeptide (EC:3.6.3.54) ATP7A protein results in decreased susceptibility to Paclitaxel decreases response to substance
protein 17510416
D017239 538 ATP7A
DSMAX
MK
MNK
SMAX3
ATPase, Cu++ transporting, alpha polypeptide (EC:3.6.3.54) Paclitaxel results in increased expression of ATP7A mRNA increases expression
mRNA 20737486
D017239 6790 AURKA
AIK
ARK1
AURA
AURORA2
BTAK
PPP1R47
STK15
STK6
STK7
aurora kinase A (EC:2.7.11.1) Paclitaxel results in increased expression of AURKA mRNA increases expression
mRNA 17374387
D017239 558 AXL
JTK11
UFO
AXL receptor tyrosine kinase (EC:2.7.10.1) AXL protein results in increased susceptibility to Paclitaxel increases response to substance
protein 16734730
D017239 572 BAD
BBC2
BCL2L8
BCL2-associated agonist of cell death Paclitaxel results in increased expression of BAD mRNA increases expression
mRNA 10822281
D017239 572 BAD
BBC2
BCL2L8
BCL2-associated agonist of cell death Paclitaxel results in increased expression of BAD protein increases expression
protein 10822281
D017239 572 BAD
BBC2
BCL2L8
BCL2-associated agonist of cell death [PD168393 co-treated with Paclitaxel] results in increased expression of BAD protein affects cotreatment
/ increases expression
protein 16413505
D017239 397543 BAK protein results in increased susceptibility to Paclitaxel increases response to substance
protein 17688235
D017239 578 BAK1
BAK
BAK-LIKE
BCL2L7
CDN1
BCL2-antagonist/killer 1 Paclitaxel affects the expression of BAK1 mRNA affects expression
mRNA 10822281
D017239 578 BAK1
BAK
BAK-LIKE
BCL2L7
CDN1
BCL2-antagonist/killer 1 Paclitaxel affects the expression of BAK1 protein affects expression
protein 10822281
D017239 578 BAK1
BAK
BAK-LIKE
BCL2L7
CDN1
BCL2-antagonist/killer 1 Paclitaxel results in increased expression of BAK1 mRNA increases expression
mRNA 10822281
D017239 578 BAK1
BAK
BAK-LIKE
BCL2L7
CDN1
BCL2-antagonist/killer 1 Paclitaxel results in increased expression of BAK1 protein increases expression
protein 10822281
D017239 581 BAX
BCL2L4
BCL2-associated X protein [Doxorubicin co-treated with Paclitaxel] results in increased expression of BAX protein affects cotreatment
/ increases expression
protein 16168113
D017239 581 BAX
BCL2L4
BCL2-associated X protein [esculetin co-treated with Paclitaxel] results in increased expression of BAX protein affects cotreatment
/ increases expression
protein 16051289
D017239 581 BAX
BCL2L4
BCL2-associated X protein Fluorouracil promotes the reaction [[Doxorubicin co-treated with Paclitaxel] results in increased expression of BAX protein] affects cotreatment
/ increases expression
/ increases reaction
protein 16168113
D017239 581 BAX
BCL2L4
BCL2-associated X protein Paclitaxel results in increased expression of BAX mRNA increases expression
mRNA 10822281
D017239 581 BAX
BCL2L4
BCL2-associated X protein Paclitaxel results in increased expression of BAX protein increases expression
protein 10516758
10822281
12632493
16513327
D017239 581 BAX
BCL2L4
BCL2-associated X protein [Paclitaxel results in increased expression of TP53 protein] which results in increased expression of BAX mRNA increases expression
mRNA 9041188
D017239 581 BAX
BCL2L4
BCL2-associated X protein [Paclitaxel results in increased phosphorylation of BCL2 protein] inhibits the reaction [BCL2 protein binds to BAX protein] affects binding
/ decreases reaction
/ increases phosphorylation
protein 11726273
D017239 27113 BBC3
JFY-1
JFY1
PUMA
BCL2 binding component 3 BBC3 protein results in increased susceptibility to Paclitaxel increases response to substance
protein 16481741
D017239 27113 BBC3
JFY-1
JFY1
PUMA
BCL2 binding component 3 Paclitaxel results in increased expression of BBC3 mRNA increases expression
mRNA 16481741
D017239 27113 BBC3
JFY-1
JFY1
PUMA
BCL2 binding component 3 Paclitaxel results in increased expression of BBC3 protein increases expression
protein 16481741
D017239 585 BBS4
Bardet-Biedl syndrome 4 BBS4 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] affects cotreatment
/ affects response to substance
mRNA 16896004
D017239 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 3,3'-diindolylmethane promotes the reaction [Paclitaxel results in decreased expression of BCL2 protein] decreases expression
/ increases reaction
protein 16580691
D017239 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 aspartyl-glutamyl-valyl-aspartal inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein] decreases reaction
/ increases phosphorylation
protein 11160861
D017239 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 BCL2 mRNA results in decreased susceptibility to Paclitaxel decreases response to substance
mRNA 16322897
D017239 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 BCL2 protein affects the susceptibility to Paclitaxel affects response to substance
protein 20610805
D017239 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 BCL2 protein mutant form results in increased susceptibility to Paclitaxel increases response to substance
protein 20610805
D017239 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 BCL2 protein results in decreased susceptibility to Paclitaxel decreases response to substance
protein 16275990
D017239 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 Curcumin inhibits the reaction [Paclitaxel results in increased expression of BCL2 protein] decreases reaction
/ increases expression
protein 16243823
D017239 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 Cycloheximide inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein] decreases reaction
/ increases phosphorylation
protein 11726273
D017239 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 Cyclosporine promotes the reaction [Paclitaxel results in increased phosphorylation of and results in decreased activity of BCL2 protein] decreases activity
/ increases phosphorylation
/ increases reaction
protein 12086014
D017239 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 Dactinomycin inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein] decreases reaction
/ increases phosphorylation
protein 11726273
D017239 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 Doxorubicin promotes the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein] increases phosphorylation
/ increases reaction
protein 16168113
D017239 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 Genistein inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein] decreases reaction
/ increases phosphorylation
protein 15907805
D017239 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 [IL8 results in increased expression of BCL2 mRNA] which results in decreased susceptibility to Paclitaxel decreases response to substance
/ increases expression
mRNA 21742513
D017239 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 [IL8 results in increased expression of BCL2 protein] which results in decreased susceptibility to Paclitaxel decreases response to substance
/ increases expression
protein 21742513
D017239 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 MAP3K1 protein affects the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein] affects reaction
/ increases phosphorylation
protein 11160861
D017239 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 MAPK8 protein affects the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein] affects reaction
/ increases phosphorylation
protein 11160861
D017239 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 Paclitaxel affects the localization of BCL2 protein affects localization
protein 12126962
D017239 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 [Paclitaxel co-treated with sorafenib] results in decreased expression of BCL2 protein affects cotreatment
/ decreases expression
protein 19664330
D017239 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 Paclitaxel results in decreased activity of BCL2 protein decreases activity
protein 10881025
D017239 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 Paclitaxel results in decreased degradation of BCL2 protein decreases degradation
protein 12126962
D017239 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 Paclitaxel results in decreased expression of and affects the phosphorylation of BCL2 protein affects phosphorylation
/ decreases expression
protein 10822281
D017239 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 Paclitaxel results in decreased expression of BCL2 mRNA decreases expression
mRNA 10822281
D017239 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 Paclitaxel results in decreased expression of BCL2 protein decreases expression
protein 10822281
10861090
11774260
12632493
15907983
16513327
16580691
17701358
19815708
D017239 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 Paclitaxel results in increased cleavage of BCL2 protein increases cleavage
protein 10822281
D017239 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 Paclitaxel results in increased phosphorylation of and results in decreased activity of BCL2 protein decreases activity
/ increases phosphorylation
protein 12086014
D017239 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 Paclitaxel results in increased phosphorylation of BCL2 protein increases phosphorylation
protein 7654318
10502406
10881025
11160861
11726273
12126962
12510025
12709826
14991574
15907805
16168113
18098270
18521433
20610805
D017239 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 [Paclitaxel results in increased phosphorylation of BCL2 protein] inhibits the reaction [BCL2 protein binds to BAX protein] affects binding
/ decreases reaction
/ increases phosphorylation
protein 11726273
D017239 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 [Paclitaxel results in increased phosphorylation of BCL2 protein] which results in increased susceptibility to Cisplatin increases phosphorylation
/ increases response to substance
protein 12709826
D017239 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 [pifithrin co-treated with Paclitaxel] results in increased phosphorylation of BCL2 protein affects cotreatment
/ increases phosphorylation
protein 18516295
D017239 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 resveratrol inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein] decreases reaction
/ increases phosphorylation
protein 12510025
D017239 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 Staurosporine inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein] decreases reaction
/ increases phosphorylation
protein 15907805
D017239 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 [Tretinoin co-treated with Paclitaxel] results in decreased expression of BCL2 protein affects cotreatment
/ decreases expression
protein 17701358
D017239 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 [Tretinoin co-treated with Paclitaxel] results in increased phosphorylation of BCL2 protein affects cotreatment
/ increases phosphorylation
protein 18098270
D017239 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 TYMP inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein] decreases reaction
/ increases phosphorylation
protein 15907805
D017239 598 BCL2L1
BCL-XL/S
BCL2L
BCLX
BCLXL
BCLXS
Bcl-X
PPP1R52
bcl-xL
bcl-xS
BCL2-like 1 BCL2L1 protein results in decreased susceptibility to Paclitaxel decreases response to substance
protein 11468182
16080463
16275990
D017239 598 BCL2L1
BCL-XL/S
BCL2L
BCLX
BCLXL
BCLXS
Bcl-X
PPP1R52
bcl-xL
bcl-xS
BCL2-like 1 Curcumin inhibits the reaction [Paclitaxel results in increased expression of BCL2L1 protein] decreases reaction
/ increases expression
protein 16243823
D017239 598 BCL2L1
BCL-XL/S
BCL2L
BCLX
BCLXL
BCLXS
Bcl-X
PPP1R52
bcl-xL
bcl-xS
BCL2-like 1 [esculetin co-treated with Paclitaxel] results in decreased expression of BCL2L1 protein affects cotreatment
/ decreases expression
protein 16051289
D017239 598 BCL2L1
BCL-XL/S
BCL2L
BCLX
BCLXL
BCLXS
Bcl-X
PPP1R52
bcl-xL
bcl-xS
BCL2-like 1 [IL8 results in increased expression of BCL2L1 mRNA] which results in decreased susceptibility to Paclitaxel decreases response to substance
/ increases expression
mRNA 21742513
D017239 598 BCL2L1
BCL-XL/S
BCL2L
BCLX
BCLXL
BCLXS
Bcl-X
PPP1R52
bcl-xL
bcl-xS
BCL2-like 1 [IL8 results in increased expression of BCL2L1 protein] which results in decreased susceptibility to Paclitaxel decreases response to substance
/ increases expression
protein 21742513
D017239 598 BCL2L1
BCL-XL/S
BCL2L
BCLX
BCLXL
BCLXS
Bcl-X
PPP1R52
bcl-xL
bcl-xS
BCL2-like 1 Paclitaxel results in decreased expression of BCL2L1 mRNA decreases expression
mRNA 18058816
D017239 598 BCL2L1
BCL-XL/S
BCL2L
BCLX
BCLXL
BCLXS
Bcl-X
PPP1R52
bcl-xL
bcl-xS
BCL2-like 1 Paclitaxel results in decreased expression of BCL2L1 protein decreases expression
protein 11774260
14749477
D017239 598 BCL2L1
BCL-XL/S
BCL2L
BCLX
BCLXL
BCLXS
Bcl-X
PPP1R52
bcl-xL
bcl-xS
BCL2-like 1 Paclitaxel results in increased expression of BCL2L1 mRNA increases expression
mRNA 10822281
D017239 598 BCL2L1
BCL-XL/S
BCL2L
BCLX
BCLXL
BCLXS
Bcl-X
PPP1R52
bcl-xL
bcl-xS
BCL2-like 1 Paclitaxel results in increased expression of BCL2L1 protein increases expression
protein 10822281
D017239 598 BCL2L1
BCL-XL/S
BCL2L
BCLX
BCLXL
BCLXS
Bcl-X
PPP1R52
bcl-xL
bcl-xS
BCL2-like 1 Paclitaxel results in increased phosphorylation of BCL2L1 protein increases phosphorylation
protein 18521433
D017239 8678 BECN1
ATG6
VPS30
beclin1
beclin 1, autophagy related BECN1 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] affects cotreatment
/ affects response to substance
mRNA 16896004
D017239 633 BGN
DSPG1
PG-S1
PGI
SLRR1A
biglycan BGN protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 637 BID
FP497
BH3 interacting domain death agonist Paclitaxel results in increased cleavage of BID protein increases cleavage
protein 18098270
D017239 637 BID
FP497
BH3 interacting domain death agonist Paclitaxel results in increased expression of BID protein increases expression
protein 14749477
D017239 637 BID
FP497
BH3 interacting domain death agonist [Tretinoin co-treated with Paclitaxel] results in increased cleavage of BID protein affects cotreatment
/ increases cleavage
protein 18098270
D017239 274 BIN1
AMPH2
AMPHL
SH3P9
bridging integrator 1 Paclitaxel results in increased expression of BIN1 mRNA increases expression
mRNA 19682730
D017239 55909 BIN3
bridging integrator 3 Paclitaxel results in decreased expression of BIN3 protein decreases expression
protein 15907983
D017239 329 BIRC2
API1
HIAP2
Hiap-2
MIHB
RNF48
c-IAP1
cIAP1
baculoviral IAP repeat containing 2 BIRC2 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 329 BIRC2
API1
HIAP2
Hiap-2
MIHB
RNF48
c-IAP1
cIAP1
baculoviral IAP repeat containing 2 Curcumin inhibits the reaction [Paclitaxel results in increased expression of BIRC2 protein] decreases reaction
/ increases expression
protein 16243823
D017239 329 BIRC2
API1
HIAP2
Hiap-2
MIHB
RNF48
c-IAP1
cIAP1
baculoviral IAP repeat containing 2 Paclitaxel results in decreased expression of BIRC2 protein decreases expression
protein 14749477
17701358
18098270
D017239 329 BIRC2
API1
HIAP2
Hiap-2
MIHB
RNF48
c-IAP1
cIAP1
baculoviral IAP repeat containing 2 [Tretinoin co-treated with Paclitaxel] results in decreased expression of BIRC2 protein affects cotreatment
/ decreases expression
protein 17701358
18098270
D017239 330 BIRC3
AIP1
API2
CIAP2
HAIP1
HIAP1
MALT2
MIHC
RNF49
c-IAP2
baculoviral IAP repeat containing 3 Curcumin inhibits the reaction [Paclitaxel results in increased expression of BIRC3 protein] decreases reaction
/ increases expression
protein 16243823
D017239 330 BIRC3
AIP1
API2
CIAP2
HAIP1
HIAP1
MALT2
MIHC
RNF49
c-IAP2
baculoviral IAP repeat containing 3 Paclitaxel results in decreased expression of BIRC3 protein decreases expression
protein 14749477
17701358
18098270
D017239 330 BIRC3
AIP1
API2
CIAP2
HAIP1
HIAP1
MALT2
MIHC
RNF49
c-IAP2
baculoviral IAP repeat containing 3 [Tretinoin co-treated with Paclitaxel] results in decreased expression of BIRC3 protein affects cotreatment
/ decreases expression
protein 17701358
18098270
D017239 332 BIRC5
API4
EPR-1
baculoviral IAP repeat containing 5 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Paclitaxel results in increased expression of BIRC5] decreases reaction
/ increases expression
16211241
D017239 332 BIRC5
API4
EPR-1
baculoviral IAP repeat containing 5 [4-(6-cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-diethylbenzamide co-treated with Paclitaxel] results in decreased expression of BIRC5 protein affects cotreatment
/ decreases expression
protein 16170024
D017239 332 BIRC5
API4
EPR-1
baculoviral IAP repeat containing 5 BIRC5 protein results in decreased susceptibility to Paclitaxel decreases response to substance
protein 16202317
D017239 332 BIRC5
API4
EPR-1
baculoviral IAP repeat containing 5 BIRC5 results in decreased susceptibility to Paclitaxel decreases response to substance
19133282
D017239 332 BIRC5
API4
EPR-1
baculoviral IAP repeat containing 5 Paclitaxel affects the reaction [BIRC5 protein affects the susceptibility to Melphalan] affects reaction
/ affects response to substance
protein 16373717
D017239 332 BIRC5
API4
EPR-1
baculoviral IAP repeat containing 5 Paclitaxel results in decreased expression of BIRC5 mRNA decreases expression
mRNA 15970709
D017239 332 BIRC5
API4
EPR-1
baculoviral IAP repeat containing 5 Paclitaxel results in decreased expression of BIRC5 promoter decreases expression
promoter 12517802
D017239 332 BIRC5
API4
EPR-1
baculoviral IAP repeat containing 5 Paclitaxel results in decreased expression of BIRC5 protein decreases expression
protein 14749477
17399942
17701358
D017239 332 BIRC5
API4
EPR-1
baculoviral IAP repeat containing 5 Paclitaxel results in increased expression of BIRC5 increases expression
16211241
D017239 332 BIRC5
API4
EPR-1
baculoviral IAP repeat containing 5 Paclitaxel results in increased expression of BIRC5 protein increases expression
protein 12517802
17399942
19133282
19875160
D017239 332 BIRC5
API4
EPR-1
baculoviral IAP repeat containing 5 Prodigiosin inhibits the reaction [Paclitaxel results in increased expression of BIRC5 protein] decreases reaction
/ increases expression
protein 19133282
D017239 332 BIRC5
API4
EPR-1
baculoviral IAP repeat containing 5 [Tretinoin co-treated with Paclitaxel] results in decreased expression of BIRC5 protein affects cotreatment
/ decreases expression
protein 17701358
18098270
D017239 332 BIRC5
API4
EPR-1
baculoviral IAP repeat containing 5 vorinostat inhibits the reaction [Paclitaxel results in increased expression of BIRC5 protein] decreases reaction
/ increases expression
protein 19875160
D017239 655 BMP7
OP-1
bone morphogenetic protein 7 BMP7 mRNA results in increased susceptibility to Paclitaxel increases response to substance
mRNA 16322897
D017239 672 BRCA1
BRCAI
BRCC1
BROVCA1
IRIS
PNCA4
PPP1R53
PSCP
RNF53
breast cancer 1, early onset Paclitaxel results in decreased expression of BRCA1 mRNA decreases expression
mRNA 15607317
D017239 10950 BTG3
ANA
TOB5
TOB55
TOFA
BTG family, member 3 BTG3 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] affects cotreatment
/ affects response to substance
mRNA 16896004
D017239 10950 BTG3
ANA
TOB5
TOB55
TOFA
BTG family, member 3 Paclitaxel results in increased expression of BTG3 protein increases expression
protein 15907983
D017239 701 BUB1B
BUB1beta
BUBR1
Bub1A
MAD3L
MVA1
SSK1
hBUBR1
BUB1 mitotic checkpoint serine/threonine kinase B (EC:2.7.11.1) [arsenic trioxide co-treated with Paclitaxel] promotes the reaction [BUB1B protein binds to CDC20 protein] affects binding
/ affects cotreatment
/ increases reaction
protein 19781537
D017239 701 BUB1B
BUB1beta
BUBR1
Bub1A
MAD3L
MVA1
SSK1
hBUBR1
BUB1 mitotic checkpoint serine/threonine kinase B (EC:2.7.11.1) [arsenic trioxide co-treated with Paclitaxel] results in increased expression of BUB1B protein modified form affects cotreatment
/ increases expression
protein 19781537
D017239 701 BUB1B
BUB1beta
BUBR1
Bub1A
MAD3L
MVA1
SSK1
hBUBR1
BUB1 mitotic checkpoint serine/threonine kinase B (EC:2.7.11.1) BUB1B protein affects the susceptibility to Paclitaxel affects response to substance
protein 18691855
D017239 9184 BUB3
BUB3L
hBUB3
BUB3 mitotic checkpoint protein Paclitaxel results in increased expression of BUB3 protein increases expression
protein 15907983
D017239 57035 C1orf63
DJ465N24.2.1
NPD014
RP3-465N24.4
chromosome 1 open reading frame 63 C1ORF63 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 771 CA12
CAXII
HsT18816
carbonic anhydrase XII (EC:4.2.1.1) CA12 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] affects cotreatment
/ affects response to substance
mRNA 16896004
D017239 816 CAMK2B
CAM2
CAMK2
CAMKB
calcium/calmodulin-dependent protein kinase II beta (EC:2.7.11.17) CAMK2B protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 4076 CAPRIN1
GPIAP1
GPIP137
M11S1
RNG105
p137GPI
cell cycle associated protein 1 Paclitaxel results in decreased expression of CAPRIN1 mRNA decreases expression
mRNA 18058816
D017239 843 CASP10
ALPS2
FLICE2
MCH4
caspase 10, apoptosis-related cysteine peptidase (EC:3.4.22.63) Paclitaxel results in increased expression of CASP10 mRNA increases expression
mRNA 18058816
D017239 100506742 CASP12
CASP-12
CASP12P1
caspase 12 (gene/pseudogene) Paclitaxel results in decreased expression of CASP12 protein decreases expression
protein 17701358
D017239 100506742 CASP12
CASP-12
CASP12P1
caspase 12 (gene/pseudogene) Paclitaxel results in increased expression of CASP12 protein increases expression
protein 18098270
D017239 100506742 CASP12
CASP-12
CASP12P1
caspase 12 (gene/pseudogene) [Tretinoin co-treated with Paclitaxel] results in increased expression of CASP12 protein affects cotreatment
/ increases expression
protein 17701358
D017239 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) [4-(6-cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-diethylbenzamide co-treated with Paclitaxel] results in increased activity of CASP3 protein affects cotreatment
/ increases activity
protein 16170024
D017239 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) [6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine co-treated with Paclitaxel] results in increased activity of CASP3 protein affects cotreatment
/ increases activity
protein 16170024
D017239 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) AKT1 protein affects the reaction [Paclitaxel results in increased activity of CASP3 protein] affects reaction
/ increases activity
protein 10075725
D017239 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) alvocidib promotes the reaction [Paclitaxel results in increased activity of CASP3 protein] increases activity
/ increases reaction
protein 10430095
D017239 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) ARHGDIA mRNA affects the reaction [Paclitaxel results in increased activity of CASP3 protein] affects reaction
/ increases activity
protein 17264767
D017239 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) CD40LG protein inhibits the reaction [Paclitaxel promotes the reaction [CASP3 protein results in increased cleavage of PARP protein]] decreases reaction
/ increases cleavage
/ increases reaction
protein 16545138
D017239 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) [Doxorubicin co-treated with Paclitaxel co-treated with Fluorouracil] results in increased activity of CASP3 protein affects cotreatment
/ increases activity
protein 16168113
D017239 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) [Doxorubicin co-treated with Paclitaxel] results in increased activity of CASP3 protein affects cotreatment
/ increases activity
protein 16168113
D017239 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) [esculetin co-treated with Paclitaxel] results in increased cleavage of and results in increased activity of CASP3 protein affects cotreatment
/ increases activity
/ increases cleavage
protein 16051289
D017239 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) IL8 inhibits the reaction [Paclitaxel results in increased activity of CASP3 protein] decreases reaction
/ increases activity
protein 21742513
D017239 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) inostamycin promotes the reaction [Paclitaxel results in increased expression of CASP3 protein modified form] increases expression
/ increases reaction
protein 9818034
D017239 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) MAP2K4 protein affects the reaction [Paclitaxel results in increased activity of CASP3 protein] affects reaction
/ increases activity
protein 10075725
D017239 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) MAP3K5 protein affects the reaction [Paclitaxel results in increased activity of CASP3 protein] affects reaction
/ increases activity
protein 10075725
D017239 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) MAPK8 protein affects the reaction [Paclitaxel results in increased activity of CASP3 protein] affects reaction
/ increases activity
protein 10075725
D017239 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Nicotine inhibits the reaction [Paclitaxel results in increased activity of CASP3 protein] decreases reaction
/ increases activity
protein 20106947
D017239 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) [Paclitaxel co-treated with Cisplatin] results in increased activity of CASP3 protein affects cotreatment
/ increases activity
protein 12709826
D017239 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Paclitaxel promotes the reaction [arsenic tetraoxide results in increased activity of CASP3 protein] increases activity
/ increases reaction
protein 19424586
D017239 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Paclitaxel promotes the reaction [CASP3 protein results in increased cleavage of PARP protein] increases cleavage
/ increases reaction
protein 16545138
D017239 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Paclitaxel results in increased activity of and results in increased cleavage of CASP3 protein increases activity
/ increases cleavage
protein 10516758
17399942
D017239 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Paclitaxel results in increased activity of CASP3 protein increases activity
protein 10075725
10430095
10733772
10822281
11716366
11774260
12086014
12709826
17264767
17701358
18098270
20106947
21742513
D017239 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Paclitaxel results in increased cleavage of and results in increased activity of CASP3 protein increases activity
/ increases cleavage
protein 18521433
19815708
D017239 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Paclitaxel results in increased cleavage of CASP3 protein increases cleavage
protein 15492279
18071906
D017239 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Paclitaxel results in increased expression of and results in increased activity of CASP3 protein increases activity
/ increases expression
protein 16140185
D017239 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Paclitaxel results in increased expression of CASP3 mRNA increases expression
mRNA 16140185
D017239 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Paclitaxel results in increased expression of CASP3 protein increases expression
protein 18098270
D017239 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Paclitaxel results in increased expression of CASP3 protein modified form increases expression
protein 9818034
D017239 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) [PD168393 co-treated with Paclitaxel] results in increased cleavage of and results in increased activity of CASP3 protein affects cotreatment
/ increases activity
/ increases cleavage
protein 16413505
D017239 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) [pifithrin co-treated with Paclitaxel] results in increased cleavage of and results in increased activity of CASP3 protein affects cotreatment
/ increases activity
/ increases cleavage
protein 18516295
D017239 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) [Sirolimus co-treated with Paclitaxel] results in increased cleavage of CASP3 protein affects cotreatment
/ increases cleavage
protein 15753396
D017239 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) [tipifarnib co-treated with Paclitaxel] results in increased activity of CASP3 protein affects cotreatment
/ increases activity
protein 15728126
D017239 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) [Tretinoin co-treated with Paclitaxel] results in increased activity of CASP3 protein affects cotreatment
/ increases activity
protein 17701358
D017239 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) TYMP mutant form promotes the reaction [Paclitaxel results in increased cleavage of CASP3 protein] increases cleavage
/ increases reaction
protein 15492279
D017239 837 CASP4
ICE(rel)II
ICEREL-II
ICH-2
Mih1/TX
TX
caspase 4, apoptosis-related cysteine peptidase (EC:3.4.22.57) Paclitaxel results in increased expression of CASP4 mRNA increases expression
mRNA 18058816
D017239 838 CASP5
ICE(rel)III
ICEREL-III
ICH-3
caspase 5, apoptosis-related cysteine peptidase (EC:3.4.22.58) Paclitaxel results in increased expression of CASP5 mRNA increases expression
mRNA 18058816
D017239 838 CASP5
ICE(rel)III
ICEREL-III
ICH-3
caspase 5, apoptosis-related cysteine peptidase (EC:3.4.22.58) Paclitaxel results in increased expression of CASP5 protein increases expression
protein 15907983
D017239 840 CASP7
CASP-7
CMH-1
ICE-LAP3
LICE2
MCH3
caspase 7, apoptosis-related cysteine peptidase (EC:3.4.22.60) [Doxorubicin co-treated with Paclitaxel co-treated with Fluorouracil] results in increased activity of CASP7 protein affects cotreatment
/ increases activity
protein 16168113
D017239 840 CASP7
CASP-7
CMH-1
ICE-LAP3
LICE2
MCH3
caspase 7, apoptosis-related cysteine peptidase (EC:3.4.22.60) Paclitaxel results in increased expression of CASP7 mRNA increases expression
mRNA 18058816
D017239 840 CASP7
CASP-7
CMH-1
ICE-LAP3
LICE2
MCH3
caspase 7, apoptosis-related cysteine peptidase (EC:3.4.22.60) [resveratrol co-treated with Paclitaxel] results in increased cleavage of and results in increased activity of CASP7 protein affects cotreatment
/ increases activity
/ increases cleavage
protein 14749477
D017239 840 CASP7
CASP-7
CMH-1
ICE-LAP3
LICE2
MCH3
caspase 7, apoptosis-related cysteine peptidase (EC:3.4.22.60) [Sirolimus co-treated with Paclitaxel] results in increased cleavage of CASP7 protein affects cotreatment
/ increases cleavage
protein 15753396
D017239 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) [Doxorubicin co-treated with Paclitaxel co-treated with Fluorouracil] results in increased activity of CASP8 protein affects cotreatment
/ increases activity
protein 16168113
D017239 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) [Doxorubicin co-treated with Paclitaxel] results in increased activity of CASP8 protein affects cotreatment
/ increases activity
protein 16168113
D017239 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) [esculetin co-treated with Paclitaxel] results in increased cleavage of and results in increased activity of CASP8 protein affects cotreatment
/ increases activity
/ increases cleavage
protein 16051289
D017239 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) Paclitaxel results in increased activity of CASP8 protein increases activity
protein 11716366
D017239 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) Paclitaxel results in increased cleavage of CASP8 protein increases cleavage
protein 18071906
18098270
D017239 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) Paclitaxel results in increased expression of CASP8 mRNA increases expression
mRNA 18058816
D017239 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) Paclitaxel results in increased expression of CASP8 protein increases expression
protein 15907983
D017239 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) [resveratrol co-treated with Paclitaxel] results in increased cleavage of and results in increased activity of CASP8 protein affects cotreatment
/ increases activity
/ increases cleavage
protein 14749477
D017239 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) [Tretinoin co-treated with Paclitaxel] results in increased cleavage of CASP8 protein affects cotreatment
/ increases cleavage
protein 18098270
D017239 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) [TYMP mutant form co-treated with Paclitaxel] results in increased cleavage of CASP8 protein affects cotreatment
/ increases cleavage
protein 15492279
D017239 842 CASP9
APAF-3
APAF3
ICE-LAP6
MCH6
PPP1R56
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) [4-(6-cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-diethylbenzamide co-treated with Paclitaxel] results in increased activity of CASP9 protein affects cotreatment
/ increases activity
protein 16170024
D017239 842 CASP9
APAF-3
APAF3
ICE-LAP6
MCH6
PPP1R56
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) [6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine co-treated with Paclitaxel] results in increased activity of CASP9 protein affects cotreatment
/ increases activity
protein 16170024
D017239 842 CASP9
APAF-3
APAF3
ICE-LAP6
MCH6
PPP1R56
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) [benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone results in decreased activity of CASP9 protein] affects the reaction [SOD2 protein results in decreased susceptibility to Paclitaxel] affects reaction
/ decreases activity
/ decreases response to substance
protein 18594523
D017239 842 CASP9
APAF-3
APAF3
ICE-LAP6
MCH6
PPP1R56
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) [benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone results in decreased activity of CASP9 protein] which results in decreased susceptibility to Paclitaxel decreases activity
/ decreases response to substance
protein 18594523
D017239 842 CASP9
APAF-3
APAF3
ICE-LAP6
MCH6
PPP1R56
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) CASP9 protein affects the susceptibility to Paclitaxel affects response to substance
protein 17652622
D017239 842 CASP9
APAF-3
APAF3
ICE-LAP6
MCH6
PPP1R56
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) [Doxorubicin co-treated with Paclitaxel] results in increased activity of CASP9 protein affects cotreatment
/ increases activity
protein 16168113
D017239 842 CASP9
APAF-3
APAF3
ICE-LAP6
MCH6
PPP1R56
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) Fluorouracil promotes the reaction [[Doxorubicin co-treated with Paclitaxel] results in increased activity of CASP9 protein] affects cotreatment
/ increases activity
/ increases reaction
protein 16168113
D017239 842 CASP9
APAF-3
APAF3
ICE-LAP6
MCH6
PPP1R56
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) Paclitaxel results in increased activity of CASP9 protein increases activity
protein 18098270
D017239 842 CASP9
APAF-3
APAF3
ICE-LAP6
MCH6
PPP1R56
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) Paclitaxel results in increased expression of CASP9 mRNA increases expression
mRNA 18058816
D017239 842 CASP9
APAF-3
APAF3
ICE-LAP6
MCH6
PPP1R56
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) Paclitaxel results in increased expression of CASP9 protein increases expression
protein 15907983
D017239 842 CASP9
APAF-3
APAF3
ICE-LAP6
MCH6
PPP1R56
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) [resveratrol co-treated with Paclitaxel] results in increased cleavage of and results in increased activity of CASP9 protein affects cotreatment
/ increases activity
/ increases cleavage
protein 14749477
D017239 842 CASP9
APAF-3
APAF3
ICE-LAP6
MCH6
PPP1R56
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) [Sirolimus co-treated with Paclitaxel] results in increased cleavage of CASP9 protein affects cotreatment
/ increases cleavage
protein 15753396
D017239 842 CASP9
APAF-3
APAF3
ICE-LAP6
MCH6
PPP1R56
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) [Tretinoin co-treated with Paclitaxel] results in increased cleavage of and results in increased activity of CASP9 protein affects cotreatment
/ increases activity
/ increases cleavage
protein 17701358
D017239 847 CAT
catalase (EC:1.11.1.6) CAT protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 847 CAT
catalase (EC:1.11.1.6) CAT results in increased susceptibility to Paclitaxel increases response to substance
21689642
D017239 857 CAV1
BSCL3
CGL3
MSTP085
PPH3
VIP21
CAV
caveolin 1, caveolae protein, 22kDa CAV1 mRNA results in increased susceptibility to Paclitaxel increases response to substance
mRNA 16322897
D017239 55749 CCAR1
RP11-437A18.1
cell division cycle and apoptosis regulator 1 Paclitaxel results in increased expression of CCAR1 mRNA increases expression
mRNA 18058816
D017239 6347 CCL2
GDCF-2
HC11
HSMCR30
MCAF
MCP-1
MCP1
SCYA2
SMC-CF
chemokine (C-C motif) ligand 2 CCL2 results in increased susceptibility to Paclitaxel increases response to substance
21187454
D017239 891 CCNB1
CCNB
cyclin B1 alvocidib inhibits the reaction [Paclitaxel results in increased expression of CCNB1 protein] decreases reaction
/ increases expression
protein 10430095
D017239 891 CCNB1
CCNB
cyclin B1 CCNB1 protein results in increased susceptibility to Paclitaxel increases response to substance
protein 16849574
D017239 891 CCNB1
CCNB
cyclin B1 CDK7 protein affects the reaction [Paclitaxel results in increased activity of [CDK2 protein binds to CCNB1 protein]] affects binding
/ affects reaction
/ increases activity
protein 14646529
D017239 891 CCNB1
CCNB
cyclin B1 Paclitaxel results in increased activity of [CDK2 protein binds to CCNB1 protein] affects binding
/ increases activity
protein 14646529
D017239 891 CCNB1
CCNB
cyclin B1 Paclitaxel results in increased expression of and results in increased activity of CCNB1 protein increases activity
/ increases expression
protein 16356831
D017239 891 CCNB1
CCNB
cyclin B1 Paclitaxel results in increased expression of CCNB1 protein increases expression
protein 10430095
D017239 891 CCNB1
CCNB
cyclin B1 [pifithrin co-treated with Paclitaxel] results in increased expression of CCNB1 protein affects cotreatment
/ increases expression
protein 18516295
D017239 9133 CCNB2
HsT17299
cyclin B2 CCNB2 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 595 CCND1
BCL1
D11S287E
PRAD1
U21B31
cyclin D1 Curcumin inhibits the reaction [Paclitaxel results in increased expression of CCND1 protein] decreases reaction
/ increases expression
protein 16243823
D017239 9134 CCNE2
CYCE2
cyclin E2 Paclitaxel results in decreased expression of CCNE2 mRNA decreases expression
mRNA 15000894
D017239 902 CCNH
CAK
p34
p37
cyclin H Paclitaxel results in increased expression of CCNH protein increases expression
protein 15907983
D017239 100133941 CD24
CD24A
CD24 molecule Paclitaxel results in decreased expression of CD24 mRNA decreases expression
mRNA 19682730
D017239 29126 CD274
B7-H
B7H1
PD-L1
PDCD1L1
PDCD1LG1
PDL1
CD274 molecule Paclitaxel results in increased expression of CD274 protein increases expression
protein 17920123
D017239 959 CD40LG
CD154
CD40L
HIGM1
IGM
IMD3
T-BAM
TNFSF5
TRAP
gp39
hCD40L
CD40 ligand CD40LG protein inhibits the reaction [Paclitaxel promotes the reaction [CASP3 protein results in increased cleavage of PARP protein]] decreases reaction
/ increases cleavage
/ increases reaction
protein 16545138
D017239 959 CD40LG
CD154
CD40L
HIGM1
IGM
IMD3
T-BAM
TNFSF5
TRAP
gp39
hCD40L
CD40 ligand CD40LG protein results in decreased susceptibility to Paclitaxel decreases response to substance
protein 16545138
D017239 4179 CD46
AHUS2
MCP
MIC10
TLX
TRA2.10
CD46 molecule, complement regulatory protein CD46 mRNA results in increased susceptibility to Paclitaxel increases response to substance
mRNA 16322897
D017239 961 CD47
IAP
MER6
OA3
CD47 molecule CD47 mRNA results in decreased susceptibility to Paclitaxel decreases response to substance
mRNA 16322897
D017239 978 CDA
CDD
cytidine deaminase (EC:3.5.4.5) CDA protein affects the susceptibility to Paclitaxel affects response to substance
protein 18728667
D017239 8555 CDC14B
CDC14B3
Cdc14B1
Cdc14B2
hCDC14B
cell division cycle 14B (EC:3.1.3.16 3.1.3.48) Paclitaxel results in decreased expression of CDC14B mRNA decreases expression
mRNA 18058816
D017239 991 CDC20
CDC20A
bA276H19.3
p55CDC
cell division cycle 20 [arsenic trioxide co-treated with Paclitaxel] promotes the reaction [BUB1B protein binds to CDC20 protein] affects binding
/ affects cotreatment
/ increases reaction
protein 19781537
D017239 995 CDC25C
CDC25
PPP1R60
cell division cycle 25C (EC:3.1.3.48) [arsenic trioxide co-treated with Paclitaxel] results in increased expression of CDC25C protein modified form affects cotreatment
/ increases expression
protein 19781537
D017239 995 CDC25C
CDC25
PPP1R60
cell division cycle 25C (EC:3.1.3.48) Paclitaxel results in decreased expression of CDC25C mRNA decreases expression
mRNA 18058816
D017239 995 CDC25C
CDC25
PPP1R60
cell division cycle 25C (EC:3.1.3.48) [pifithrin co-treated with Paclitaxel] results in increased phosphorylation of CDC25C protein affects cotreatment
/ increases phosphorylation
protein 18516295
D017239 996 CDC27
ANAPC3
APC3
CDC27Hs
D0S1430E
D17S978E
HNUC
NUC2
cell division cycle 27 [arsenic trioxide co-treated with Paclitaxel] results in increased expression of CDC27 protein modified form affects cotreatment
/ increases expression
protein 19781537
D017239 988 CDC5L
CDC5
CDC5-LIKE
CEF1
PCDC5RP
dJ319D22.1
cell division cycle 5-like Paclitaxel results in decreased expression of CDC5L mRNA decreases expression
mRNA 18058816
D017239 79577 CDC73
C1orf28
HPTJT
HRPT2
HYX
cell division cycle 73 Paclitaxel results in decreased expression of CDC73 mRNA decreases expression
mRNA 18058816
D017239 83879 CDCA7
JPO1
cell division cycle associated 7 Paclitaxel results in decreased expression of CDCA7 mRNA decreases expression
mRNA 18058816
D017239 1009 CDH11
CAD11
CDHOB
OB
OSF-4
cadherin 11, type 2, OB-cadherin (osteoblast) Paclitaxel results in increased expression of CDH11 mRNA increases expression
mRNA 19682730
D017239 983 CDK1
CDC2
CDC28A
P34CDC2
cyclin-dependent kinase 1 (EC:2.7.11.23 2.7.11.22) [arsenic trioxide co-treated with Paclitaxel] results in increased activity of CDK1 protein affects cotreatment
/ increases activity
protein 19781537
D017239 983 CDK1
CDC2
CDC28A
P34CDC2
cyclin-dependent kinase 1 (EC:2.7.11.23 2.7.11.22) [arsenic trioxide co-treated with Paclitaxel] results in increased expression of CDK1 protein modified form affects cotreatment
/ increases expression
protein 19781537
D017239 983 CDK1
CDC2
CDC28A
P34CDC2
cyclin-dependent kinase 1 (EC:2.7.11.23 2.7.11.22) bryostatin 1 inhibits the reaction [Paclitaxel results in increased activity of CDK1 protein] decreases reaction
/ increases activity
protein 10516758
D017239 983 CDK1
CDC2
CDC28A
P34CDC2
cyclin-dependent kinase 1 (EC:2.7.11.23 2.7.11.22) Paclitaxel results in decreased expression of CDK1 mRNA decreases expression
mRNA 18058816
D017239 983 CDK1
CDC2
CDC28A
P34CDC2
cyclin-dependent kinase 1 (EC:2.7.11.23 2.7.11.22) Paclitaxel results in increased activity of CDK1 protein increases activity
protein 10516758
D017239 983 CDK1
CDC2
CDC28A
P34CDC2
cyclin-dependent kinase 1 (EC:2.7.11.23 2.7.11.22) [pifithrin co-treated with Paclitaxel] results in decreased phosphorylation of CDK1 protein affects cotreatment
/ decreases phosphorylation
protein 18516295
D017239 1017 CDK2
p33(CDK2)
cyclin-dependent kinase 2 (EC:2.7.11.22) alvocidib inhibits the reaction [Paclitaxel results in increased activity of CDK2 protein] decreases reaction
/ increases activity
protein 10430095
D017239 1017 CDK2
p33(CDK2)
cyclin-dependent kinase 2 (EC:2.7.11.22) CDK7 protein affects the reaction [Paclitaxel results in increased activity of [CDK2 protein binds to CCNB1 protein]] affects binding
/ affects reaction
/ increases activity
protein 14646529
D017239 1017 CDK2
p33(CDK2)
cyclin-dependent kinase 2 (EC:2.7.11.22) Paclitaxel results in increased activity of CDK2 protein increases activity
protein 10430095
14646529
D017239 1017 CDK2
p33(CDK2)
cyclin-dependent kinase 2 (EC:2.7.11.22) Paclitaxel results in increased activity of [CDK2 protein binds to CCNB1 protein] affects binding
/ increases activity
protein 14646529
D017239 23552 CDK20
CCRK
CDCH
P42
PNQALRE
cyclin-dependent kinase 20 (EC:2.7.11.22) Paclitaxel results in decreased expression of CDK20 mRNA decreases expression
mRNA 18058816
D017239 1022 CDK7
CAK1
CDKN7
HCAK
MO15
STK1
p39MO15
cyclin-dependent kinase 7 (EC:2.7.11.23 2.7.11.22) CDK7 protein affects the reaction [Paclitaxel results in increased activity of [CDK2 protein binds to CCNB1 protein]] affects binding
/ affects reaction
/ increases activity
protein 14646529
D017239 1022 CDK7
CAK1
CDKN7
HCAK
MO15
STK1
p39MO15
cyclin-dependent kinase 7 (EC:2.7.11.23 2.7.11.22) Paclitaxel results in increased activity of CDK7 protein increases activity
protein 14646529
D017239 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) [Doxorubicin co-treated with Paclitaxel] results in increased expression of CDKN1A protein affects cotreatment
/ increases expression
protein 16168113
D017239 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) Fluorouracil promotes the reaction [[Doxorubicin co-treated with Paclitaxel] results in increased expression of CDKN1A protein] affects cotreatment
/ increases expression
/ increases reaction
protein 16168113
D017239 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) Nicotine inhibits the reaction [Paclitaxel results in increased expression of CDKN1A protein] decreases reaction
/ increases expression
protein 16601104
D017239 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) Paclitaxel results in increased expression of CDKN1A protein increases expression
protein 16601104
18516295
D017239 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) [Paclitaxel results in increased expression of TP53 protein] which results in increased expression of CDKN1A mRNA increases expression
mRNA 9041188
D017239 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) [PD168393 co-treated with Paclitaxel] results in increased expression of CDKN1A protein affects cotreatment
/ increases expression
protein 16413505
D017239 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) pifithrin inhibits the reaction [Paclitaxel results in increased expression of CDKN1A protein] decreases reaction
/ increases expression
protein 18516295
D017239 1031 CDKN2C
INK4C
p18
p18-INK4C
cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) CDKN2C protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 1063 CENPF
CENF
PRO1779
hcp-1
centromere protein F, 350/400kDa Lovastatin promotes the reaction [Paclitaxel results in increased expression of CENPF protein] increases expression
/ increases reaction
protein 12467231
D017239 1063 CENPF
CENF
PRO1779
hcp-1
centromere protein F, 350/400kDa Mevalonic Acid inhibits the reaction [Paclitaxel results in increased expression of CENPF protein] decreases reaction
/ increases expression
protein 12467231
D017239 1063 CENPF
CENF
PRO1779
hcp-1
centromere protein F, 350/400kDa Paclitaxel results in increased expression of CENPF protein increases expression
protein 12467231
D017239 8837 CFLAR
CASH
CASP8AP1
CLARP
Casper
FLAME
FLAME-1
FLAME1
FLIP
I-FLICE
MRIT
c-FLIP
c-FLIPL
c-FLIPR
c-FLIPS
CASP8 and FADD-like apoptosis regulator CFLAR protein results in decreased susceptibility to Paclitaxel decreases response to substance
protein 16080463
D017239 55743 CHFR
RNF116
RNF196
checkpoint with forkhead and ring finger domains, E3 ubiquitin protein ligase CHFR protein modified form affects the susceptibility to Paclitaxel affects response to substance
protein 17786301
D017239 55743 CHFR
RNF116
RNF196
checkpoint with forkhead and ring finger domains, E3 ubiquitin protein ligase CHFR protein results in decreased susceptibility to Paclitaxel decreases response to substance
protein 17786301
D017239 1365 CLDN3
C7orf1
CPE-R2
CPETR2
HRVP1
RVP1
claudin 3 CLDN3 protein results in decreased susceptibility to Paclitaxel decreases response to substance
protein 16734730
D017239 6320 CLEC11A
CLECSF3
LSLCL
P47
SCGF
C-type lectin domain family 11, member A Paclitaxel results in increased expression of CLEC11A mRNA increases expression
mRNA 19682730
D017239 10845 CLPX
caseinolytic mitochondrial matrix peptidase chaperone subunit Paclitaxel results in increased expression of CLPX protein increases expression
protein 15907983
D017239 1191 CLU
APO-J
APOJ
CLI
CLU1
CLU2
KUB1
NA1/NA2
SGP-2
SGP2
SP-40
TRPM-2
TRPM2
clusterin CLU protein results in decreased susceptibility to Paclitaxel decreases response to substance
protein 15955107
16308731
D017239 80781 COL18A1
KNO
KNO1
KS
collagen, type XVIII, alpha 1 Paclitaxel results in increased expression of COL18A1 mRNA increases expression
mRNA 19682730
D017239 1277 COL1A1
OI4
collagen, type I, alpha 1 Paclitaxel results in increased expression of COL1A1 mRNA increases expression
mRNA 19682730
D017239 1278 COL1A2
OI4
collagen, type I, alpha 2 Paclitaxel results in increased expression of COL1A2 mRNA increases expression
mRNA 19682730
D017239 1282 COL4A1
HANAC
ICH
POREN1
arresten
collagen, type IV, alpha 1 Paclitaxel results in increased expression of COL4A1 mRNA increases expression
mRNA 19682730
D017239 1284 COL4A2
ICH
POREN2
collagen, type IV, alpha 2 Paclitaxel results in increased expression of COL4A2 mRNA increases expression
mRNA 19682730
D017239 1291 COL6A1
OPLL
collagen, type VI, alpha 1 Paclitaxel results in increased expression of COL6A1 mRNA increases expression
mRNA 19682730
D017239 1292 COL6A2
PP3610
collagen, type VI, alpha 2 Paclitaxel results in increased expression of COL6A2 mRNA increases expression
mRNA 19682730
D017239 1293 COL6A3
collagen, type VI, alpha 3 COL6A3 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 1294 COL7A1
EBD1
EBDCT
EBR1
collagen, type VII, alpha 1 COL7A1 protein results in increased susceptibility to Paclitaxel increases response to substance
protein 16734730
D017239 11316 COPE
epsilon-COP
coatomer protein complex, subunit epsilon COPE protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 1355 COX15
CEMCOX2
cytochrome c oxidase assembly homolog 15 (yeast) Paclitaxel results in decreased expression of COX15 mRNA decreases expression
mRNA 15000894
D017239 10063 COX17
COX17 cytochrome c oxidase copper chaperone COX17 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 8804 CREG1
CREG
cellular repressor of E1A-stimulated genes 1 CREG1 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 1440 CSF3
C17orf33
CSF3OS
GCSF
G-CSF
colony stimulating factor 3 (granulocyte) [CSF3 protein co-treated with Paclitaxel] results in decreased abundance of Choline affects cotreatment
/ decreases abundance
protein 9018096
D017239 1440 CSF3
C17orf33
CSF3OS
GCSF
G-CSF
colony stimulating factor 3 (granulocyte) [CSF3 protein co-treated with Paclitaxel] results in decreased abundance of Creatine affects cotreatment
/ decreases abundance
protein 9018096
D017239 1440 CSF3
C17orf33
CSF3OS
GCSF
G-CSF
colony stimulating factor 3 (granulocyte) [CSF3 protein co-treated with Paclitaxel] results in decreased abundance of Inositol affects cotreatment
/ decreases abundance
protein 9018096
D017239 10664 CTCF
MRD21
CCCTC-binding factor (zinc finger protein) CTCF mRNA results in decreased susceptibility to Paclitaxel decreases response to substance
mRNA 16322897
D017239 1499 CTNNB1
CTNNB
MRD19
armadillo
catenin (cadherin-associated protein), beta 1, 88kDa CTNNB1 results in decreased susceptibility to Paclitaxel decreases response to substance
22000491
D017239 1501 CTNND2
GT24
NPRAP
catenin (cadherin-associated protein), delta 2 CTNND2 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] affects cotreatment
/ affects response to substance
mRNA 16896004
D017239 1514 CTSL
CATL
CTSL1
MEP
cathepsin L (EC:3.4.22.15) CTSL mRNA results in increased susceptibility to Paclitaxel increases response to substance
mRNA 16322897
D017239 2017 CTTN
EMS1
cortactin Paclitaxel results in decreased expression of CTTN protein decreases expression
protein 15907983
D017239 6374 CXCL5
ENA-78
SCYB5
chemokine (C-X-C motif) ligand 5 CXCL5 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 7852 CXCR4
CD184
D2S201E
FB22
HM89
HSY3RR
LAP3
LCR1
LESTR
NPY3R
NPYR
NPYRL
NPYY3R
WHIM
chemokine (C-X-C motif) receptor 4 CXCR4 mRNA results in decreased susceptibility to Paclitaxel decreases response to substance
mRNA 16322897
D017239 10663 CXCR6
BONZO
CD186
STRL33
TYMSTR
chemokine (C-X-C motif) receptor 6 CXCR6 mRNA results in decreased susceptibility to Paclitaxel decreases response to substance
mRNA 16322897
D017239 54205 CYCS
CYC
HCS
THC4
cytochrome c, somatic [esculetin co-treated with Paclitaxel] affects the localization of CYCS protein affects cotreatment
/ affects localization
protein 16051289
D017239 54205 CYCS
CYC
HCS
THC4
cytochrome c, somatic Paclitaxel affects the localization of CYCS protein affects localization
protein 17404021
18521433
D017239 54205 CYCS
CYC
HCS
THC4
cytochrome c, somatic Paclitaxel results in increased expression of CYCS protein increases expression
protein 15907983
D017239 54205 CYCS
CYC
HCS
THC4
cytochrome c, somatic Paclitaxel results in increased secretion of CYCS protein increases secretion
protein 10516758
D017239 54205 CYCS
CYC
HCS
THC4
cytochrome c, somatic [PD168393 co-treated with Paclitaxel] affects the localization of CYCS protein affects cotreatment
/ affects localization
protein 16413505
D017239 54205 CYCS
CYC
HCS
THC4
cytochrome c, somatic [resveratrol co-treated with Paclitaxel] affects the localization of CYCS protein affects cotreatment
/ affects localization
protein 14749477
D017239 54205 CYCS
CYC
HCS
THC4
cytochrome c, somatic [tipifarnib co-treated with Paclitaxel] affects the localization of CYCS protein affects cotreatment
/ affects localization
protein 15728126
D017239 1588 CYP19A1
ARO
ARO1
CPV1
CYAR
CYP19
CYPXIX
P-450AROM
cytochrome P450, family 19, subfamily A, polypeptide 1 (EC:1.14.14.1) Paclitaxel results in increased activity of CYP19A1 protein increases activity
protein 14691014
D017239 1544 CYP1A2
CP12
P3-450
P450(PA)
cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) Paclitaxel results in decreased activity of CYP1A2 protein decreases activity
protein 19909766
D017239 1558 CYP2C8
CPC8
CYPIIC8
MP-12/MP-20
cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) Cyclohexenes analog inhibits the reaction [CYP2C8 protein results in increased metabolism of Paclitaxel] decreases reaction
/ increases metabolic processing
protein 20452209
D017239 1558 CYP2C8
CPC8
CYPIIC8
MP-12/MP-20
cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) CYP2C8 mRNA results in increased susceptibility to Paclitaxel increases response to substance
mRNA 15239142
D017239 1558 CYP2C8
CPC8
CYPIIC8
MP-12/MP-20
cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) CYP2C8 protein affects the metabolism of Paclitaxel affects metabolic processing
protein 15901749
15933212
D017239 1558 CYP2C8
CPC8
CYPIIC8
MP-12/MP-20
cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) CYP2C8 protein results in increased hydroxylation of Paclitaxel increases hydroxylation
protein 21964418
D017239 1558 CYP2C8
CPC8
CYPIIC8
MP-12/MP-20
cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) CYP2C8 protein results in increased metabolism of Paclitaxel increases metabolic processing
protein 12401345
12464242
15716363
16124035
17994679
19309152
20452209
D017239 1558 CYP2C8
CPC8
CYPIIC8
MP-12/MP-20
cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) CYP2C8 protein results in increased oxidation of Paclitaxel increases oxidation
protein 17478480
D017239 1558 CYP2C8
CPC8
CYPIIC8
MP-12/MP-20
cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) perfluorooctane sulfonic acid inhibits the reaction [CYP2C8 protein results in increased hydroxylation of Paclitaxel] decreases reaction
/ increases hydroxylation
protein 21964418
D017239 1559 CYP2C9
CPC9
CYP2C
CYP2C10
CYPIIC9
P450IIC9
cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) Paclitaxel results in decreased activity of CYP2C9 protein decreases activity
protein 19909766
D017239 1559 CYP2C9
CPC9
CYP2C
CYP2C10
CYPIIC9
P450IIC9
cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) Paclitaxel results in increased activity of CYP2C9 protein increases activity
protein 19202563
D017239 1565 CYP2D6
CPD6
CYP2D
CYP2D7AP
CYP2D7BP
CYP2D7P2
CYP2D8P2
CYP2DL1
CYPIID6
P450-DB1
P450C2D
P450DB1
cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) Paclitaxel results in decreased activity of CYP2D6 protein decreases activity
protein 19909766
D017239 1576 CYP3A4
CP33
CP34
CYP3A
CYP3A3
CYPIIIA3
CYPIIIA4
HLP
NF-25
P450C3
P450PCN1
cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) CYP3A4 protein affects the metabolism of Paclitaxel affects metabolic processing
protein 15901749
D017239 1576 CYP3A4
CP33
CP34
CYP3A
CYP3A3
CYPIIIA3
CYPIIIA4
HLP
NF-25
P450C3
P450PCN1
cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) CYP3A4 protein results in increased hydroxylation of Paclitaxel increases hydroxylation
protein 19695866
D017239 1576 CYP3A4
CP33
CP34
CYP3A
CYP3A3
CYPIIIA3
CYPIIIA4
HLP
NF-25
P450C3
P450PCN1
cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) Oxygen deficiency inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Paclitaxel] decreases reaction
/ increases hydroxylation
protein 19695866
D017239 1576 CYP3A4
CP33
CP34
CYP3A
CYP3A3
CYPIIIA3
CYPIIIA4
HLP
NF-25
P450C3
P450PCN1
cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) Paclitaxel results in decreased activity of CYP3A4 protein decreases activity
protein 19909766
D017239 1576 CYP3A4
CP33
CP34
CYP3A
CYP3A3
CYPIIIA3
CYPIIIA4
HLP
NF-25
P450C3
P450PCN1
cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) Paclitaxel results in increased activity of CYP3A4 protein increases activity
protein 12065438
18839173
D017239 1576 CYP3A4
CP33
CP34
CYP3A
CYP3A3
CYPIIIA3
CYPIIIA4
HLP
NF-25
P450C3
P450PCN1
cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) Paclitaxel results in increased expression of CYP3A4 mRNA increases expression
mRNA 15650019
18839173
D017239 1576 CYP3A4
CP33
CP34
CYP3A
CYP3A3
CYPIIIA3
CYPIIIA4
HLP
NF-25
P450C3
P450PCN1
cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) Paclitaxel results in increased expression of CYP3A4 protein increases expression
protein 15650019
18839173
D017239 3491 CYR61
CCN1
GIG1
IGFBP10
cysteine-rich, angiogenic inducer, 61 CYR61 protein results in increased susceptibility to Paclitaxel increases response to substance
protein 16734730
D017239 1635 DCTD
dCMP deaminase (EC:3.5.4.12) DCTD protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 9416 DDX23
PRPF28
SNRNP100
U5-100K
U5-100KD
prp28
DEAD (Asp-Glu-Ala-Asp) box polypeptide 23 (EC:3.6.4.13) DDX23 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 9191 DEDD
CASP8IP1
DEDD1
DEFT
FLDED1
death effector domain containing Paclitaxel results in decreased expression of DEDD mRNA decreases expression
mRNA 15000894
D017239 1676 DFFA
DFF-45
DFF1
ICAD
DNA fragmentation factor, 45kDa, alpha polypeptide Paclitaxel results in decreased expression of DFFA protein decreases expression
protein 15907983
D017239 1676 DFFA
DFF-45
DFF1
ICAD
DNA fragmentation factor, 45kDa, alpha polypeptide Paclitaxel results in increased cleavage of DFFA protein increases cleavage
protein 18098270
D017239 1676 DFFA
DFF-45
DFF1
ICAD
DNA fragmentation factor, 45kDa, alpha polypeptide [Tretinoin co-treated with Paclitaxel] results in increased cleavage of DFFA protein affects cotreatment
/ increases cleavage
protein 17701358
D017239 1718 DHCR24
DCE
Nbla03646
SELADIN1
seladin-1
24-dehydrocholesterol reductase (EC:1.3.1.72) DHCR24 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 56616 DIABLO
DFNA64
SMAC
diablo, IAP-binding mitochondrial protein Paclitaxel affects the localization of DIABLO protein affects localization
protein 18098270
D017239 56616 DIABLO
DFNA64
SMAC
diablo, IAP-binding mitochondrial protein Paclitaxel results in increased expression of DIABLO protein increases expression
protein 17701358
D017239 56616 DIABLO
DFNA64
SMAC
diablo, IAP-binding mitochondrial protein [resveratrol co-treated with Paclitaxel] affects the localization of DIABLO protein affects cotreatment
/ affects localization
protein 14749477
D017239 56616 DIABLO
DFNA64
SMAC
diablo, IAP-binding mitochondrial protein [Tretinoin co-treated with Paclitaxel] affects the localization of DIABLO protein affects cotreatment
/ affects localization
protein 18098270
D017239 56616 DIABLO
DFNA64
SMAC
diablo, IAP-binding mitochondrial protein [Tretinoin co-treated with Paclitaxel] results in increased expression of DIABLO protein affects cotreatment
/ increases expression
protein 17701358
D017239 9988 DMTF1
DMP1
DMTF
hDMP1
cyclin D binding myb-like transcription factor 1 Paclitaxel results in decreased expression of DMTF1 mRNA decreases expression
mRNA 15000894
D017239 1806 DPYD
DHP
DHPDHASE
DPD
dihydropyrimidine dehydrogenase (EC:1.3.1.2) Paclitaxel affects the expression of DPYD mRNA affects expression
mRNA 18630517
D017239 1806 DPYD
DHP
DHPDHASE
DPD
dihydropyrimidine dehydrogenase (EC:1.3.1.2) [Paclitaxel co-treated with doxifluridine] affects the expression of DPYD mRNA affects cotreatment
/ affects expression
mRNA 18630517
D017239 1806 DPYD
DHP
DHPDHASE
DPD
dihydropyrimidine dehydrogenase (EC:1.3.1.2) Paclitaxel results in decreased expression of DPYD mRNA decreases expression
mRNA 16568373
D017239 1832 DSP
DP
DPI
DPII
desmoplakin DSP protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 1845 DUSP3
VHR
dual specificity phosphatase 3 (EC:3.1.3.16 3.1.3.48) Paclitaxel results in decreased expression of DUSP3 mRNA decreases expression
mRNA 15000894
D017239 1869 E2F1
E2F-1
RBAP1
RBBP3
RBP3
E2F transcription factor 1 E2F1 protein results in increased susceptibility to Paclitaxel increases response to substance
protein 16849574
D017239 1871 E2F3
E2F-3
E2F transcription factor 3 E2F3 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] affects cotreatment
/ affects response to substance
mRNA 16896004
D017239 1875 E2F5
E2F-5
E2F transcription factor 5, p130-binding Paclitaxel results in increased expression of E2F5 mRNA increases expression
mRNA 15000894
D017239 1938 EEF2
EEF-2
EF-2
EF2
SCA26
eukaryotic translation elongation factor 2 Paclitaxel results in decreased expression of EEF2 mRNA decreases expression
mRNA 15000894
D017239 84455 EFCAB7
RP4-534K7.1
EF-hand calcium binding domain 7 EFCAB7 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 1942 EFNA1
B61
ECKLG
EFL1
EPLG1
LERK-1
LERK1
TNFAIP4
ephrin-A1 Paclitaxel results in decreased expression of EFNA1 mRNA decreases expression
mRNA 19682730
D017239 1950 EGF
HOMG4
URG
epidermal growth factor Paclitaxel inhibits the reaction [EGF protein results in increased expression of PSA mRNA] decreases reaction
/ increases expression
protein 20807808
D017239 1950 EGF
HOMG4
URG
epidermal growth factor Paclitaxel results in decreased expression of EGF mRNA decreases expression
mRNA 18058816
D017239 1956 EGFR
ERBB
ERBB1
HER1
PIG61
mENA
epidermal growth factor receptor (EC:2.7.10.1) Paclitaxel promotes the reaction [HER3 protein binds to EGFR protein] affects binding
/ increases reaction
protein 20726858
D017239 1956 EGFR
ERBB
ERBB1
HER1
PIG61
mENA
epidermal growth factor receptor (EC:2.7.10.1) Paclitaxel results in decreased expression of EGFR mRNA decreases expression
mRNA 18058816
D017239 1956 EGFR
ERBB
ERBB1
HER1
PIG61
mENA
epidermal growth factor receptor (EC:2.7.10.1) Paclitaxel results in increased phosphorylation of EGFR protein increases phosphorylation
protein 16211241
20726858
D017239 1956 EGFR
ERBB
ERBB1
HER1
PIG61
mENA
epidermal growth factor receptor (EC:2.7.10.1) [PD168393 co-treated with Paclitaxel] results in decreased phosphorylation of EGFR protein affects cotreatment
/ decreases phosphorylation
protein 16413505
D017239 26298 EHF
ESE3
ESE3B
ESEJ
ets homologous factor Paclitaxel results in decreased expression of EHF mRNA decreases expression
mRNA 19682730
D017239 9451 EIF2AK3
PEK
PERK
WRS
eukaryotic translation initiation factor 2-alpha kinase 3 (EC:2.7.11.1) EIF2AK3 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 1973 EIF4A1
DDX2A
EIF-4A
EIF4A
eIF-4A-I
eIF4A-I
eukaryotic translation initiation factor 4A1 (EC:3.6.4.13) Paclitaxel results in decreased expression of EIF4A1 protein decreases expression
protein 15907983
D017239 1984 EIF5A
EIF-5A
EIF5A1
eIF5AI
eukaryotic translation initiation factor 5A EIF5A protein results in increased susceptibility to Paclitaxel increases response to substance
protein 16734730
D017239 79767 ELMO3
CED-12
CED12
ELMO-3
engulfment and cell motility 3 Paclitaxel results in increased expression of ELMO3 protein increases expression
protein 15907983
D017239 2014 EMP3
YMP
epithelial membrane protein 3 Paclitaxel results in increased expression of EMP3 mRNA increases expression
mRNA 19682730
D017239 5168 ENPP2
ATX
ATX-X
AUTOTAXIN
LysoPLD
NPP2
PD-IALPHA
PDNP2
ectonucleotide pyrophosphatase/phosphodiesterase 2 (EC:3.1.4.39) Paclitaxel results in increased expression of ENPP2 mRNA increases expression
mRNA 19682730
D017239 4072 EPCAM
DIAR5
EGP-2
EGP314
EGP40
ESA
HNPCC8
KS1/4
KSA
M4S1
MIC18
MK-1
TACSTD1
TROP1
epithelial cell adhesion molecule [Paclitaxel co-treated with Carboplatin] results in increased expression of EPCAM protein affects cotreatment
/ increases expression
protein 12695858
D017239 4072 EPCAM
DIAR5
EGP-2
EGP314
EGP40
ESA
HNPCC8
KS1/4
KSA
M4S1
MIC18
MK-1
TACSTD1
TROP1
epithelial cell adhesion molecule Paclitaxel results in decreased expression of EPCAM mRNA decreases expression
mRNA 19682730
D017239 4072 EPCAM
DIAR5
EGP-2
EGP314
EGP40
ESA
HNPCC8
KS1/4
KSA
M4S1
MIC18
MK-1
TACSTD1
TROP1
epithelial cell adhesion molecule Paclitaxel results in decreased expression of EPCAM protein decreases expression
protein 15907983
D017239 4072 EPCAM
DIAR5
EGP-2
EGP314
EGP40
ESA
HNPCC8
KS1/4
KSA
M4S1
MIC18
MK-1
TACSTD1
TROP1
epithelial cell adhesion molecule Paclitaxel results in increased expression of EPCAM protein increases expression
protein 12695858
D017239 2056 EPO
EP
MVCD2
erythropoietin EPO protein results in decreased susceptibility to Paclitaxel decreases response to substance
protein 17010629
D017239 2064 ERBB2
CD340
HER-2
HER-2/neu
HER2
MLN_19
NEU
NGL
TKR1
v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (EC:2.7.10.1) 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in decreased susceptibility to Paclitaxel] decreases reaction
/ decreases response to substance
21712253
D017239 2064 ERBB2
CD340
HER-2
HER-2/neu
HER2
MLN_19
NEU
NGL
TKR1
v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (EC:2.7.10.1) 3,3'-diindolylmethane promotes the reaction [Paclitaxel results in decreased phosphorylation of and results in decreased activity of ERBB2 protein] decreases activity
/ decreases phosphorylation
/ increases reaction
protein 16580691
D017239 2064 ERBB2
CD340
HER-2
HER-2/neu
HER2
MLN_19
NEU
NGL
TKR1
v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (EC:2.7.10.1) 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [ERBB2 results in decreased susceptibility to Paclitaxel] decreases reaction
/ decreases response to substance
21712253
D017239 2064 ERBB2
CD340
HER-2
HER-2/neu
HER2
MLN_19
NEU
NGL
TKR1
v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (EC:2.7.10.1) ERBB2 protein affects the susceptibility to Paclitaxel affects response to substance
protein 10327070
D017239 2064 ERBB2
CD340
HER-2
HER-2/neu
HER2
MLN_19
NEU
NGL
TKR1
v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (EC:2.7.10.1) ERBB2 results in decreased susceptibility to Paclitaxel decreases response to substance
21712253
D017239 2064 ERBB2
CD340
HER-2
HER-2/neu
HER2
MLN_19
NEU
NGL
TKR1
v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (EC:2.7.10.1) [ERBB2 results in increased expression of ABCG2] which results in decreased susceptibility to Paclitaxel decreases response to substance
/ increases expression
21712253
D017239 2064 ERBB2
CD340
HER-2
HER-2/neu
HER2
MLN_19
NEU
NGL
TKR1
v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (EC:2.7.10.1) Paclitaxel results in decreased phosphorylation of and results in decreased activity of ERBB2 protein decreases activity
/ decreases phosphorylation
protein 16580691
D017239 2065 ERBB3
ErbB-3
HER3
LCCS2
MDA-BF-1
c-erbB-3
c-erbB3
erbB3-S
p180-ErbB3
p45-sErbB3
p85-sErbB3
v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 (EC:2.7.10.1) ERBB3 protein results in decreased susceptibility to Paclitaxel decreases response to substance
protein 16734730
D017239 2066 ERBB4
ALS19
HER4
p180erbB4
v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 4 (EC:2.7.10.1) ERBB4 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] affects cotreatment
/ affects response to substance
mRNA 16896004
D017239 2099 ESR1
ER
ESR
ESRA
ESTRR
Era
NR3A1
estrogen receptor 1 alitretinoin inhibits the reaction [Paclitaxel results in increased expression of ESR1 mRNA] decreases reaction
/ increases expression
mRNA 19340624
D017239 2099 ESR1
ER
ESR
ESRA
ESTRR
Era
NR3A1
estrogen receptor 1 beta Carotene inhibits the reaction [Paclitaxel results in increased expression of ESR1 mRNA] decreases reaction
/ increases expression
mRNA 19340624
D017239 2099 ESR1
ER
ESR
ESRA
ESTRR
Era
NR3A1
estrogen receptor 1 Paclitaxel inhibits the reaction [Tamoxifen binds to ESR1 protein] affects binding
/ decreases reaction
protein 15283693
D017239 2099 ESR1
ER
ESR
ESRA
ESTRR
Era
NR3A1
estrogen receptor 1 Paclitaxel results in increased expression of ESR1 mRNA increases expression
mRNA 19340624
D017239 2099 ESR1
ER
ESR
ESRA
ESTRR
Era
NR3A1
estrogen receptor 1 Vitamin A inhibits the reaction [Paclitaxel results in increased expression of ESR1 mRNA] decreases reaction
/ increases expression
mRNA 19340624
D017239 2100 ESR2
ER-BETA
ESR-BETA
ESRB
ESTRB
Erb
NR3A2
estrogen receptor 2 (ER beta) alitretinoin inhibits the reaction [Paclitaxel results in increased expression of ESR2 mRNA] decreases reaction
/ increases expression
mRNA 19340624
D017239 2100 ESR2
ER-BETA
ESR-BETA
ESRB
ESTRB
Erb
NR3A2
estrogen receptor 2 (ER beta) Paclitaxel results in increased expression of ESR2 mRNA increases expression
mRNA 19340624
D017239 2147 F2
PT
RPRGL2
THPH1
coagulation factor II (thrombin) (EC:3.4.21.5) anthra(1,9-cd)pyrazol-6(2H)-one inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased expression of F3 protein] affects cotreatment
/ decreases reaction
/ increases expression
protein 19944065
D017239 2147 F2
PT
RPRGL2
THPH1
coagulation factor II (thrombin) (EC:3.4.21.5) epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased activity of F3 protein] affects cotreatment
/ decreases reaction
/ increases activity
protein 19944065
D017239 2147 F2
PT
RPRGL2
THPH1
coagulation factor II (thrombin) (EC:3.4.21.5) epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased expression of F3 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
protein 19944065
D017239 2147 F2
PT
RPRGL2
THPH1
coagulation factor II (thrombin) (EC:3.4.21.5) epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased expression of F3 protein] affects cotreatment
/ decreases reaction
/ increases expression
protein 19944065
D017239 2147 F2
PT
RPRGL2
THPH1
coagulation factor II (thrombin) (EC:3.4.21.5) epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased phosphorylation of MAPK8 protein] affects cotreatment
/ decreases reaction
/ increases phosphorylation
protein 19944065
D017239 2147 F2
PT
RPRGL2
THPH1
coagulation factor II (thrombin) (EC:3.4.21.5) epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased phosphorylation of MAPK9 protein] affects cotreatment
/ decreases reaction
/ increases phosphorylation
protein 19944065
D017239 2147 F2
PT
RPRGL2
THPH1
coagulation factor II (thrombin) (EC:3.4.21.5) [Paclitaxel co-treated with F2 protein] affects the localization of RELA protein affects cotreatment
/ affects localization
protein 19944065
D017239 2147 F2
PT
RPRGL2
THPH1
coagulation factor II (thrombin) (EC:3.4.21.5) [Paclitaxel co-treated with F2 protein] results in increased activity of F3 protein affects cotreatment
/ increases activity
protein 19944065
D017239 2147 F2
PT
RPRGL2
THPH1
coagulation factor II (thrombin) (EC:3.4.21.5) [Paclitaxel co-treated with F2 protein] results in increased expression of F3 mRNA affects cotreatment
/ increases expression
protein 19944065
D017239 2147 F2
PT
RPRGL2
THPH1
coagulation factor II (thrombin) (EC:3.4.21.5) [Paclitaxel co-treated with F2 protein] results in increased expression of F3 protein affects cotreatment
/ increases expression
protein 19944065
D017239 2147 F2
PT
RPRGL2
THPH1
coagulation factor II (thrombin) (EC:3.4.21.5) [Paclitaxel co-treated with F2 protein] results in increased phosphorylation of MAPK8 protein affects cotreatment
/ increases phosphorylation
protein 19944065
D017239 2147 F2
PT
RPRGL2
THPH1
coagulation factor II (thrombin) (EC:3.4.21.5) [Paclitaxel co-treated with F2 protein] results in increased phosphorylation of MAPK9 protein affects cotreatment
/ increases phosphorylation
protein 19944065
D017239 2152 F3
CD142
TF
TFA
coagulation factor III (thromboplastin, tissue factor) anthra(1,9-cd)pyrazol-6(2H)-one inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased expression of F3 protein] affects cotreatment
/ decreases reaction
/ increases expression
protein 19944065
D017239 2152 F3
CD142
TF
TFA
coagulation factor III (thromboplastin, tissue factor) epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased activity of F3 protein] affects cotreatment
/ decreases reaction
/ increases activity
protein 19944065
D017239 2152 F3
CD142
TF
TFA
coagulation factor III (thromboplastin, tissue factor) epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased expression of F3 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 19944065
D017239 2152 F3
CD142
TF
TFA
coagulation factor III (thromboplastin, tissue factor) epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased expression of F3 protein] affects cotreatment
/ decreases reaction
/ increases expression
protein 19944065
D017239 2152 F3
CD142
TF
TFA
coagulation factor III (thromboplastin, tissue factor) [Paclitaxel co-treated with F2 protein] results in increased activity of F3 protein affects cotreatment
/ increases activity
protein 19944065
D017239 2152 F3
CD142
TF
TFA
coagulation factor III (thromboplastin, tissue factor) [Paclitaxel co-treated with F2 protein] results in increased expression of F3 mRNA affects cotreatment
/ increases expression
mRNA 19944065
D017239 2152 F3
CD142
TF
TFA
coagulation factor III (thromboplastin, tissue factor) [Paclitaxel co-treated with F2 protein] results in increased expression of F3 protein affects cotreatment
/ increases expression
protein 19944065
D017239 8772 FADD
MORT1
Fas (TNFRSF6)-associated via death domain anthra(1,9-cd)pyrazol-6(2H)-one inhibits the reaction [Paclitaxel results in increased phosphorylation of FADD protein] decreases reaction
/ increases phosphorylation
protein 16450001
D017239 8772 FADD
MORT1
Fas (TNFRSF6)-associated via death domain Paclitaxel results in increased expression of FADD mRNA increases expression
mRNA 18058816
D017239 8772 FADD
MORT1
Fas (TNFRSF6)-associated via death domain Paclitaxel results in increased phosphorylation of FADD protein increases phosphorylation
protein 16450001
D017239 10447 FAM3C
ILEI
family with sequence similarity 3, member C FAM3C protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 55120 FANCL
FAAP43
PHF9
POG
Fanconi anemia, complementation group L FANCL protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 355 FAS
ALPS1A
APO-1
APT1
CD95
FAS1
FASTM
TNFRSF6
Fas cell surface death receptor cacalol promotes the reaction [Paclitaxel results in decreased expression of FAS mRNA] decreases expression
/ increases reaction
mRNA 20665104
D017239 355 FAS
ALPS1A
APO-1
APT1
CD95
FAS1
FASTM
TNFRSF6
Fas cell surface death receptor [esculetin co-treated with Paclitaxel] results in increased expression of FAS protein affects cotreatment
/ increases expression
protein 16051289
D017239 355 FAS
ALPS1A
APO-1
APT1
CD95
FAS1
FASTM
TNFRSF6
Fas cell surface death receptor FAS protein results in increased susceptibility to Paclitaxel increases response to substance
protein 18074150
D017239 355 FAS
ALPS1A
APO-1
APT1
CD95
FAS1
FASTM
TNFRSF6
Fas cell surface death receptor Paclitaxel promotes the reaction [cacalol results in decreased expression of FAS mRNA] decreases expression
/ increases reaction
mRNA 20665104
D017239 355 FAS
ALPS1A
APO-1
APT1
CD95
FAS1
FASTM
TNFRSF6
Fas cell surface death receptor Paclitaxel results in decreased expression of FAS mRNA decreases expression
mRNA 20665104
D017239 355 FAS
ALPS1A
APO-1
APT1
CD95
FAS1
FASTM
TNFRSF6
Fas cell surface death receptor Paclitaxel results in increased expression of FAS protein increases expression
protein 18074150
D017239 356 FASLG
ALPS1B
APT1LG1
APTL
CD178
CD95-L
CD95L
FASL
TNFSF6
Fas ligand (TNF superfamily, member 6) [esculetin co-treated with Paclitaxel] results in increased expression of FASLG protein affects cotreatment
/ increases expression
protein 16051289
D017239 356 FASLG
ALPS1B
APT1LG1
APTL
CD178
CD95-L
CD95L
FASL
TNFSF6
Fas ligand (TNF superfamily, member 6) FASLG protein results in increased susceptibility to Paclitaxel increases response to substance
protein 18074150
D017239 356 FASLG
ALPS1B
APT1LG1
APTL
CD178
CD95-L
CD95L
FASL
TNFSF6
Fas ligand (TNF superfamily, member 6) Paclitaxel results in increased expression of FASLG mRNA increases expression
mRNA 15907805
D017239 356 FASLG
ALPS1B
APT1LG1
APTL
CD178
CD95-L
CD95L
FASL
TNFSF6
Fas ligand (TNF superfamily, member 6) Paclitaxel results in increased expression of FASLG protein increases expression
protein 10502406
11716366
15907805
18074150
D017239 356 FASLG
ALPS1B
APT1LG1
APTL
CD178
CD95-L
CD95L
FASL
TNFSF6
Fas ligand (TNF superfamily, member 6) TYMP inhibits the reaction [Paclitaxel results in increased expression of FASLG mRNA] decreases reaction
/ increases expression
mRNA 15907805
D017239 356 FASLG
ALPS1B
APT1LG1
APTL
CD178
CD95-L
CD95L
FASL
TNFSF6
Fas ligand (TNF superfamily, member 6) TYMP inhibits the reaction [Paclitaxel results in increased expression of FASLG protein] decreases reaction
/ increases expression
protein 15907805
D017239 2200 FBN1
ACMICD
ECTOL1
FBN
GPHYSD2
MASS
MFS1
OCTD
SGS
SSKS
WMS
WMS2
fibrillin 1 Paclitaxel results in increased expression of FBN1 mRNA increases expression
mRNA 19682730
D017239 2222 FDFT1
DGPT
ERG9
SQS
SS
farnesyl-diphosphate farnesyltransferase 1 (EC:2.5.1.21) FDFT1 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 2224 FDPS
FPPS
FPS
farnesyl diphosphate synthase (EC:2.5.1.1 2.5.1.10) FDPS mRNA results in increased susceptibility to Paclitaxel increases response to substance
mRNA 16322897
D017239 2247 FGF2
BFGF
FGF-2
FGFB
HBGF-2
fibroblast growth factor 2 (basic) FGF2 protein results in decreased susceptibility to Paclitaxel decreases response to substance
protein 16741658
D017239 2250 FGF5
HBGF-5
Smag-82
fibroblast growth factor 5 FGF5 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 2273 FHL1
FHL-1
FHL1A
FHL1B
FLH1A
KYOT
SLIM
SLIM-1
SLIM1
SLIMMER
XMPMA
four and a half LIM domains 1 FHL1 protein results in increased susceptibility to Paclitaxel increases response to substance
protein 16734730
D017239 6624 FSCN1
FAN1
HSN
SNL
p55
fascin homolog 1, actin-bundling protein (Strongylocentrotus purpuratus) FSCN1 protein results in increased susceptibility to Paclitaxel increases response to substance
protein 16734730
D017239 2495 FTH1
FHC
FTH
FTHL6
PIG15
PLIF
ferritin, heavy polypeptide 1 (EC:1.16.3.1) FTH1 mRNA results in decreased susceptibility to Paclitaxel decreases response to substance
mRNA 16322897
D017239 2512 FTL
NBIA3
ferritin, light polypeptide FTL mRNA results in decreased susceptibility to Paclitaxel decreases response to substance
mRNA 16322897
D017239 5045 FURIN
FUR
PACE
PCSK3
SPC1
furin (paired basic amino acid cleaving enzyme) (EC:3.4.21.75) FURIN mRNA results in decreased susceptibility to Paclitaxel decreases response to substance
mRNA 16322897
D017239 5349 FXYD3
MAT8
PLML
FXYD domain containing ion transport regulator 3 FXYD3 mRNA results in increased susceptibility to Paclitaxel increases response to substance
mRNA 16322897
D017239 5349 FXYD3
MAT8
PLML
FXYD domain containing ion transport regulator 3 Paclitaxel results in decreased expression of FXYD3 mRNA decreases expression
mRNA 19682730
D017239 1647 GADD45A
DDIT1
GADD45
growth arrest and DNA-damage-inducible, alpha GADD45A mRNA results in decreased susceptibility to Paclitaxel decreases response to substance
mRNA 16322897
D017239 1647 GADD45A
DDIT1
GADD45
growth arrest and DNA-damage-inducible, alpha [Paclitaxel results in increased expression of TP53 protein] which results in increased expression of GADD45A mRNA increases expression
mRNA 9041188
D017239 51809 GALNT7
GALNAC-T7
GalNAcT7
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7 (GalNAc-T7) (EC:2.4.1.41) GALNT7 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 2593 GAMT
CCDS2
PIG2
TP53I2
guanidinoacetate N-methyltransferase (EC:2.1.1.2) GAMT mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] affects cotreatment
/ affects response to substance
mRNA 16896004
D017239 2644 GCHFR
GFRP
HsT16933
P35
GTP cyclohydrolase I feedback regulator GCHFR protein results in decreased susceptibility to Paclitaxel decreases response to substance
protein 16734730
D017239 2670 GFAP
glial fibrillary acidic protein Paclitaxel results in increased expression of GFAP protein increases expression
protein 18098270
D017239 2670 GFAP
glial fibrillary acidic protein [Tretinoin co-treated with Paclitaxel] results in increased expression of GFAP protein affects cotreatment
/ increases expression
protein 18098270
D017239 2673 GFPT1
CMSTA1
GFA
GFAT
GFAT_1
GFAT1
GFAT1m
GFPT
GFPT1L
MSLG
glutamine--fructose-6-phosphate transaminase 1 (EC:2.6.1.16) GFPT1 protein results in decreased susceptibility to Paclitaxel decreases response to substance
protein 16734730
D017239 2674 GFRA1
GDNFR
GDNFRA
GFR-ALPHA-1
RET1L
RETL1
TRNR1
GDNF family receptor alpha 1 GFRA1 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] affects cotreatment
/ affects response to substance
mRNA 16896004
D017239 2821 GPI
AMF
GNPI
NLK
PGI
PHI
SA-36
SA36
glucose-6-phosphate isomerase (EC:5.3.1.9) GPI protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 2859 GPR35
G protein-coupled receptor 35 GPR35 protein results in decreased susceptibility to Paclitaxel decreases response to substance
protein 16734730
D017239 2934 GSN
ADF
AGEL
gelsolin Paclitaxel results in decreased expression of GSN mRNA decreases expression
mRNA 15000894
D017239 2944 GSTM1
GST1
GSTM1-1
GSTM1a-1a
GSTM1b-1b
GTH4
GTM1
H-B
MU
MU-1
glutathione S-transferase mu 1 (EC:2.5.1.18) GSTM1 gene polymorphism affects the susceptibility to [Paclitaxel co-treated with Cisplatin] affects cotreatment
/ affects response to substance
gene 12851839
D017239 2949 GSTM5
GSTM5-5
GTM5
glutathione S-transferase mu 5 (EC:2.5.1.18) GSTM5 mRNA results in decreased susceptibility to Paclitaxel decreases response to substance
mRNA 16322897
D017239 2950 GSTP1
DFN7
FAEES3
GST3
GSTP
PI
glutathione S-transferase pi 1 (EC:2.5.1.18) GSTP1 mRNA results in increased susceptibility to Paclitaxel increases response to substance
mRNA 15239142
D017239 2950 GSTP1
DFN7
FAEES3
GST3
GSTP
PI
glutathione S-transferase pi 1 (EC:2.5.1.18) GSTP1 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 2952 GSTT1
glutathione S-transferase theta 1 (EC:2.5.1.18) GSTT1 gene polymorphism affects the susceptibility to [Paclitaxel co-treated with Cisplatin] affects cotreatment
/ affects response to substance
gene 12851839
D017239 2969 GTF2I
BAP135
BTKAP1
DIWS
GTFII-I
IB291
SPIN
TFII-I
WBS
WBSCR6
general transcription factor IIi Paclitaxel results in decreased expression of GTF2I mRNA decreases expression
mRNA 15000894
D017239 51512 GTSE1
B99
G-2 and S-phase expressed 1 Paclitaxel results in increased expression of GTSE1 protein increases expression
protein 15907983
D017239 2990 GUSB
BG
MPS7
glucuronidase, beta (EC:3.2.1.31) GUSB protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 3014 H2AFX
H2A.X
H2A/X
H2AX
H2A histone family, member X Paclitaxel results in increased expression of H2AFX protein modified form increases expression
protein 18451153
D017239 9734 HDAC9
HD7
HD7b
HD9
HDAC
HDAC7
HDAC7B
HDAC9B
HDAC9FL
HDRP
MITR
histone deacetylase 9 (EC:3.5.1.98) HDAC9 protein results in increased susceptibility to Paclitaxel increases response to substance
protein 16734730
D017239 30289 Paclitaxel promotes the reaction [HER3 protein binds to EGFR protein] affects binding
/ increases reaction
protein 20726858
D017239 30289 Paclitaxel results in increased phosphorylation of HER3 protein increases phosphorylation
protein 20726858
D017239 3146 HMGB1
HMG1
HMG3
SBP-1
high mobility group box 1 HMGB1 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 9324 HMGN3
PNAS-25
TRIP7
high mobility group nucleosomal binding domain 3 HMGN3 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 3161 HMMR
CD168
IHABP
RHAMM
hyaluronan-mediated motility receptor (RHAMM) Paclitaxel results in decreased expression of HMMR protein decreases expression
protein 15907983
D017239 3181 HNRNPA2B1
HNRNPA2
HNRNPB1
HNRPA2
HNRPA2B1
HNRPB1
IBMPFD2
RNPA2
SNRPB1
heterogeneous nuclear ribonucleoprotein A2/B1 Paclitaxel results in decreased expression of HNRNPA2B1 mRNA decreases expression
mRNA 15000894
D017239 3182 HNRNPAB
ABBP1
HNRPAB
heterogeneous nuclear ribonucleoprotein A/B Paclitaxel results in decreased expression of HNRNPAB mRNA decreases expression
mRNA 15000894
D017239 3187 HNRNPH1
HNRPH
HNRPH1
hnRNPH
heterogeneous nuclear ribonucleoprotein H1 (H) Paclitaxel results in decreased expression of HNRNPH1 mRNA decreases expression
mRNA 15000894
D017239 51361 HOOK1
HK1
hook microtubule-tethering protein 1 Paclitaxel results in decreased expression of HOOK1 mRNA decreases expression
mRNA 19682730
D017239 3295 HSD17B4
DBP
MFE-2
MPF-2
PRLTS1
SDR8C1
hydroxysteroid (17-beta) dehydrogenase 4 (EC:4.2.1.107 4.2.1.119 1.1.1.n12) HSD17B4 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 3311 HSPA7
HSP70B
heat shock 70kDa protein 7 (HSP70B) Paclitaxel results in increased expression of HSPA7 protein increases expression
protein 15907983
D017239 8988 HSPB3
DHMN2C
HMN2C
HSPL27
heat shock 27kDa protein 3 Paclitaxel results in increased expression of HSPB3 protein increases expression
protein 15907983
D017239 3383 ICAM1
BB2
CD54
P3.58
intercellular adhesion molecule 1 Curcumin inhibits the reaction [Paclitaxel results in increased expression of ICAM1 protein] decreases reaction
/ increases expression
protein 16243823
D017239 3383 ICAM1
BB2
CD54
P3.58
intercellular adhesion molecule 1 Paclitaxel results in decreased expression of ICAM1 mRNA decreases expression
mRNA 12649748
18058816
D017239 3383 ICAM1
BB2
CD54
P3.58
intercellular adhesion molecule 1 Paclitaxel results in decreased expression of ICAM1 protein decreases expression
protein 12649748
D017239 3418 IDH2
D2HGA2
ICD-M
IDH
IDHM
IDP
IDPM
mNADP-IDH
isocitrate dehydrogenase 2 (NADP+), mitochondrial (EC:1.1.1.42) IDH2 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 3418 IDH2
D2HGA2
ICD-M
IDH
IDHM
IDP
IDPM
mNADP-IDH
isocitrate dehydrogenase 2 (NADP+), mitochondrial (EC:1.1.1.42) Paclitaxel results in decreased expression of IDH2 mRNA decreases expression
mRNA 15000894
D017239 10437 IFI30
GILT
IFI-30
IP30
interferon, gamma-inducible protein 30 IFI30 mRNA results in decreased susceptibility to Paclitaxel decreases response to substance
mRNA 16322897
D017239 3487 IGFBP4
BP-4
HT29-IGFBP
IBP4
IGFBP-4
insulin-like growth factor binding protein 4 IGFBP4 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] affects cotreatment
/ affects response to substance
mRNA 16896004
D017239 3487 IGFBP4
BP-4
HT29-IGFBP
IBP4
IGFBP-4
insulin-like growth factor binding protein 4 Paclitaxel results in increased expression of IGFBP4 mRNA increases expression
mRNA 19682730
D017239 3586 IL10
CSIF
GVHDS
IL-10
IL10A
TGIF
interleukin 10 Paclitaxel results in increased expression of IL10 protein increases expression
protein 14698135
D017239 3598 IL13RA2
CD213A2
CT19
IL-13R
IL13BP
interleukin 13 receptor, alpha 2 IL13RA2 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 55540 IL17RB
CRL4
EVI27
IL17BR
IL17RH1
interleukin 17 receptor B IL17RB protein results in decreased susceptibility to Paclitaxel decreases response to substance
protein 16734730
D017239 3554 IL1R1
CD121A
D2S1473
IL-1R-alpha
IL1R
IL1RA
P80
interleukin 1 receptor, type I Paclitaxel results in decreased expression of IL1R1 protein decreases expression
protein 15907983
D017239 3569 IL6
BSF2
HGF
HSF
IFNB2
IL-6
interleukin 6 (interferon, beta 2) Paclitaxel results in increased expression of IL6 protein increases expression
protein 14698135
D017239 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [IL8 results in decreased susceptibility to Paclitaxel] decreases reaction
/ decreases response to substance
21742513
D017239 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 IL8 inhibits the reaction [Paclitaxel results in increased activity of CASP3 protein] decreases reaction
/ increases activity
21742513
D017239 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 IL8 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 IL8 results in decreased susceptibility to Paclitaxel decreases response to substance
21742513
D017239 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 [IL8 results in increased expression of ABCB1 mRNA] which results in decreased susceptibility to Paclitaxel decreases response to substance
/ increases expression
21742513
D017239 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 [IL8 results in increased expression of ABCB1 protein] which results in decreased susceptibility to Paclitaxel decreases response to substance
/ increases expression
21742513
D017239 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 [IL8 results in increased expression of BCL2L1 mRNA] which results in decreased susceptibility to Paclitaxel decreases response to substance
/ increases expression
21742513
D017239 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 [IL8 results in increased expression of BCL2L1 protein] which results in decreased susceptibility to Paclitaxel decreases response to substance
/ increases expression
21742513
D017239 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 [IL8 results in increased expression of BCL2 mRNA] which results in decreased susceptibility to Paclitaxel decreases response to substance
/ increases expression
21742513
D017239 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 [IL8 results in increased expression of BCL2 protein] which results in decreased susceptibility to Paclitaxel decreases response to substance
/ increases expression
21742513
D017239 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 [IL8 results in increased expression of XIAP mRNA] which results in decreased susceptibility to Paclitaxel decreases response to substance
/ increases expression
21742513
D017239 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 [IL8 results in increased expression of XIAP protein] which results in decreased susceptibility to Paclitaxel decreases response to substance
/ increases expression
21742513
D017239 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 Paclitaxel inhibits the reaction [Vinblastine results in increased stability of IL8 mRNA] decreases reaction
/ increases stability
mRNA 16499908
D017239 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 Paclitaxel results in increased expression of IL8 protein increases expression
protein 14698135
D017239 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 wortmannin inhibits the reaction [IL8 results in decreased susceptibility to Paclitaxel] decreases reaction
/ decreases response to substance
21742513
D017239 3638 INSIG1
CL-6
CL6
insulin induced gene 1 INSIG1 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 9636 ISG15
G1P2
IFI15
IP17
UCRP
hUCRP
ISG15 ubiquitin-like modifier ISG15 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 3683 ITGAL
CD11A
LFA-1
LFA1A
integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide) Paclitaxel results in decreased expression of ITGAL mRNA decreases expression
mRNA 12649748
D017239 3683 ITGAL
CD11A
LFA-1
LFA1A
integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide) Paclitaxel results in decreased expression of ITGAL protein decreases expression
protein 12649748
D017239 9270 ITGB1BP1
ICAP-1A
ICAP-1B
ICAP-1alpha
ICAP1
ICAP1A
ICAP1B
integrin beta 1 binding protein 1 ITGB1BP1 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 3693 ITGB5
integrin, beta 5 ITGB5 mRNA results in decreased susceptibility to Paclitaxel decreases response to substance
mRNA 16322897
D017239 3694 ITGB6
integrin, beta 6 Paclitaxel results in decreased expression of ITGB6 mRNA decreases expression
mRNA 19682730
D017239 9445 ITM2B
ABRI
BRI
BRI2
BRICD2B
E25B
E3-16
FBD
imBRI2
integral membrane protein 2B ITM2B protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 3725 JUN
AP-1
AP1
c-Jun
jun proto-oncogene Paclitaxel results in increased phosphorylation of JUN protein increases phosphorylation
protein 15585644
D017239 3777 KCNK3
K2p3.1
OAT1
PPH4
TASK
TASK-1
TBAK1
potassium channel, subfamily K, member 3 Paclitaxel results in increased expression of KCNK3 protein increases expression
protein 15907983
D017239 3778 KCNMA1
BKTM
KCa1.1
MaxiK
SAKCA
SLO
SLO-ALPHA
SLO1
bA205K10.1
mSLO1
potassium large conductance calcium-activated channel, subfamily M, alpha member 1 KCNMA1 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 23030 KDM4B
JMJD2B
TDRD14B
lysine (K)-specific demethylase 4B KDM4B mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] affects cotreatment
/ affects response to substance
mRNA 16896004
D017239 9817 KEAP1
INrf2
KLHL19
kelch-like ECH-associated protein 1 [KEAP1 protein results in decreased stability of NFE2L2 protein] which results in increased susceptibility to Paclitaxel decreases stability
/ increases response to substance
protein 20530669
D017239 57613 KIAA1467 KIAA1467 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] affects cotreatment
/ affects response to substance
mRNA 16896004
D017239 11127 KIF3A
FLA10
KLP-20
kinesin family member 3A KIF3A mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] affects cotreatment
/ affects response to substance
mRNA 16896004
D017239 354 KLK3
APS
KLK2A1
PSA
hK3
kallikrein-related peptidase 3 (EC:3.4.21.77) [Paclitaxel co-treated with Carboplatin] results in decreased expression of KLK3 protein affects cotreatment
/ decreases expression
protein 16442593
D017239 354 KLK3
APS
KLK2A1
PSA
hK3
kallikrein-related peptidase 3 (EC:3.4.21.77) Paclitaxel inhibits the reaction [Dihydrotestosterone results in increased expression of KLK3 mRNA] decreases reaction
/ increases expression
mRNA 20807808
D017239 3860 KRT13
CK13
K13
keratin 13 KRT13 mRNA results in decreased susceptibility to Paclitaxel decreases response to substance
mRNA 16322897
D017239 3855 KRT7
CK7
K2C7
K7
SCL
keratin 7 KRT7 protein results in increased susceptibility to Paclitaxel increases response to substance
protein 16734730
D017239 3920 LAMP2
CD107b
LAMP-2
LAMPB
LGP110
lysosomal-associated membrane protein 2 LAMP2 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 3937 LCP2
SLP-76
SLP76
lymphocyte cytosolic protein 2 (SH2 domain containing leukocyte protein of 76kDa) Paclitaxel results in increased expression of LCP2 protein increases expression
protein 15907983
D017239 3949 LDLR
FH
FHC
LDLCQ2
low density lipoprotein receptor LDLR protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 3960 LGALS4
GAL4
L36LBP
lectin, galactoside-binding, soluble, 4 LGALS4 protein results in decreased susceptibility to Paclitaxel decreases response to substance
protein 16734730
D017239 3978 LIG1
ligase I, DNA, ATP-dependent (EC:6.5.1.1) Paclitaxel results in decreased expression of LIG1 mRNA decreases expression
mRNA 15000894
D017239 9516 LITAF
PIG7
SIMPLE
TP53I7
lipopolysaccharide-induced TNF factor LITAF protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 4053 LTBP2
C14orf141
GLC3D
LTBP3
MSPKA
MSTP031
WMS3
latent transforming growth factor beta binding protein 2 LTBP2 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 4085 MAD2L1
HSMAD2
MAD2
MAD2 mitotic arrest deficient-like 1 (yeast) MAD2L1 protein affects the susceptibility to Paclitaxel affects response to substance
protein 18691855
D017239 8567 MADD
DENN
IG20
RAB3GEP
MAP-kinase activating death domain Paclitaxel results in decreased expression of MADD mRNA decreases expression
mRNA 15000894
D017239 81631 MAP1LC3B
ATG8F
LC3B
MAP1A/1BLC3
MAP1LC3B-a
microtubule-associated protein 1 light chain 3 beta Paclitaxel results in increased expression of MAP1LC3B mRNA increases expression
mRNA 19815708
D017239 81631 MAP1LC3B
ATG8F
LC3B
MAP1A/1BLC3
MAP1LC3B-a
microtubule-associated protein 1 light chain 3 beta Paclitaxel results in increased expression of MAP1LC3B protein increases expression
protein 19815708
D017239 5604 MAP2K1
CFC3
MAPKK1
MEK1
MKK1
PRKMK1
mitogen-activated protein kinase kinase 1 (EC:2.7.12.2) [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of MAP2K1 protein] affects the reaction [SOD2 protein results in decreased susceptibility to Paclitaxel] affects reaction
/ decreases activity
/ decreases response to substance
protein 18594523
D017239 5604 MAP2K1
CFC3
MAPKK1
MEK1
MKK1
PRKMK1
mitogen-activated protein kinase kinase 1 (EC:2.7.12.2) [MAP2K1 protein affects the activity of [MAPK1 protein co-treated with MAPK3 protein]] affects the reaction [SOD2 protein results in decreased susceptibility to Paclitaxel] affects activity
/ affects cotreatment
/ affects reaction
/ decreases response to substance
protein 18594523
D017239 5604 MAP2K1
CFC3
MAPKK1
MEK1
MKK1
PRKMK1
mitogen-activated protein kinase kinase 1 (EC:2.7.12.2) [Tretinoin co-treated with Paclitaxel] results in decreased expression of MAP2K1 protein affects cotreatment
/ decreases expression
protein 18098270
D017239 6416 MAP2K4
JNKK
JNKK1
MAPKK4
MEK4
MKK4
PRKMK4
SAPKK-1
SAPKK1
SEK1
SERK1
SKK1
mitogen-activated protein kinase kinase 4 (EC:2.7.12.2) MAP2K4 protein affects the reaction [Paclitaxel results in increased activity of CASP3 protein] affects reaction
/ increases activity
protein 10075725
D017239 6416 MAP2K4
JNKK
JNKK1
MAPKK4
MEK4
MKK4
PRKMK4
SAPKK-1
SAPKK1
SEK1
SERK1
SKK1
mitogen-activated protein kinase kinase 4 (EC:2.7.12.2) MAP2K4 protein affects the reaction [Paclitaxel results in increased cleavage of PARP1 protein] affects reaction
/ increases cleavage
protein 10075725
D017239 4214 MAP3K1
MAPKKK1
MEKK
MEKK_1
MEKK1
SRXY6
mitogen-activated protein kinase kinase kinase 1, E3 ubiquitin protein ligase (EC:2.7.11.25) aspartyl-glutamyl-valyl-aspartal inhibits the reaction [Paclitaxel results in increased cleavage of MAP3K1 protein] decreases reaction
/ increases cleavage
protein 11160861
D017239 4214 MAP3K1
MAPKKK1
MEKK
MEKK_1
MEKK1
SRXY6
mitogen-activated protein kinase kinase kinase 1, E3 ubiquitin protein ligase (EC:2.7.11.25) MAP3K1 protein affects the reaction [Paclitaxel results in increased activity of MAPK8 protein] affects reaction
/ increases activity
protein 11160861
D017239 4214 MAP3K1
MAPKKK1
MEKK
MEKK_1
MEKK1
SRXY6
mitogen-activated protein kinase kinase kinase 1, E3 ubiquitin protein ligase (EC:2.7.11.25) MAP3K1 protein affects the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein] affects reaction
/ increases phosphorylation
protein 11160861
D017239 4214 MAP3K1
MAPKKK1
MEKK
MEKK_1
MEKK1
SRXY6
mitogen-activated protein kinase kinase kinase 1, E3 ubiquitin protein ligase (EC:2.7.11.25) Paclitaxel affects the localization of MAP3K1 protein affects localization
protein 11160861
D017239 4214 MAP3K1
MAPKKK1
MEKK
MEKK_1
MEKK1
SRXY6
mitogen-activated protein kinase kinase kinase 1, E3 ubiquitin protein ligase (EC:2.7.11.25) Paclitaxel promotes the reaction [MAPK8 protein binds to MAP3K1 protein modified form] affects binding
/ increases reaction
protein 11160861
D017239 4214 MAP3K1
MAPKKK1
MEKK
MEKK_1
MEKK1
SRXY6
mitogen-activated protein kinase kinase kinase 1, E3 ubiquitin protein ligase (EC:2.7.11.25) Paclitaxel results in increased cleavage of MAP3K1 protein increases cleavage
protein 11160861
D017239 4217 MAP3K5
ASK1
MAPKKK5
MEKK5
mitogen-activated protein kinase kinase kinase 5 (EC:2.7.11.25) MAP3K5 protein affects the reaction [Paclitaxel results in increased activity of CASP3 protein] affects reaction
/ increases activity
protein 10075725
D017239 4217 MAP3K5
ASK1
MAPKKK5
MEKK5
mitogen-activated protein kinase kinase kinase 5 (EC:2.7.11.25) MAP3K5 protein affects the reaction [Paclitaxel results in increased cleavage of PARP1 protein] affects reaction
/ increases cleavage
protein 10075725
D017239 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Paclitaxel results in increased activity of MAPK1 protein] decreases reaction
/ increases activity
protein 16211241
D017239 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) 3,3'-diindolylmethane promotes the reaction [Paclitaxel results in decreased phosphorylation of and results in decreased activity of MAPK1 protein] decreases activity
/ decreases phosphorylation
/ increases reaction
protein 16580691
D017239 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Paclitaxel results in increased activity of MAPK1 protein] decreases reaction
/ increases activity
protein 16211241
D017239 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) [esculetin co-treated with Paclitaxel] results in decreased expression of MAPK1 protein affects cotreatment
/ decreases expression
protein 16051289
D017239 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) [MAP2K1 protein affects the activity of [MAPK1 protein co-treated with MAPK3 protein]] affects the reaction [SOD2 protein results in decreased susceptibility to Paclitaxel] affects activity
/ affects cotreatment
/ affects reaction
/ decreases response to substance
protein 18594523
D017239 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) Nicotine inhibits the reaction [Paclitaxel results in increased activity of MAPK1 protein] decreases reaction
/ increases activity
protein 20106947
D017239 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) Paclitaxel results in decreased activity of MAPK1 protein decreases activity
protein 19815708
D017239 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) Paclitaxel results in decreased phosphorylation of and results in decreased activity of MAPK1 protein decreases activity
/ decreases phosphorylation
protein 16580691
D017239 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) Paclitaxel results in increased activity of MAPK1 protein increases activity
protein 16211241
20106947
D017239 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) Paclitaxel results in increased phosphorylation of and results in increased activity of MAPK1 protein increases activity
/ increases phosphorylation
protein 15907805
D017239 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) Paclitaxel results in increased phosphorylation of and results in increased expression of MAPK1 protein increases expression
/ increases phosphorylation
protein 16051289
D017239 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) Paclitaxel results in increased phosphorylation of MAPK1 protein increases phosphorylation
protein 12510025
18594523
D017239 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) [PD168393 co-treated with Paclitaxel] results in decreased phosphorylation of and results in decreased activity of MAPK1 protein affects cotreatment
/ decreases activity
/ decreases phosphorylation
protein 16413505
D017239 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) SOD2 protein affects the reaction [Paclitaxel results in increased phosphorylation of MAPK1 protein] affects reaction
/ increases phosphorylation
protein 18594523
D017239 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) U 0126 inhibits the reaction [Paclitaxel results in increased activity of MAPK1 protein] decreases reaction
/ increases activity
protein 16211241
20106947
D017239 5603 MAPK13
MAPK_13
MAPK-13
PRKM13
SAPK4
p38delta
mitogen-activated protein kinase 13 (EC:2.7.11.24) Paclitaxel results in increased expression of MAPK13 protein increases expression
protein 15907983
D017239 1432 MAPK14
CSBP
CSBP1
CSBP2
CSPB1
EXIP
Mxi2
PRKM14
PRKM15
RK
SAPK2A
p38
p38ALPHA
mitogen-activated protein kinase 14 (EC:2.7.11.24) [esculetin co-treated with Paclitaxel] results in decreased expression of MAPK14 protein affects cotreatment
/ decreases expression
protein 16051289
D017239 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Paclitaxel results in increased activity of MAPK3 protein] decreases reaction
/ increases activity
protein 16211241
D017239 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) 3,3'-diindolylmethane promotes the reaction [Paclitaxel results in decreased phosphorylation of and results in decreased activity of MAPK3 protein] decreases activity
/ decreases phosphorylation
/ increases reaction
protein 16580691
D017239 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Paclitaxel results in increased activity of MAPK3 protein] decreases reaction
/ increases activity
protein 16211241
D017239 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) [esculetin co-treated with Paclitaxel] results in decreased expression of MAPK3 protein affects cotreatment
/ decreases expression
protein 16051289
D017239 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) [MAP2K1 protein affects the activity of [MAPK1 protein co-treated with MAPK3 protein]] affects the reaction [SOD2 protein results in decreased susceptibility to Paclitaxel] affects activity
/ affects cotreatment
/ affects reaction
/ decreases response to substance
protein 18594523
D017239 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) Nicotine inhibits the reaction [Paclitaxel results in increased activity of MAPK3 protein] decreases reaction
/ increases activity
protein 20106947
D017239 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) Paclitaxel results in decreased phosphorylation of and results in decreased activity of MAPK3 protein decreases activity
/ decreases phosphorylation
protein 16580691
D017239 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) Paclitaxel results in increased activity of MAPK3 protein increases activity
protein 16211241
20106947
D017239 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) Paclitaxel results in increased phosphorylation of and results in increased activity of MAPK3 protein increases activity
/ increases phosphorylation
protein 15907805
D017239 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) Paclitaxel results in increased phosphorylation of and results in increased expression of MAPK3 protein increases expression
/ increases phosphorylation
protein 16051289
D017239 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) Paclitaxel results in increased phosphorylation of MAPK3 protein increases phosphorylation
protein 12510025
18098270
18594523
D017239 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) [PD168393 co-treated with Paclitaxel] results in decreased phosphorylation of and results in decreased activity of MAPK3 protein affects cotreatment
/ decreases activity
/ decreases phosphorylation
protein 16413505
D017239 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) SOD2 protein affects the reaction [Paclitaxel results in increased phosphorylation of MAPK3 protein] affects reaction
/ increases phosphorylation
protein 18594523
D017239 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) [Tretinoin co-treated with Paclitaxel] results in increased phosphorylation of MAPK3 protein affects cotreatment
/ increases phosphorylation
protein 18098270
D017239 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) U 0126 inhibits the reaction [Paclitaxel results in increased activity of MAPK3 protein] decreases reaction
/ increases activity
protein 16211241
20106947
D017239 5599 MAPK8
JNK
JNK-46
JNK1
JNK1A2
JNK21B1/2
PRKM8
SAPK1
SAPK1c
mitogen-activated protein kinase 8 (EC:2.7.11.24) aspartyl-glutamyl-valyl-aspartal inhibits the reaction [Paclitaxel results in increased activity of MAPK8 protein] decreases reaction
/ increases activity
protein 11160861
D017239 5599 MAPK8
JNK
JNK-46
JNK1
JNK1A2
JNK21B1/2
PRKM8
SAPK1
SAPK1c
mitogen-activated protein kinase 8 (EC:2.7.11.24) epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased phosphorylation of MAPK8 protein] affects cotreatment
/ decreases reaction
/ increases phosphorylation
protein 19944065
D017239 5599 MAPK8
JNK
JNK-46
JNK1
JNK1A2
JNK21B1/2
PRKM8
SAPK1
SAPK1c
mitogen-activated protein kinase 8 (EC:2.7.11.24) [esculetin co-treated with Paclitaxel] results in increased expression of MAPK8 protein affects cotreatment
/ increases expression
protein 16051289
D017239 5599 MAPK8
JNK
JNK-46
JNK1
JNK1A2
JNK21B1/2
PRKM8
SAPK1
SAPK1c
mitogen-activated protein kinase 8 (EC:2.7.11.24) MAP3K1 protein affects the reaction [Paclitaxel results in increased activity of MAPK8 protein] affects reaction
/ increases activity
protein 11160861
D017239 5599 MAPK8
JNK
JNK-46
JNK1
JNK1A2
JNK21B1/2
PRKM8
SAPK1
SAPK1c
mitogen-activated protein kinase 8 (EC:2.7.11.24) MAPK8 protein affects the reaction [Paclitaxel results in increased activity of CASP3 protein] affects reaction
/ increases activity
protein 10075725
D017239 5599 MAPK8
JNK
JNK-46
JNK1
JNK1A2
JNK21B1/2
PRKM8
SAPK1
SAPK1c
mitogen-activated protein kinase 8 (EC:2.7.11.24) MAPK8 protein affects the reaction [Paclitaxel results in increased cleavage of PARP1 protein] affects reaction
/ increases cleavage
protein 10075725
D017239 5599 MAPK8
JNK
JNK-46
JNK1
JNK1A2
JNK21B1/2
PRKM8
SAPK1
SAPK1c
mitogen-activated protein kinase 8 (EC:2.7.11.24) MAPK8 protein affects the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein] affects reaction
/ increases phosphorylation
protein 11160861
D017239 5599 MAPK8
JNK
JNK-46
JNK1
JNK1A2
JNK21B1/2
PRKM8
SAPK1
SAPK1c
mitogen-activated protein kinase 8 (EC:2.7.11.24) [Paclitaxel co-treated with F2 protein] results in increased phosphorylation of MAPK8 protein affects cotreatment
/ increases phosphorylation
protein 19944065
D017239 5599 MAPK8
JNK
JNK-46
JNK1
JNK1A2
JNK21B1/2
PRKM8
SAPK1
SAPK1c
mitogen-activated protein kinase 8 (EC:2.7.11.24) Paclitaxel promotes the reaction [MAPK8 protein binds to MAP3K1 protein modified form] affects binding
/ increases reaction
protein 11160861
D017239 5599 MAPK8
JNK
JNK-46
JNK1
JNK1A2
JNK21B1/2
PRKM8
SAPK1
SAPK1c
mitogen-activated protein kinase 8 (EC:2.7.11.24) Paclitaxel results in increased activity of MAPK8 protein increases activity
protein 11160861
D017239 5599 MAPK8
JNK
JNK-46
JNK1
JNK1A2
JNK21B1/2
PRKM8
SAPK1
SAPK1c
mitogen-activated protein kinase 8 (EC:2.7.11.24) Paclitaxel results in increased expression of MAPK8 protein increases expression
protein 16051289
D017239 5601 MAPK9
JNK-55
JNK2
JNK2A
JNK2ALPHA
JNK2B
JNK2BETA
PRKM9
SAPK
SAPK1a
p54a
p54aSAPK
mitogen-activated protein kinase 9 (EC:2.7.11.24) epigallocatechin gallate inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased phosphorylation of MAPK9 protein] affects cotreatment
/ decreases reaction
/ increases phosphorylation
protein 19944065
D017239 5601 MAPK9
JNK-55
JNK2
JNK2A
JNK2ALPHA
JNK2B
JNK2BETA
PRKM9
SAPK
SAPK1a
p54a
p54aSAPK
mitogen-activated protein kinase 9 (EC:2.7.11.24) [esculetin co-treated with Paclitaxel] results in increased expression of MAPK9 protein affects cotreatment
/ increases expression
protein 16051289
D017239 5601 MAPK9
JNK-55
JNK2
JNK2A
JNK2ALPHA
JNK2B
JNK2BETA
PRKM9
SAPK
SAPK1a
p54a
p54aSAPK
mitogen-activated protein kinase 9 (EC:2.7.11.24) [Paclitaxel co-treated with F2 protein] results in increased phosphorylation of MAPK9 protein affects cotreatment
/ increases phosphorylation
protein 19944065
D017239 5601 MAPK9
JNK-55
JNK2
JNK2A
JNK2ALPHA
JNK2B
JNK2BETA
PRKM9
SAPK
SAPK1a
p54a
p54aSAPK
mitogen-activated protein kinase 9 (EC:2.7.11.24) Paclitaxel results in increased expression of MAPK9 protein increases expression
protein 16051289
D017239 8550 MAPKAPK5
MAPKAP-K5
MK-5
MK5
PRAK
mitogen-activated protein kinase-activated protein kinase 5 (EC:2.7.11.1) MAPKAPK5 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 22919 MAPRE1
EB1
microtubule-associated protein, RP/EB family, member 1 olesoxime inhibits the reaction [Paclitaxel results in decreased localization of MAPRE1 protein] decreases localization
/ decreases reaction
protein 20417191
D017239 22919 MAPRE1
EB1
microtubule-associated protein, RP/EB family, member 1 Paclitaxel results in decreased localization of MAPRE1 protein decreases localization
protein 20417191
D017239 22924 MAPRE3
EB3
EBF3
EBF3-S
RP3
microtubule-associated protein, RP/EB family, member 3 olesoxime inhibits the reaction [Paclitaxel results in decreased localization of MAPRE3 protein] decreases localization
/ decreases reaction
protein 20417191
D017239 22924 MAPRE3
EB3
EBF3
EBF3-S
RP3
microtubule-associated protein, RP/EB family, member 3 Paclitaxel affects the localization of MAPRE3 protein affects localization
protein 20417191
D017239 4137 MAPT
DDPAC
FTDP-17
MAPTL
MSTD
MTBT1
MTBT2
PPND
TAU
microtubule-associated protein tau MAPT mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] affects cotreatment
/ affects response to substance
mRNA 16896004
D017239 4137 MAPT
DDPAC
FTDP-17
MAPTL
MSTD
MTBT1
MTBT2
PPND
TAU
microtubule-associated protein tau Paclitaxel results in decreased expression of MAPT mRNA decreases expression
mRNA 16930453
D017239 4137 MAPT
DDPAC
FTDP-17
MAPTL
MSTD
MTBT1
MTBT2
PPND
TAU
microtubule-associated protein tau Paclitaxel results in decreased expression of MAPT protein decreases expression
protein 16930453
D017239 4170 MCL1
BCL2L3
EAT
MCL1-ES
MCL1L
MCL1S
Mcl-1
TM
bcl2-L-3
mcl1/EAT
myeloid cell leukemia sequence 1 (BCL2-related) Paclitaxel results in decreased expression of MCL1 protein decreases expression
protein 14749477
D017239 4193 MDM2
ACTFS
HDMX
hdm2
MDM2 oncogene, E3 ubiquitin protein ligase MDM2 protein results in decreased susceptibility to Paclitaxel decreases response to substance
protein 13130078
D017239 5469 MED1
CRSP1
CRSP200
DRIP205
DRIP230
PBP
PPARBP
PPARGBP
RB18A
TRAP220
TRIP2
mediator complex subunit 1 Paclitaxel promotes the reaction [NR1I2 protein binds to MED1 protein] affects binding
/ increases reaction
protein 15650019
D017239 23389 MED13L
PROSIT240
THRAP2
TRAP240L
mediator complex subunit 13-like MED13L mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] affects cotreatment
/ affects response to substance
mRNA 16896004
D017239 29079 MED4
ARC36
DRIP36
HSPC126
TRAP36
VDRIP
mediator complex subunit 4 MED4 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 9833 MELK
HPK38
maternal embryonic leucine zipper kinase (EC:2.7.11.1 2.7.10.2) MELK mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] affects cotreatment
/ affects response to substance
mRNA 16896004
D017239 79006 METRN
C16orf23
c380A1.2
meteorin, glial cell differentiation regulator METRN mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] affects cotreatment
/ affects response to substance
mRNA 16896004
D017239 4277 MICB
PERB11.2
MHC class I polypeptide-related sequence B MICB protein results in increased susceptibility to Paclitaxel increases response to substance
protein 16734730
D017239 9761 MLEC
KIAA0152
malectin MLEC protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 4312 MMP1
CLG
CLGN
matrix metallopeptidase 1 (interstitial collagenase) (EC:3.4.24.7) MMP1 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 4325 MMP16
C8orf57
MMP-X2
MT-MMP2
MT-MMP3
MT3-MMP
matrix metallopeptidase 16 (membrane-inserted) (EC:3.4.24.-) Paclitaxel results in decreased expression of MMP16 mRNA decreases expression
mRNA 18058816
D017239 4326 MMP17
MT4-MMP
matrix metallopeptidase 17 (membrane-inserted) (EC:3.4.24.-) Paclitaxel results in decreased expression of MMP17 mRNA decreases expression
mRNA 18058816
D017239 4318 MMP9
CLG4B
GELB
MANDP2
MMP-9
matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) (EC:3.4.24.35) Curcumin inhibits the reaction [Paclitaxel results in increased expression of MMP9 protein] decreases reaction
/ increases expression
protein 16243823
D017239 5891 MOK
RAGE
RAGE-1
RAGE1
MOK protein kinase (EC:2.7.11.22) MOK protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 10200 MPHOSPH6
MPP
MPP-6
MPP6
M-phase phosphoprotein 6 Paclitaxel results in decreased expression of MPHOSPH6 protein decreases expression
protein 15907983
D017239 4356 MPP3
DLG3
membrane protein, palmitoylated 3 (MAGUK p55 subfamily member 3) Paclitaxel results in increased expression of MPP3 protein increases expression
protein 15907983
D017239 10205 MPZL2
EVA
EVA1
myelin protein zero-like 2 Paclitaxel results in decreased expression of MPZL2 mRNA decreases expression
mRNA 19682730
D017239 78988 MRP63
bMRP63
mitochondrial ribosomal protein 63 MRP63 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 64976 MRPL40
MRP-L22
MRPL22
NLVCF
URIM
mitochondrial ribosomal protein L40 MRPL40 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 64960 MRPS15
MPR-S15
RPMS15
S15mt
mitochondrial ribosomal protein S15 MRPS15 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 28973 MRPS18B
C6orf14
HSPC183
HumanS18a
MRP-S18-2
MRPS18-2
PTD017
S18amt
mitochondrial ribosomal protein S18B Paclitaxel results in decreased expression of MRPS18B protein decreases expression
protein 15907983
D017239 6307 MSMO1
DESP4
ERG25
SC4MOL
methylsterol monooxygenase 1 (EC:1.14.13.72) MSMO1 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 4493 MT1E
MT1
MTD
metallothionein 1E MT1E mRNA results in increased susceptibility to Paclitaxel increases response to substance
mRNA 16322897
D017239 4502 MT2A
MT2
metallothionein 2A MT2A mRNA results in increased susceptibility to Paclitaxel increases response to substance
mRNA 16322897
D017239 94025 MUC16
CA125
mucin 16, cell surface associated [Paclitaxel co-treated with Cisplatin] results in decreased expression of MUC16 protein affects cotreatment
/ decreases expression
protein 8751544
D017239 94025 MUC16
CA125
mucin 16, cell surface associated Paclitaxel results in decreased expression of MUC16 protein decreases expression
protein 11706781
D017239 4609 MYC
MRTL
MYCC
bHLHe39
c-Myc
v-myc avian myelocytomatosis viral oncogene homolog Curcumin inhibits the reaction [Paclitaxel results in increased expression of MYC protein] decreases reaction
/ increases expression
protein 16243823
D017239 4609 MYC
MRTL
MYCC
bHLHe39
c-Myc
v-myc avian myelocytomatosis viral oncogene homolog MYC protein affects the susceptibility to Paclitaxel affects response to substance
protein 18802399
D017239 4609 MYC
MRTL
MYCC
bHLHe39
c-Myc
v-myc avian myelocytomatosis viral oncogene homolog Paclitaxel results in decreased expression of MYC protein decreases expression
protein 15907983
D017239 4644 MYO5A
GS1
MYH12
MYO5
MYR12
myosin VA (heavy chain 12, myoxin) MYO5A protein results in increased susceptibility to Paclitaxel increases response to substance
protein 16734730
D017239 9 NAT1
AAC1
MNAT
NAT-1
NATI
N-acetyltransferase 1 (arylamine N-acetyltransferase) (EC:2.3.1.5) Paclitaxel results in decreased activity of NAT1 mRNA decreases activity
mRNA 17564303
D017239 9 NAT1
AAC1
MNAT
NAT-1
NATI
N-acetyltransferase 1 (arylamine N-acetyltransferase) (EC:2.3.1.5) Paclitaxel results in decreased activity of NAT1 protein decreases activity
protein 17564303
D017239 9 NAT1
AAC1
MNAT
NAT-1
NATI
N-acetyltransferase 1 (arylamine N-acetyltransferase) (EC:2.3.1.5) Paclitaxel results in decreased expression of NAT1 mRNA decreases expression
mRNA 15015580
D017239 89795 NAV3
POMFIL1
STEERIN3
unc53H3
neuron navigator 3 NAV3 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 64151 NCAPG
CAPG
CHCG
NY-MEL-3
non-SMC condensin I complex, subunit G NCAPG protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 8202 NCOA3
ACTR
AIB-1
AIB1
CAGH16
CTG26
KAT13B
RAC3
SRC-3
SRC3
TNRC14
TNRC16
TRAM-1
bHLHe42
pCIP
nuclear receptor coactivator 3 (EC:2.3.1.48) Paclitaxel promotes the reaction [NR1I2 protein binds to NCOA3 protein] affects binding
/ increases reaction
protein 15650019
D017239 4694 NDUFA1
CI-MWFE
MWFE
ZNF183
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1, 7.5kDa (EC:1.6.99.3) NDUFA1 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 51079 NDUFA13
B16.6
CDA016
GRIM-19
GRIM19
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 13 NDUFA13 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 4696 NDUFA3
B9
CI-B9
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3, 9kDa NDUFA3 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 4708 NDUFB2
AGGG
CI-AGGG
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 2, 8kDa (EC:1.6.5.3 1.6.99.3) NDUFB2 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 4713 NDUFB7
B18
CI-B18
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 7, 18kDa (EC:1.6.5.3 1.6.99.3) NDUFB7 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 4728 NDUFS8
CI-23k
CI23KD
TYKY
NADH dehydrogenase (ubiquinone) Fe-S protein 8, 23kDa (NADH-coenzyme Q reductase) (EC:1.6.5.3 1.6.99.3) NDUFS8 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 4723 NDUFV1
CI-51K
CI51KD
UQOR1
NADH dehydrogenase (ubiquinone) flavoprotein 1, 51kDa (EC:1.6.5.3 1.6.99.3) Paclitaxel results in decreased expression of NDUFV1 mRNA decreases expression
mRNA 15000894
D017239 4780 NFE2L2
NRF2
nuclear factor, erythroid 2-like 2 [KEAP1 protein results in decreased stability of NFE2L2 protein] which results in increased susceptibility to Paclitaxel decreases stability
/ increases response to substance
protein 20530669
D017239 4780 NFE2L2
NRF2
nuclear factor, erythroid 2-like 2 NFE2L2 results in decreased susceptibility to Paclitaxel decreases response to substance
20530669
D017239 4790 NFKB1
EBP-1
KBF1
NF-kB1
NF-kappa-B
NF-kappaB
NFKB-p105
NFKB-p50
NFkappaB
p105
p50
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 Curcumin inhibits the reaction [Paclitaxel results in increased activity of NFKB1 protein] decreases reaction
/ increases activity
protein 16243823
D017239 4792 NFKBIA
IKBA
MAD-3
NFKBI
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha Curcumin inhibits the reaction [Paclitaxel results in increased phosphorylation of and results in increased degradation of NFKBIA protein] decreases reaction
/ increases degradation
/ increases phosphorylation
protein 16243823
D017239 79570 NKAIN1
FAM77C
Na+/K+ transporting ATPase interacting 1 NKAIN1 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] affects cotreatment
/ affects response to substance
mRNA 16896004
D017239 4833 NME4
NDPK-D
NM23H4
nm23-H4
NME/NM23 nucleoside diphosphate kinase 4 (EC:2.7.4.6) Paclitaxel results in decreased expression of NME4 protein decreases expression
protein 15907983
D017239 4846 NOS3
ECNOS
eNOS
nitric oxide synthase 3 (endothelial cell) (EC:1.14.13.39) Aspirin inhibits the reaction [Paclitaxel results in decreased expression of NOS3 protein] decreases expression
/ decreases reaction
protein 19520256
D017239 4846 NOS3
ECNOS
eNOS
nitric oxide synthase 3 (endothelial cell) (EC:1.14.13.39) cilostazol inhibits the reaction [Paclitaxel results in decreased expression of NOS3 protein] decreases expression
/ decreases reaction
protein 19520256
D017239 4846 NOS3
ECNOS
eNOS
nitric oxide synthase 3 (endothelial cell) (EC:1.14.13.39) Paclitaxel results in decreased expression of NOS3 mRNA decreases expression
mRNA 19815708
D017239 4846 NOS3
ECNOS
eNOS
nitric oxide synthase 3 (endothelial cell) (EC:1.14.13.39) Paclitaxel results in decreased expression of NOS3 protein decreases expression
protein 19520256
D017239 8856 NR1I2
BXR
ONR1
PAR
PAR1
PAR2
PARq
PRR
PXR
SAR
SXR
nuclear receptor subfamily 1, group I, member 2 NR1I2 protein promotes the reaction [Paclitaxel results in increased expression of and results in increased activity of ABCB1 protein] increases activity
/ increases expression
/ increases reaction
protein 20041327
D017239 8856 NR1I2
BXR
ONR1
PAR
PAR1
PAR2
PARq
PRR
PXR
SAR
SXR
nuclear receptor subfamily 1, group I, member 2 Paclitaxel binds to and results in increased activity of NR1I2 protein affects binding
/ increases activity
protein 14977870
15864135
18839173
D017239 8856 NR1I2
BXR
ONR1
PAR
PAR1
PAR2
PARq
PRR
PXR
SAR
SXR
nuclear receptor subfamily 1, group I, member 2 Paclitaxel promotes the reaction [NR1I2 protein binds to MED1 protein] affects binding
/ increases reaction
protein 15650019
D017239 8856 NR1I2
BXR
ONR1
PAR
PAR1
PAR2
PARq
PRR
PXR
SAR
SXR
nuclear receptor subfamily 1, group I, member 2 Paclitaxel promotes the reaction [NR1I2 protein binds to NCOA3 protein] affects binding
/ increases reaction
protein 15650019
D017239 8856 NR1I2
BXR
ONR1
PAR
PAR1
PAR2
PARq
PRR
PXR
SAR
SXR
nuclear receptor subfamily 1, group I, member 2 Paclitaxel results in increased activity of NR1I2 protein increases activity
protein 12065438
15650019
20041327
D017239 8856 NR1I2
BXR
ONR1
PAR
PAR1
PAR2
PARq
PRR
PXR
SAR
SXR
nuclear receptor subfamily 1, group I, member 2 [Paclitaxel results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 mRNA increases activity
/ increases expression
protein 20041327
D017239 8856 NR1I2
BXR
ONR1
PAR
PAR1
PAR2
PARq
PRR
PXR
SAR
SXR
nuclear receptor subfamily 1, group I, member 2 [SR 12813 results in increased activity of NR1I2 protein] which results in decreased susceptibility to Paclitaxel decreases response to substance
/ increases activity
protein 19746521
D017239 8829 NRP1
BDCA4
CD304
NP1
NRP
VEGF165R
neuropilin 1 Paclitaxel results in increased expression of NRP1 mRNA increases expression
mRNA 19682730
D017239 55270 NUDT15
MTH2
RP11-90M2.1
nudix (nucleoside diphosphate linked moiety X)-type motif 15 (EC:3.6.1.55) NUDT15 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 11163 NUDT4
DIPP2
DIPP2alpha
DIPP2beta
nudix (nucleoside diphosphate linked moiety X)-type motif 4 (EC:3.6.1.52) NUDT4 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 51203 NUSAP1
ANKT
BM037
LNP
NUSAP
PRO0310p1
Q0310
SAPL
nucleolar and spindle associated protein 1 NUSAP1 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 4968 OGG1
HMMH
HOGG1
MUTM
OGH1
8-oxoguanine DNA glycosylase (EC:4.2.99.18) Paclitaxel results in increased expression of OGG1 protein increases expression
protein 15907983
D017239 56944 OLFML3
HNOEL-iso
OLF44
olfactomedin-like 3 Paclitaxel results in increased expression of OLFML3 mRNA increases expression
mRNA 19682730
D017239 114884 OSBPL10
ORP10
OSBP9
oxysterol binding protein-like 10 OSBPL10 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 9180 OSMR
OSMRB
PLCA1
oncostatin M receptor OSMR protein results in increased susceptibility to Paclitaxel increases response to substance
protein 16734730
D017239 11240 PADI2
PAD-H19
PAD2
PDI2
peptidyl arginine deiminase, type II (EC:3.5.3.15) Paclitaxel results in decreased expression of PADI2 protein decreases expression
protein 15907983
D017239 3355109 CD40LG protein inhibits the reaction [Paclitaxel promotes the reaction [CASP3 protein results in increased cleavage of PARP protein]] decreases reaction
/ increases cleavage
/ increases reaction
protein 16545138
D017239 3355109 Paclitaxel promotes the reaction [CASP3 protein results in increased cleavage of PARP protein] increases cleavage
/ increases reaction
protein 16545138
D017239 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) [3,3'-diindolylmethane co-treated with Paclitaxel] results in increased cleavage of and results in increased activity of PARP1 protein affects cotreatment
/ increases activity
/ increases cleavage
protein 16580691
D017239 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) AKT1 protein affects the reaction [Paclitaxel results in increased cleavage of PARP1 protein] affects reaction
/ increases cleavage
protein 10075725
D017239 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) alvocidib promotes the reaction [Paclitaxel results in increased cleavage of PARP1 protein] increases cleavage
/ increases reaction
protein 10430095
D017239 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) MAP2K4 protein affects the reaction [Paclitaxel results in increased cleavage of PARP1 protein] affects reaction
/ increases cleavage
protein 10075725
D017239 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) MAP3K5 protein affects the reaction [Paclitaxel results in increased cleavage of PARP1 protein] affects reaction
/ increases cleavage
protein 10075725
D017239 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) MAPK8 protein affects the reaction [Paclitaxel results in increased cleavage of PARP1 protein] affects reaction
/ increases cleavage
protein 10075725
D017239 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) Paclitaxel results in increased cleavage of PARP1 protein increases cleavage
protein 10075725
10430095
10502406
11774260
15492279
15585644
15907805
17404021
18071906
18451153
20610805
D017239 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) [resveratrol co-treated with Paclitaxel] results in increased cleavage of PARP1 protein affects cotreatment
/ increases cleavage
protein 14749477
D017239 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) TYMP inhibits the reaction [Paclitaxel results in increased cleavage of PARP1 protein] decreases reaction
/ increases cleavage
protein 15907805
D017239 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) TYMP mutant form promotes the reaction [Paclitaxel results in increased cleavage of PARP1 protein] increases cleavage
/ increases reaction
protein 15492279
D017239 5095 PCCA
propionyl CoA carboxylase, alpha polypeptide (EC:6.4.1.3) Paclitaxel results in decreased expression of PCCA protein decreases expression
protein 15907983
D017239 5111 PCNA
proliferating cell nuclear antigen Paclitaxel results in increased expression of PCNA increases expression
9858906
D017239 5118 PCOLCE
PCPE
PCPE-1
PCPE1
procollagen C-endopeptidase enhancer Paclitaxel results in increased expression of PCOLCE mRNA increases expression
mRNA 19682730
D017239 5163 PDK1
pyruvate dehydrogenase kinase, isozyme 1 (EC:2.7.11.2) [PDK1 protein binds to AKT1 protein] results in decreased susceptibility to [Paclitaxel co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] affects binding
/ affects cotreatment
/ decreases response to substance
protein 20361045
D017239 5163 PDK1
pyruvate dehydrogenase kinase, isozyme 1 (EC:2.7.11.2) [PDK1 protein binds to AKT1 protein] which results in decreased susceptibility to Paclitaxel affects binding
/ decreases response to substance
protein 20361045
D017239 5170 PDPK1
PDK1
PDPK2
PRO0461
3-phosphoinositide dependent protein kinase-1 (EC:2.7.11.1) PDPK1 protein results in decreased susceptibility to Paclitaxel decreases response to substance
protein 16782806
D017239 64065 PERP
KCP1
KRTCAP1
PIGPC1
RP3-496H19.1
THW
dJ496H19.1
PERP, TP53 apoptosis effector Paclitaxel results in increased expression of PERP mRNA increases expression
mRNA 18058816
D017239 5286 PIK3C2A
CPK
PI3-K-C2(ALPHA)
PI3-K-C2A
phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 alpha (EC:2.7.1.154) PIK3C2A protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 5311 PKD2
APKD2
PC2
PKD4
Pc-2
TRPP2
polycystic kidney disease 2 (autosomal dominant) PKD2 protein results in increased susceptibility to Paclitaxel increases response to substance
protein 16734730
D017239 5315 PKM
CTHBP
OIP3
PK3
PKM2
TCB
THBP1
pyruvate kinase, muscle (EC:2.7.1.40) PKM protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 5318 PKP2
ARVD9
plakophilin 2 PKP2 protein results in decreased susceptibility to Paclitaxel decreases response to substance
protein 16734730
D017239 51196 PLCE1
NPHS3
PLCE
PPLC
phospholipase C, epsilon 1 (EC:3.1.4.11) PLCE1 protein results in decreased susceptibility to Paclitaxel decreases response to substance
protein 16734730
D017239 5347 PLK1
PLK
STPK13
polo-like kinase 1 (EC:2.7.11.21) [pifithrin co-treated with Paclitaxel] results in increased expression of PLK1 protein affects cotreatment
/ increases expression
protein 18516295
D017239 10733 PLK4
SAK
STK18
polo-like kinase 4 (EC:2.7.11.21) Paclitaxel results in decreased expression of PLK4 mRNA decreases expression
mRNA 15000894
D017239 5376 PMP22
CMT1A
CMT1E
DSS
GAS-3
HMSNIA
HNPP
Sp110
peripheral myelin protein 22 PMP22 mRNA results in decreased susceptibility to Paclitaxel decreases response to substance
mRNA 16322897
D017239 51426 POLK
DINB1
DINP
POLQ
polymerase (DNA directed) kappa (EC:2.7.7.7) Paclitaxel results in decreased expression of POLK mRNA decreases expression
mRNA 15000894
D017239 22932 POMZP3
POM-ZP3
POM121
POM121 and ZP3 fusion POMZP3 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 5447 POR
CPR
CYPOR
P450R
P450 (cytochrome) oxidoreductase (EC:1.6.2.4) POR mRNA results in increased susceptibility to Paclitaxel increases response to substance
mRNA 15239142
D017239 10631 POSTN
OSF-2
OSF2
PDLPOSTN
PN
periostin
periostin, osteoblast specific factor Paclitaxel results in increased expression of POSTN mRNA increases expression
mRNA 19682730
D017239 8611 PPAP2A
LLP1a
LPP1
PAP-2a
PAP2
phosphatidic acid phosphatase type 2A (EC:3.1.3.4) PPAP2A protein results in decreased susceptibility to Paclitaxel decreases response to substance
protein 16734730
D017239 8612 PPAP2C
LPP2
PAP-2c
PAP2-g
phosphatidic acid phosphatase type 2C (EC:3.1.3.4) Paclitaxel results in decreased expression of PPAP2C mRNA decreases expression
mRNA 19682730
D017239 5479 PPIB
CYP-S1
CYPB
OI9
SCYLP
peptidylprolyl isomerase B (cyclophilin B) (EC:5.2.1.8) PPIB protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 5500 PPP1CB
PP-1B
PP1B
PP1beta
PPP1CD
protein phosphatase 1, catalytic subunit, beta isozyme (EC:3.1.3.16 3.1.3.53) PPP1CB protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 55607 PPP1R9A
NRB1
NRBI
Neurabin-I
protein phosphatase 1, regulatory subunit 9A Paclitaxel results in decreased expression of PPP1R9A mRNA decreases expression
mRNA 15000894
D017239 9055 PRC1
ASE1
protein regulator of cytokinesis 1 Paclitaxel results in increased expression of PRC1 mRNA increases expression
mRNA 17374387
D017239 11108 PRDM4
PFM1
PR domain containing 4 Paclitaxel results in decreased expression of PRDM4 protein decreases expression
protein 15907983
D017239 7001 PRDX2
NKEF-B
NKEFB
PRP
PRX2
PRXII
PTX1
TDPX1
TPX1
TSA
peroxiredoxin 2 (EC:1.11.1.15) PRDX2 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 8842 PROM1
AC133
CD133
CORD12
MCDR2
PROML1
RP41
STGD4
prominin 1 PROM1 results in decreased susceptibility to Paclitaxel decreases response to substance
21919130
D017239 79056 PRRG4
PRGP4
TMG4
proline rich Gla (G-carboxyglutamic acid) 4 (transmembrane) Paclitaxel results in decreased expression of PRRG4 mRNA decreases expression
mRNA 19682730
D017239 38175 Paclitaxel inhibits the reaction [EGF protein results in increased expression of PSA mRNA] decreases reaction
/ increases expression
mRNA 20807808
D017239 5660 PSAP
GLBA
SAP1
prosaposin Paclitaxel results in decreased expression of PSAP mRNA decreases expression
mRNA 15000894
D017239 5685 PSMA4
HC9
HsT17706
PSC9
proteasome (prosome, macropain) subunit, alpha type, 4 (EC:3.4.25.1) PSMA4 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 5689 PSMB1
HC5
PMSB1
PSC5
proteasome (prosome, macropain) subunit, beta type, 1 (EC:3.4.25.1) PSMB1 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 5694 PSMB6
DELTA
LMPY
Y
proteasome (prosome, macropain) subunit, beta type, 6 (EC:3.4.25.1) PSMB6 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 5728 PTEN
10q23del
BZS
CWS1
DEC
GLM2
MHAM
MMAC1
PTEN1
TEP1
phosphatase and tensin homolog (EC:3.1.3.67 3.1.3.16 3.1.3.48) Paclitaxel results in increased activity of PTEN protein increases activity
protein 11707646
D017239 5728 PTEN
10q23del
BZS
CWS1
DEC
GLM2
MHAM
MMAC1
PTEN1
TEP1
phosphatase and tensin homolog (EC:3.1.3.67 3.1.3.16 3.1.3.48) PTEN results in increased susceptibility to Paclitaxel increases response to substance
15548710
D017239 10728 PTGES3
P23
TEBP
cPGES
prostaglandin E synthase 3 (cytosolic) (EC:5.3.99.3) PTGES3 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 5743 PTGS2
COX-2
COX2
GRIPGHS
PGG/HS
PGHS-2
PHS-2
hCox-2
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) ciglitazone inhibits the reaction [Paclitaxel results in increased expression of PTGS2 protein] decreases reaction
/ increases expression
protein 11278336
D017239 5743 PTGS2
COX-2
COX2
GRIPGHS
PGG/HS
PGHS-2
PHS-2
hCox-2
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) Curcumin inhibits the reaction [Paclitaxel results in increased expression of PTGS2 mRNA] decreases reaction
/ increases expression
mRNA 16243823
D017239 5743 PTGS2
COX-2
COX2
GRIPGHS
PGG/HS
PGHS-2
PHS-2
hCox-2
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) Curcumin inhibits the reaction [Paclitaxel results in increased expression of PTGS2 protein] decreases reaction
/ increases expression
protein 16243823
D017239 5743 PTGS2
COX-2
COX2
GRIPGHS
PGG/HS
PGHS-2
PHS-2
hCox-2
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) Paclitaxel results in decreased expression of PTGS2 protein decreases expression
protein 15907983
D017239 5743 PTGS2
COX-2
COX2
GRIPGHS
PGG/HS
PGHS-2
PHS-2
hCox-2
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) Paclitaxel results in increased expression of PTGS2 protein increases expression
protein 11278336
D017239 5743 PTGS2
COX-2
COX2
GRIPGHS
PGG/HS
PGHS-2
PHS-2
hCox-2
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) PTGS2 protein results in decreased susceptibility to [Platinum co-treated with Paclitaxel] affects cotreatment
/ decreases response to substance
protein 16831230
D017239 5753 PTK6
BRK
protein tyrosine kinase 6 (EC:2.7.10.2) Paclitaxel results in increased expression of PTK6 mRNA increases expression
mRNA 15000894
D017239 5783 PTPN13
FAP-1
PNP1
PTP-BAS
PTP-BL
PTP1E
PTPL1
PTPLE
hPTP1E
protein tyrosine phosphatase, non-receptor type 13 (APO-1/CD95 (Fas)-associated phosphatase) (EC:3.1.3.48) PTPN13 protein results in increased susceptibility to Paclitaxel increases response to substance
protein 16734730
D017239 5778 PTPN7
BPTP-4
HEPTP
LC-PTP
LPTP
PTPNI
protein tyrosine phosphatase, non-receptor type 7 (EC:3.1.3.48) Paclitaxel results in increased expression of PTPN7 protein increases expression
protein 15907983
D017239 54870 QRICH1
glutamine-rich 1 Paclitaxel results in increased phosphorylation of QRICH1 protein increases phosphorylation
protein 17510977
D017239 5768 QSOX1
Q6
QSCN6
quiescin Q6 sulfhydryl oxidase 1 (EC:1.8.3.2) Paclitaxel results in decreased expression of QSOX1 mRNA decreases expression
mRNA 15000894
D017239 5879 RAC1
Rac-1
TC-25
p21-Rac1
ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1) Paclitaxel results in decreased expression of RAC1 mRNA decreases expression
mRNA 15000894
D017239 5894 RAF1
CRAF
NS5
Raf-1
c-Raf
v-raf-1 murine leukemia viral oncogene homolog 1 (EC:2.7.11.1) Paclitaxel results in increased phosphorylation of RAF1 protein increases phosphorylation
protein 12510025
D017239 5894 RAF1
CRAF
NS5
Raf-1
c-Raf
v-raf-1 murine leukemia viral oncogene homolog 1 (EC:2.7.11.1) [pifithrin co-treated with Paclitaxel] results in increased phosphorylation of RAF1 protein affects cotreatment
/ increases phosphorylation
protein 18516295
D017239 5894 RAF1
CRAF
NS5
Raf-1
c-Raf
v-raf-1 murine leukemia viral oncogene homolog 1 (EC:2.7.11.1) resveratrol inhibits the reaction [Paclitaxel results in increased phosphorylation of RAF1 protein] decreases reaction
/ increases phosphorylation
protein 12510025
D017239 10267 RAMP1
receptor (G protein-coupled) activity modifying protein 1 RAMP1 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] affects cotreatment
/ affects response to substance
mRNA 16896004
D017239 9771 RAPGEF5
GFR
MR-GEF
REPAC
Rap guanine nucleotide exchange factor (GEF) 5 Paclitaxel results in increased expression of RAPGEF5 protein increases expression
protein 15907983
D017239 5925 RB1
OSRC
RB
p105-Rb
pRb
pp110
retinoblastoma 1 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Paclitaxel results in increased phosphorylation of RB1 protein] decreases reaction
/ increases phosphorylation
protein 15138593
D017239 5925 RB1
OSRC
RB
p105-Rb
pRb
pp110
retinoblastoma 1 Paclitaxel results in increased phosphorylation of RB1 protein increases phosphorylation
protein 15138593
D017239 10741 RBBP9
BOG
RBBP10
retinoblastoma binding protein 9 Paclitaxel results in decreased expression of RBBP9 mRNA decreases expression
mRNA 15000894
D017239 5947 RBP1
CRABP-I
CRBP
CRBP1
CRBPI
RBPC
retinol binding protein 1, cellular RBP1 protein results in increased susceptibility to Paclitaxel increases response to substance
protein 16734730
D017239 5970 RELA
NFKB3
p65
v-rel avian reticuloendotheliosis viral oncogene homolog A caffeic acid phenethyl ester inhibits the reaction [Paclitaxel results in increased activity of RELA protein] decreases reaction
/ increases activity
protein 15291876
D017239 5970 RELA
NFKB3
p65
v-rel avian reticuloendotheliosis viral oncogene homolog A Curcumin inhibits the reaction [Paclitaxel results in increased activity of RELA protein] decreases reaction
/ increases activity
protein 16243823
D017239 5970 RELA
NFKB3
p65
v-rel avian reticuloendotheliosis viral oncogene homolog A [gemcitabine co-treated with Doxorubicin co-treated with Paclitaxel] affects the localization of RELA protein affects cotreatment
/ affects localization
protein 17039268
D017239 5970 RELA
NFKB3
p65
v-rel avian reticuloendotheliosis viral oncogene homolog A [gemcitabine co-treated with Doxorubicin co-treated with Paclitaxel] results in increased expression of RELA protein affects cotreatment
/ increases expression
protein 17039268
D017239 5970 RELA
NFKB3
p65
v-rel avian reticuloendotheliosis viral oncogene homolog A [Paclitaxel co-treated with F2 protein] affects the localization of RELA protein affects cotreatment
/ affects localization
protein 19944065
D017239 5970 RELA
NFKB3
p65
v-rel avian reticuloendotheliosis viral oncogene homolog A Paclitaxel results in decreased expression of RELA protein decreases expression
protein 17701358
18098270
D017239 5970 RELA
NFKB3
p65
v-rel avian reticuloendotheliosis viral oncogene homolog A [Tretinoin co-treated with Paclitaxel] results in decreased expression of RELA protein affects cotreatment
/ decreases expression
protein 17701358
18098270
D017239 5985 RFC5
RFC36
replication factor C (activator 1) 5, 36.5kDa Paclitaxel results in decreased expression of RFC5 protein decreases expression
protein 15907983
D017239 5993 RFX5
regulatory factor X, 5 (influences HLA class II expression) RFX5 mRNA results in decreased susceptibility to Paclitaxel decreases response to substance
mRNA 16322897
D017239 8625 RFXANK
ANKRA1
BLS
F14150_1
RFX-B
regulatory factor X-associated ankyrin-containing protein RFXANK protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 89941 RHOT2
ARHT2
C16orf39
MIRO-2
MIRO2
RASL
ras homolog family member T2 (EC:3.6.5.-) RHOT2 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 6093 ROCK1
P160ROCK
ROCK-I
Rho-associated, coiled-coil containing protein kinase 1 (EC:2.7.11.1) Paclitaxel results in increased expression of ROCK1 mRNA increases expression
mRNA 15000894
D017239 6134 RPL10
AUTSX5
DXS648
DXS648E
L10
NOV
QM
ribosomal protein L10 RPL10 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 6147 RPL23A
L23A
MDA20
ribosomal protein L23a RPL23A mRNA results in decreased susceptibility to Paclitaxel decreases response to substance
mRNA 16322897
D017239 6176 RPLP1
LP1
P1
RPP1
ribosomal protein, large, P1 RPLP1 mRNA results in decreased susceptibility to Paclitaxel decreases response to substance
mRNA 16322897
D017239 393715 RPS26L protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 6241 RRM2
R2
RR2
RR2M
ribonucleotide reductase M2 (EC:1.17.4.1) RRM2 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] affects cotreatment
/ affects response to substance
mRNA 16896004
D017239 50484 RRM2B
MTDPS8A
MTDPS8B
P53R2
ribonucleotide reductase M2 B (TP53 inducible) (EC:1.17.4.1) Paclitaxel results in increased expression of RRM2B mRNA increases expression
mRNA 21704725
D017239 6247 RS1
RS
XLRS1
retinoschisin 1 Paclitaxel results in decreased secretion of RS1 protein decreases secretion
protein 21738583
D017239 6242 RTKN
rhotekin Curcumin inhibits the reaction [RTKN protein results in decreased susceptibility to Paclitaxel] decreases reaction
/ decreases response to substance
protein 15480428
D017239 6242 RTKN
rhotekin RTKN protein results in decreased susceptibility to Paclitaxel decreases response to substance
protein 15480428
D017239 10856 RUVBL2
ECP51
INO80J
REPTIN
RVB2
TIH2
TIP48
TIP49B
RuvB-like AAA ATPase 2 (EC:3.6.4.12) Paclitaxel results in decreased expression of RUVBL2 protein decreases expression
protein 15907983
D017239 6275 S100A4
18A2
42A
CAPL
FSP1
MTS1
P9KA
PEL98
S100 calcium binding protein A4 Paclitaxel results in increased expression of S100A4 mRNA increases expression
mRNA 19682730
D017239 6286 S100P
MIG9
S100 calcium binding protein P Paclitaxel results in decreased expression of S100P mRNA decreases expression
mRNA 19682730
D017239 6286 S100P
MIG9
S100 calcium binding protein P S100P mRNA results in increased susceptibility to Paclitaxel increases response to substance
mRNA 16322897
D017239 6286 S100P
MIG9
S100 calcium binding protein P S100P protein results in increased susceptibility to Paclitaxel increases response to substance
protein 18636193
D017239 6447 SCG5
7B2
P7B2
SGNE1
SgV
secretogranin V (7B2 protein) SCG5 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 57758 SCUBE2
CEGB1
CEGF1
CEGP1
signal peptide, CUB domain, EGF-like 2 SCUBE2 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] affects cotreatment
/ affects response to substance
mRNA 16896004
D017239 6383 SDC2
CD362
HSPG
HSPG1
SYND2
syndecan 2 Paclitaxel results in increased expression of SDC2 mRNA increases expression
mRNA 19682730
D017239 5055 SERPINB2
HsT1201
PAI
PAI-2
PAI2
PLANH2
serpin peptidase inhibitor, clade B (ovalbumin), member 2 SERPINB2 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 5054 SERPINE1
PAI
PAI-1
PAI1
PLANH1
serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 SERPINE1 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 5176 SERPINF1
EPC-1
OI12
OI6
PEDF
serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 1 Paclitaxel results in increased expression of SERPINF1 mRNA increases expression
mRNA 19682730
D017239 6443 SGCB
A3b
LGMD2E
SGC
sarcoglycan, beta (43kDa dystrophin-associated glycoprotein) SGCB protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 6452 SH3BP2
3BP-2
3BP2
CRBM
CRPM
SH3-domain binding protein 2 Paclitaxel results in decreased expression of SH3BP2 protein decreases expression
protein 15907983
D017239 23411 SIRT1
SIR2L1
sirtuin 1 Aspirin inhibits the reaction [Paclitaxel results in decreased expression of SIRT1 protein] decreases expression
/ decreases reaction
protein 19520256
D017239 23411 SIRT1
SIR2L1
sirtuin 1 cilostazol inhibits the reaction [Paclitaxel results in decreased expression of SIRT1 protein] decreases expression
/ decreases reaction
protein 19520256
D017239 23411 SIRT1
SIR2L1
sirtuin 1 Paclitaxel results in decreased expression of SIRT1 protein decreases expression
protein 19520256
D017239 6502 SKP2
FBL1
FBXL1
FLB1
p45
S-phase kinase-associated protein 2, E3 ubiquitin protein ligase SKP2 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 6558 SLC12A2
BSC
BSC2
NKCC1
solute carrier family 12 (sodium/potassium/chloride transporter), member 2 SLC12A2 protein results in decreased susceptibility to Paclitaxel decreases response to substance
protein 16734730
D017239 5002 SLC22A18
BWR1A
BWSCR1A
HET
IMPT1
ITM
ORCTL2
SLC22A1L
TSSC5
p45-BWR1A
solute carrier family 22, member 18 SLC22A18 protein results in decreased susceptibility to Paclitaxel decreases response to substance
protein 16734730
D017239 6581 SLC22A3
EMT
EMTH
OCT3
solute carrier family 22 (organic cation transporter), member 3 SLC22A3 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 10864 SLC22A7
NLT
OAT2
solute carrier family 22 (organic anion transporter), member 7 SLC22A7 protein results in increased transport of Paclitaxel increases transport
protein 15901346
D017239 291 SLC25A4
1
AAC1
ANT
ANT_1
ANT1
MTDPS12
PEO2
PEO3
T1
solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 4 Paclitaxel results in decreased expression of SLC25A4 mRNA decreases expression
mRNA 15000894
D017239 1317 SLC31A1
COPT1
CTR1
solute carrier family 31 (copper transporter), member 1 Paclitaxel results in increased expression of SLC31A1 mRNA increases expression
mRNA 20737486
D017239 6548 SLC9A1
APNH
NHE-1
NHE1
solute carrier family 9, subfamily A (NHE1, cation proton antiporter 1), member 1 Paclitaxel results in decreased activity of SLC9A1 protein decreases activity
protein 12796407
D017239 6617 SNAPC1
PTFgamma
SNAP43
small nuclear RNA activating complex, polypeptide 1, 43kDa SNAPC1 protein results in increased susceptibility to Paclitaxel increases response to substance
protein 16734730
D017239 79622 SNRNP25
C16orf33
small nuclear ribonucleoprotein 25kDa (U11/U12) SNRNP25 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 6627 SNRPA1
Lea1
small nuclear ribonucleoprotein polypeptide A' SNRPA1 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 29887 SNX10
OPTB8
sorting nexin 10 SNX10 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 6648 SOD2
IPOB
MNSOD
MVCD6
superoxide dismutase 2, mitochondrial (EC:1.15.1.1) [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of MAP2K1 protein] affects the reaction [SOD2 protein results in decreased susceptibility to Paclitaxel] affects reaction
/ decreases activity
/ decreases response to substance
protein 18594523
D017239 6648 SOD2
IPOB
MNSOD
MVCD6
superoxide dismutase 2, mitochondrial (EC:1.15.1.1) Acetylcysteine affects the reaction [SOD2 protein results in decreased susceptibility to Paclitaxel] affects reaction
/ decreases response to substance
protein 18594523
D017239 6648 SOD2
IPOB
MNSOD
MVCD6
superoxide dismutase 2, mitochondrial (EC:1.15.1.1) [benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone results in decreased activity of CASP9 protein] affects the reaction [SOD2 protein results in decreased susceptibility to Paclitaxel] affects reaction
/ decreases activity
/ decreases response to substance
protein 18594523
D017239 6648 SOD2
IPOB
MNSOD
MVCD6
superoxide dismutase 2, mitochondrial (EC:1.15.1.1) Glutathione affects the reaction [SOD2 protein results in decreased susceptibility to Paclitaxel] affects reaction
/ decreases response to substance
protein 18594523
D017239 6648 SOD2
IPOB
MNSOD
MVCD6
superoxide dismutase 2, mitochondrial (EC:1.15.1.1) [MAP2K1 protein affects the activity of [MAPK1 protein co-treated with MAPK3 protein]] affects the reaction [SOD2 protein results in decreased susceptibility to Paclitaxel] affects activity
/ affects cotreatment
/ affects reaction
/ decreases response to substance
protein 18594523
D017239 6648 SOD2
IPOB
MNSOD
MVCD6
superoxide dismutase 2, mitochondrial (EC:1.15.1.1) SOD2 protein affects the reaction [Paclitaxel results in increased phosphorylation of MAPK1 protein] affects reaction
/ increases phosphorylation
protein 18594523
D017239 6648 SOD2
IPOB
MNSOD
MVCD6
superoxide dismutase 2, mitochondrial (EC:1.15.1.1) SOD2 protein affects the reaction [Paclitaxel results in increased phosphorylation of MAPK3 protein] affects reaction
/ increases phosphorylation
protein 18594523
D017239 6648 SOD2
IPOB
MNSOD
MVCD6
superoxide dismutase 2, mitochondrial (EC:1.15.1.1) SOD2 protein results in decreased susceptibility to Paclitaxel decreases response to substance
protein 18594523
D017239 11262 SP140
LYSP100
LYSP100-A
LYSP100-B
SP140 nuclear body protein SP140 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 6678 SPARC
ON
secreted protein, acidic, cysteine-rich (osteonectin) Paclitaxel results in increased expression of SPARC mRNA increases expression
mRNA 19682730
D017239 10653 SPINT2
DIAR3
HAI-2
HAI2
Kop
PB
serine peptidase inhibitor, Kunitz type, 2 Paclitaxel results in decreased expression of SPINT2 mRNA decreases expression
mRNA 19682730
D017239 5552 SRGN
PPG
PRG
PRG1
serglycin SRGN protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 6717 SRI
CP-22
CP22
SCN
V19
sorcin SRI protein results in decreased susceptibility to Paclitaxel decreases response to substance
protein 18423116
D017239 6734 SRPR
DP
Sralpha
signal recognition particle receptor (docking protein) SRPR protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 6774 STAT3
APRF
HIES
signal transducer and activator of transcription 3 (acute-phase response factor) Nicotine inhibits the reaction [Paclitaxel results in decreased activity of STAT3 protein] decreases activity
/ decreases reaction
protein 20106947
D017239 6774 STAT3
APRF
HIES
signal transducer and activator of transcription 3 (acute-phase response factor) Paclitaxel results in decreased activity of STAT3 protein decreases activity
protein 20106947
D017239 6774 STAT3
APRF
HIES
signal transducer and activator of transcription 3 (acute-phase response factor) STAT3 protein results in decreased susceptibility to Paclitaxel decreases response to substance
protein 20106947
D017239 6781 STC1
STC
stanniocalcin 1 STC1 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 10963 STIP1
HOP
IEF-SSP-3521
P60
STI1
STI1L
stress-induced-phosphoprotein 1 Paclitaxel results in increased expression of STIP1 protein increases expression
protein 15907983
D017239 3925 STMN1
C1orf215
LAP18
Lag
OP18
PP17
PP19
PR22
SMN
stathmin 1 STMN1 affects the susceptibility to Paclitaxel affects response to substance
17172428
D017239 10923 SUB1
P15
PC4
p14
SUB1 homolog (S. cerevisiae) Paclitaxel results in decreased expression of SUB1 protein decreases expression
protein 15907983
D017239 8803 SUCLA2
A-BETA
MTDPS5
SCS-betaA
succinate-CoA ligase, ADP-forming, beta subunit (EC:6.2.1.5) SUCLA2 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 10460 TACC3
ERIC-1
ERIC1
transforming, acidic coiled-coil containing protein 3 Paclitaxel results in decreased expression of TACC3 protein decreases expression
protein 15907983
D017239 6890 TAP1
ABC17
ABCB2
APT1
D6S114E
PSF-1
PSF1
RING4
TAP1*0102N
TAP1N
transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) Paclitaxel results in increased expression of TAP1 mRNA increases expression
mRNA 20737486
D017239 6996 TDG
hTDG
thymine-DNA glycosylase (EC:3.2.2.29) TDG protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 7015 TERT
CMM9
DKCA2
DKCB4
EST2
PFBMFT1
TCS1
TP2
TRT
hEST2
hTRT
telomerase reverse transcriptase (EC:2.7.7.49) [decitabine results in decreased activity of TERT protein] which results in increased susceptibility to Paclitaxel decreases activity
/ increases response to substance
protein 18021753
D017239 7015 TERT
CMM9
DKCA2
DKCB4
EST2
PFBMFT1
TCS1
TP2
TRT
hEST2
hTRT
telomerase reverse transcriptase (EC:2.7.7.49) Paclitaxel results in decreased expression of TERT protein decreases expression
protein 17701358
18098270
D017239 7015 TERT
CMM9
DKCA2
DKCB4
EST2
PFBMFT1
TCS1
TP2
TRT
hEST2
hTRT
telomerase reverse transcriptase (EC:2.7.7.49) [Tretinoin co-treated with Paclitaxel] results in decreased expression of TERT protein affects cotreatment
/ decreases expression
protein 17701358
18098270
D017239 7020 TFAP2A
AP-2
AP-2alpha
AP2TF
BOFS
TFAP2
transcription factor AP-2 alpha (activating enhancer binding protein 2 alpha) Paclitaxel results in increased expression of TFAP2A protein increases expression
protein 16204029
D017239 7020 TFAP2A
AP-2
AP-2alpha
AP2TF
BOFS
TFAP2
transcription factor AP-2 alpha (activating enhancer binding protein 2 alpha) TFAP2A protein results in increased susceptibility to Paclitaxel increases response to substance
protein 16204029
D017239 7022 TFAP2C
AP2-GAMMA
ERF1
TFAP2G
hAP-2g
transcription factor AP-2 gamma (activating enhancer binding protein 2 gamma) Paclitaxel results in decreased expression of TFAP2C mRNA decreases expression
mRNA 19682730
D017239 7031 TFF1
BCEI
D21S21
HP1.A
HPS2
pNR-2
pS2
trefoil factor 1 TFF1 mRNA results in increased susceptibility to Paclitaxel increases response to substance
mRNA 16322897
D017239 7980 TFPI2
PP5
REF1
TFPI-2
tissue factor pathway inhibitor 2 TFPI2 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 55258 THNSL2
SOFAT
THS2
TSH2
threonine synthase-like 2 (S. cerevisiae) (EC:4.2.3.-) THNSL2 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] affects cotreatment
/ affects response to substance
mRNA 16896004
D017239 7070 THY1
CD90
Thy-1 cell surface antigen Paclitaxel results in increased expression of THY1 mRNA increases expression
mRNA 19682730
D017239 7072 TIA1
TIA-1
WDM
TIA1 cytotoxic granule-associated RNA binding protein TIA1 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 26517 TIMM13
TIM13
TIM13B
TIMM13A
TIMM13B
ppv1
translocase of inner mitochondrial membrane 13 homolog (yeast) TIMM13 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 29928 TIMM22
TEX4
TIM22
translocase of inner mitochondrial membrane 22 homolog (yeast) Paclitaxel results in increased expression of TIMM22 protein increases expression
protein 15907983
D017239 27134 TJP3
ZO-3
ZO3
tight junction protein 3 TJP3 protein results in decreased susceptibility to Paclitaxel decreases response to substance
protein 16734730
D017239 80194 TMEM134
transmembrane protein 134 TMEM134 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 65084 TMEM135
PMP52
transmembrane protein 135 TMEM135 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 64418 TMEM168
transmembrane protein 168 TMEM168 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 79161 TMEM243
C7orf23
MM-TRAG
transmembrane protein 243, mitochondrial Paclitaxel results in increased expression of TMEM243 mRNA increases expression
mRNA 15556294
D017239 79161 TMEM243
C7orf23
MM-TRAG
transmembrane protein 243, mitochondrial TMEM243 mRNA results in decreased susceptibility to Paclitaxel decreases response to substance
mRNA 15556294
D017239 9528 TMEM59
C1orf8
HSPC001
transmembrane protein 59 TMEM59 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor Paclitaxel inhibits the reaction [Colchicine inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]] decreases reaction
/ increases expression
protein 11154858
D017239 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor Paclitaxel inhibits the reaction [Colchicine inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]] decreases reaction
/ increases expression
protein 11154858
D017239 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor Paclitaxel inhibits the reaction [Griseofulvin inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]] decreases reaction
/ increases expression
protein 11154858
D017239 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor Paclitaxel inhibits the reaction [Griseofulvin inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]] decreases reaction
/ increases expression
protein 11154858
D017239 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor [Tretinoin co-treated with Paclitaxel] results in decreased expression of TNF protein affects cotreatment
/ decreases expression
protein 18098270
D017239 7128 TNFAIP3
A20
OTUD7C
TNFA1P2
tumor necrosis factor, alpha-induced protein 3 (EC:3.4.19.12) Paclitaxel results in increased expression of TNFAIP3 mRNA increases expression
mRNA 18058816
D017239 8797 TNFRSF10A
APO2
CD261
DR4
TRAILR-1
TRAILR1
tumor necrosis factor receptor superfamily, member 10a Cycloheximide inhibits the reaction [Paclitaxel results in increased expression of TNFRSF10A protein] decreases reaction
/ increases expression
protein 11212279
D017239 8797 TNFRSF10A
APO2
CD261
DR4
TRAILR-1
TRAILR1
tumor necrosis factor receptor superfamily, member 10a Paclitaxel results in increased expression of TNFRSF10A protein increases expression
protein 11212279
D017239 8795 TNFRSF10B
CD262
DR5
KILLER
KILLER/DR5
TRAIL-R2
TRAILR2
TRICK2
TRICK2A
TRICK2B
TRICKB
ZTNFR9
tumor necrosis factor receptor superfamily, member 10b Cycloheximide inhibits the reaction [Paclitaxel results in increased expression of TNFRSF10B protein] decreases reaction
/ increases expression
protein 11212279
D017239 8795 TNFRSF10B
CD262
DR5
KILLER
KILLER/DR5
TRAIL-R2
TRAILR2
TRICK2
TRICK2A
TRICK2B
TRICKB
ZTNFR9
tumor necrosis factor receptor superfamily, member 10b Paclitaxel results in increased expression of TNFRSF10B protein increases expression
protein 11212279
D017239 8743 TNFSF10
APO2L
Apo-2L
CD253
TL2
TRAIL
tumor necrosis factor (ligand) superfamily, member 10 Paclitaxel results in increased expression of TNFSF10 protein increases expression
protein 15907983
D017239 8741 TNFSF13
APRIL
CD256
TALL-2
TALL2
TRDL-1
ZTNF2
tumor necrosis factor (ligand) superfamily, member 13 Paclitaxel results in increased expression of TNFSF13 mRNA increases expression
mRNA 18058816
D017239 10673 TNFSF13B
BAFF
BLYS
CD257
DTL
TALL-1
TALL1
THANK
TNFSF20
ZTNF4
tumor necrosis factor (ligand) superfamily, member 13b Paclitaxel results in increased expression of TNFSF13B mRNA increases expression
mRNA 18058816
D017239 7153 TOP2A
TOP2
TP2A
topoisomerase (DNA) II alpha 170kDa (EC:5.99.1.3) TOP2A mRNA results in increased susceptibility to Paclitaxel increases response to substance
mRNA 16322897
D017239 7153 TOP2A
TOP2
TP2A
topoisomerase (DNA) II alpha 170kDa (EC:5.99.1.3) TOP2A results in decreased susceptibility to [Cisplatin co-treated with Paclitaxel] affects cotreatment
/ decreases response to substance
11325482
D017239 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 [Doxorubicin co-treated with Paclitaxel] results in increased expression of TP53 protein affects cotreatment
/ increases expression
protein 16168113
D017239 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Fluorouracil promotes the reaction [[Doxorubicin co-treated with Paclitaxel] results in increased expression of TP53 protein] affects cotreatment
/ increases expression
/ increases reaction
protein 16168113
D017239 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Nicotine inhibits the reaction [Paclitaxel results in increased expression of TP53 protein] decreases reaction
/ increases expression
protein 16601104
D017239 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Paclitaxel inhibits the reaction [TP53 gene mutant form results in decreased susceptibility to Platinum Compounds] decreases reaction
/ decreases response to substance
gene 12440809
D017239 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Paclitaxel results in decreased expression of TP53 protein decreases expression
protein 11774260
D017239 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Paclitaxel results in increased expression of TP53 protein increases expression
protein 9041188
11774260
12082016
14991574
15990222
16601104
18516295
19815708
D017239 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Paclitaxel results in increased expression of TP53 protein modified form increases expression
protein 18451153
D017239 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 [Paclitaxel results in increased expression of TP53 protein] which results in increased expression of BAX mRNA increases expression
protein 9041188
D017239 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 [Paclitaxel results in increased expression of TP53 protein] which results in increased expression of CDKN1A mRNA increases expression
protein 9041188
D017239 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 [Paclitaxel results in increased expression of TP53 protein] which results in increased expression of GADD45A mRNA increases expression
protein 9041188
D017239 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 [PD168393 co-treated with Paclitaxel] results in increased expression of TP53 protein affects cotreatment
/ increases expression
protein 16413505
D017239 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 TP53 protein results in decreased susceptibility to Paclitaxel decreases response to substance
protein 15990222
16734730
D017239 7163 TPD52
D52
N8L
PC-1
PrLZ
hD52
tumor protein D52 Paclitaxel results in decreased expression of TPD52 mRNA decreases expression
mRNA 19682730
D017239 7185 TRAF1
EBI6
MGC:10353
TNF receptor-associated factor 1 Paclitaxel results in decreased expression of TRAF1 mRNA decreases expression
mRNA 18058816
D017239 7188 TRAF5
MGC:39780
RNF84
TNF receptor-associated factor 5 Paclitaxel results in decreased expression of TRAF5 mRNA decreases expression
mRNA 15000894
D017239 23321 TRIM2
CMT2R
RNF86
tripartite motif containing 2 TRIM2 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 11078 TRIOBP
DFNB28
TARA
dJ37E16.4
TRIO and F-actin binding protein Paclitaxel results in increased expression of TRIOBP protein increases expression
protein 15907983
D017239 7222 TRPC3
TRP3
transient receptor potential cation channel, subfamily C, member 3 Paclitaxel results in increased expression of TRPC3 protein increases expression
protein 15907983
D017239 203068 TUBB
M40
OK/SW-cl.56
TUBB1
TUBB5
tubulin, beta class I TUBB mRNA results in increased susceptibility to Paclitaxel increases response to substance
mRNA 15239142
D017239 1890 TYMP
ECGF
ECGF1
MEDPS1
MNGIE
MTDPS1
PDECGF
TP
hPD-ECGF
thymidine phosphorylase (EC:2.4.2.4) [Paclitaxel co-treated with doxifluridine] affects the expression of TYMP mRNA affects cotreatment
/ affects expression
mRNA 18630517
D017239 1890 TYMP
ECGF
ECGF1
MEDPS1
MNGIE
MTDPS1
PDECGF
TP
hPD-ECGF
thymidine phosphorylase (EC:2.4.2.4) Paclitaxel results in increased expression of TYMP mRNA increases expression
mRNA 18630517
D017239 1890 TYMP
ECGF
ECGF1
MEDPS1
MNGIE
MTDPS1
PDECGF
TP
hPD-ECGF
thymidine phosphorylase (EC:2.4.2.4) Paclitaxel results in increased expression of TYMP protein increases expression
protein 15492279
D017239 1890 TYMP
ECGF
ECGF1
MEDPS1
MNGIE
MTDPS1
PDECGF
TP
hPD-ECGF
thymidine phosphorylase (EC:2.4.2.4) TYMP inhibits the reaction [Paclitaxel results in increased cleavage of PARP1 protein] decreases reaction
/ increases cleavage
15907805
D017239 1890 TYMP
ECGF
ECGF1
MEDPS1
MNGIE
MTDPS1
PDECGF
TP
hPD-ECGF
thymidine phosphorylase (EC:2.4.2.4) TYMP inhibits the reaction [Paclitaxel results in increased expression of FASLG mRNA] decreases reaction
/ increases expression
15907805
D017239 1890 TYMP
ECGF
ECGF1
MEDPS1
MNGIE
MTDPS1
PDECGF
TP
hPD-ECGF
thymidine phosphorylase (EC:2.4.2.4) TYMP inhibits the reaction [Paclitaxel results in increased expression of FASLG protein] decreases reaction
/ increases expression
15907805
D017239 1890 TYMP
ECGF
ECGF1
MEDPS1
MNGIE
MTDPS1
PDECGF
TP
hPD-ECGF
thymidine phosphorylase (EC:2.4.2.4) TYMP inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein] decreases reaction
/ increases phosphorylation
15907805
D017239 1890 TYMP
ECGF
ECGF1
MEDPS1
MNGIE
MTDPS1
PDECGF
TP
hPD-ECGF
thymidine phosphorylase (EC:2.4.2.4) [TYMP mutant form co-treated with Paclitaxel] results in increased cleavage of CASP8 protein affects cotreatment
/ increases cleavage
mutant form 15492279
D017239 1890 TYMP
ECGF
ECGF1
MEDPS1
MNGIE
MTDPS1
PDECGF
TP
hPD-ECGF
thymidine phosphorylase (EC:2.4.2.4) TYMP mutant form promotes the reaction [Paclitaxel results in increased cleavage of CASP3 protein] increases cleavage
/ increases reaction
mutant form 15492279
D017239 1890 TYMP
ECGF
ECGF1
MEDPS1
MNGIE
MTDPS1
PDECGF
TP
hPD-ECGF
thymidine phosphorylase (EC:2.4.2.4) TYMP mutant form promotes the reaction [Paclitaxel results in increased cleavage of PARP1 protein] increases cleavage
/ increases reaction
mutant form 15492279
D017239 7298 TYMS
HST422
TMS
TS
thymidylate synthetase (EC:2.1.1.45) [Doxorubicin co-treated with Paclitaxel] results in decreased expression of TYMS protein affects cotreatment
/ decreases expression
protein 16168113
D017239 7298 TYMS
HST422
TMS
TS
thymidylate synthetase (EC:2.1.1.45) Fluorouracil inhibits the reaction [[Doxorubicin co-treated with Paclitaxel] results in decreased expression of TYMS protein] affects cotreatment
/ decreases expression
/ decreases reaction
protein 16168113
D017239 7298 TYMS
HST422
TMS
TS
thymidylate synthetase (EC:2.1.1.45) Paclitaxel affects the expression of TYMS mRNA affects expression
mRNA 18630517
D017239 7298 TYMS
HST422
TMS
TS
thymidylate synthetase (EC:2.1.1.45) [Paclitaxel co-treated with doxifluridine] affects the expression of TYMS mRNA affects cotreatment
/ affects expression
mRNA 18630517
D017239 7298 TYMS
HST422
TMS
TS
thymidylate synthetase (EC:2.1.1.45) Paclitaxel results in increased expression of TYMS mRNA increases expression
mRNA 16568373
D017239 7298 TYMS
HST422
TMS
TS
thymidylate synthetase (EC:2.1.1.45) TYMS gene polymorphism results in increased susceptibility to [Leucovorin co-treated with Fluorouracil co-treated with Cisplatin co-treated with Paclitaxel] affects cotreatment
/ increases response to substance
gene 16424979
D017239 9246 UBE2L6
RIG-B
UBCH8
ubiquitin-conjugating enzyme E2L 6 (EC:6.3.2.19) UBE2L6 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 7372 UMPS
OPRT
uridine monophosphate synthetase (EC:2.4.2.10 4.1.1.23) Paclitaxel results in decreased expression of UMPS mRNA decreases expression
mRNA 16568373
D017239 7374 UNG
DGU
HIGM4
HIGM5
UDG
UNG1
UNG15
UNG2
uracil-DNA glycosylase (EC:3.2.2.27) UNG protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 7389 UROD
PCT
UPD
uroporphyrinogen decarboxylase (EC:4.1.1.37) UROD protein results in decreased susceptibility to Paclitaxel decreases response to substance
protein 21270338
D017239 8078 USP5
ISOT
ubiquitin specific peptidase 5 (isopeptidase T) (EC:3.4.19.12) Paclitaxel results in decreased expression of USP5 mRNA decreases expression
mRNA 15000894
D017239 8673 VAMP8
EDB
VAMP-8
vesicle-associated membrane protein 8 VAMP8 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 7412 VCAM1
CD106
INCAM-100
vascular cell adhesion molecule 1 Paclitaxel inhibits the reaction [Colchicine inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]] decreases reaction
/ increases expression
mRNA 11154858
D017239 7412 VCAM1
CD106
INCAM-100
vascular cell adhesion molecule 1 Paclitaxel inhibits the reaction [Colchicine inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]] decreases reaction
/ increases expression
protein 11154858
D017239 7412 VCAM1
CD106
INCAM-100
vascular cell adhesion molecule 1 Paclitaxel inhibits the reaction [Griseofulvin inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]] decreases reaction
/ increases expression
mRNA 11154858
D017239 7412 VCAM1
CD106
INCAM-100
vascular cell adhesion molecule 1 Paclitaxel inhibits the reaction [Griseofulvin inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]] decreases reaction
/ increases expression
protein 11154858
D017239 7412 VCAM1
CD106
INCAM-100
vascular cell adhesion molecule 1 VCAM1 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 7422 VEGFA
MVCD1
VEGF
VPF
vascular endothelial growth factor A Curcumin inhibits the reaction [Paclitaxel results in increased expression of VEGFA protein] decreases reaction
/ increases expression
protein 16243823
D017239 80349 WDR61
REC14
SKI8
WD repeat domain 61 WDR61 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 11197 WIF1
WIF-1
WNT inhibitory factor 1 WIF1 protein results in increased susceptibility to Paclitaxel increases response to substance
protein 15389810
D017239 49856 WRAP73
WDR8
WD repeat containing, antisense to TP73 WRAP73 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 55884 WSB2
SBA2
WD repeat and SOCS box containing 2 WSB2 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 331 XIAP
API3
BIRC4
IAP-3
ILP1
MIHA
XLP2
hIAP-3
hIAP3
X-linked inhibitor of apoptosis Curcumin inhibits the reaction [Paclitaxel results in increased expression of XIAP protein] decreases reaction
/ increases expression
protein 16243823
D017239 331 XIAP
API3
BIRC4
IAP-3
ILP1
MIHA
XLP2
hIAP-3
hIAP3
X-linked inhibitor of apoptosis [IL8 results in increased expression of XIAP mRNA] which results in decreased susceptibility to Paclitaxel decreases response to substance
/ increases expression
mRNA 21742513
D017239 331 XIAP
API3
BIRC4
IAP-3
ILP1
MIHA
XLP2
hIAP-3
hIAP3
X-linked inhibitor of apoptosis [IL8 results in increased expression of XIAP protein] which results in decreased susceptibility to Paclitaxel decreases response to substance
/ increases expression
protein 21742513
D017239 331 XIAP
API3
BIRC4
IAP-3
ILP1
MIHA
XLP2
hIAP-3
hIAP3
X-linked inhibitor of apoptosis Paclitaxel affects the expression of XIAP protein affects expression
protein 18071906
D017239 331 XIAP
API3
BIRC4
IAP-3
ILP1
MIHA
XLP2
hIAP-3
hIAP3
X-linked inhibitor of apoptosis Paclitaxel results in decreased expression of XIAP protein decreases expression
protein 16356831
18451153
D017239 7514 XPO1
CRM1
emb
exp1
exportin 1 (CRM1 homolog, yeast) Paclitaxel results in decreased expression of XPO1 mRNA decreases expression
mRNA 15000894
D017239 10971 YWHAQ
14-3-3
1C5
HS1
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, theta polypeptide Paclitaxel results in increased expression of YWHAQ protein increases expression
protein 10822281
D017239 678 ZFP36L2
BRF2
ERF-2
ERF2
RNF162C
TIS11D
ZFP36 ring finger protein-like 2 ZFP36L2 protein affects the susceptibility to Paclitaxel affects response to substance
protein 16217747
D017239 79818 ZNF552
zinc finger protein 552 ZNF552 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] affects cotreatment
/ affects response to substance
mRNA 16896004
D017239 9406 ZRANB2
ZIS
ZIS1
ZIS2
ZNF265
zinc finger, RAN-binding domain containing 2 Paclitaxel results in decreased expression of ZRANB2 protein decreases expression
protein 15907983

Related Disease

Diseases related to proteins in ChEMBL interactions

OMIM (113)

OMIM preferred title UniProt
#300438 17-beta-hydroxysteroid dehydrogenase x deficiency Q99714
#100100 Abdominal muscles, absence of, with urinary tract abnormality and cryptorchidism P20309
#202300 Adrenocortical carcinoma, hereditary; adcc P04637
#103780 Alcohol dependence P08172
P14416
P31645
#614373 Amyotrophic lateral sclerosis 16, juvenile; als16 Q99720
#300068 Androgen insensitivity syndrome; ais P10275
#312300 Androgen insensitivity, partial; pais P10275
#608584 Asthma-related traits, susceptibility to, 2 Q6W5P4
#614740 Basal cell carcinoma, susceptibility to, 7; bcc7 P04637
#187800 Bleeding disorder, platelet-type, 16; bdplt16 P05106
#210900 Bloom syndrome; blm P54132
#602025 Body mass index quantitative trait locus 9; bmiq9 P41968
%606641 Body mass index; bmi P37231
#300615 Brunner syndrome P21397
#115200 Cardiomyopathy, dilated, 1a; cmd1a P02545
#212112 Cardiomyopathy, dilated, with hypergonadotropic hypogonadism P02545
#609338 Carotid intimal medial thickness 1 P37231
#118300 Charcot-marie-tooth disease and deafness Q01453
#605588 Charcot-marie-tooth disease, axonal, type 2b1; cmt2b1 P02545
#118220 Charcot-marie-tooth disease, demyelinating, type 1a; cmt1a Q01453
#605479 Cholestasis, benign recurrent intrahepatic, 2; bric2 O95342
#614972 Cholestasis, intrahepatic, of pregnancy 3; icp3 P21439
#601847 Cholestasis, progressive familial intrahepatic, 2; pfic2 O95342
#602347 Cholestasis, progressive familial intrahepatic, 3; pfic3 P21439
#114500 Colorectal cancer; crc P84022
#614039 Cortical dysplasia, complex, with other brain malformations 1; cdcbm1 Q13509
#162800 Cyclic neutropenia P08246
#127750 Dementia, lewy body; dlb P37840
#612522 Diabetes mellitus, insulin-dependent, 22; iddm22 P51681
#609535 Drug metabolism, poor, cyp2c19-related P33261
#608902 Drug metabolism, poor, cyp2d6-related P10635
#128101 Dystonia 4, torsion, autosomal dominant; dyt4 P04350
#181350 Emery-dreifuss muscular dystrophy 2, autosomal dominant; edmd2 P02545
#133239 Esophageal cancer P04637
#615363 Estrogen resistance; estrr P03372
#600638 Fibrosis of extraocular muscles, congenital, 3a, with or without extraocular involvement; cfeom3a Q13509
#600274 Frontotemporal dementia; ftd P10636
#600803 Gallbladder disease 1; gbd1 P21439
#613659 Gastric cancer P04626
#137215 Gastric cancer, hereditary diffuse; hdgc P04626
#231095 Ghosal hematodiaphyseal dysplasia; ghdd P24557
#273800 Glanzmann thrombasthenia; gt P05106
#137800 Glioma susceptibility 1; glm1 O75874
P04626
P37231
#139393 Guillain-barre syndrome, familial; gbs Q01453
#605130 Hairy elbows, short stature, facial dysmorphism, and developmental delay Q03164
#610140 Heart-hand syndrome, slovenian type P02545
#609423 Human immunodeficiency virus type 1, susceptibility to P41597
P51681
#176670 Hutchinson-gilford progeria syndrome; hgps P02545
#237450 Hyperbilirubinemia, rotor type; hblrr Q9NPD5
Q9Y6L6
#145000 Hyperparathyroidism 1; hrpt1 O00255
#145900 Hypertrophic neuropathy of dejerine-sottas Q01453
#612244 Inflammatory bowel disease 13; ibd13 P08183
#603932 Intervertebral disc disease; idd P14780
#612438 Leukodystrophy, hypomyelinating, 6; hld6 P04350
#151623 Li-fraumeni syndrome 1; lfs1 P04637
#151660 Lipodystrophy, familial partial, type 2; fpld2 P02545
#604367 Lipodystrophy, familial partial, type 3; fpld3 P37231
#611603 Lissencephaly 3; lis3 Q71U36
#613795 Loeys-dietz syndrome, type 3; lds3 P84022
#613688 Long qt syndrome 2; lqt2 Q12809
#211980 Lung cancer P00533
P04626
P04637
#613112 Macrothrombocytopenia, autosomal dominant, tubb1-related Q9H4B7
#608516 Major depressive disorder; mdd P08172
#248370 Mandibuloacral dysplasia with type a lipodystrophy; mada P02545
#300705 Mental retardation, x-linked 17; mrx17 Q99714
%300852 Mental retardation, x-linked 88; mrx88 P50052
#300220 Mental retardation, x-linked, syndromic 10; mrxs10 Q99714
#613073 Metaphyseal anadysplasia 2; mandp2 P14780
#131100 Multiple endocrine neoplasia, type i; men1 O00255
#126200 Multiple sclerosis, susceptibility to; ms P08575
#613205 Muscular dystrophy, congenital, lmna-related P02545
#159001 Muscular dystrophy, limb-girdle, type 1b; lgmd1b P02545
#607948 Mycobacterium tuberculosis, susceptibility to P11473
#159900 Myoclonic dystonia P14416
#162500 Neuropathy, hereditary, with liability to pressure palsies; hnpp Q01453
#202700 Neutropenia, severe congenital, 1, autosomal dominant; scn1 P08246
#257220 Niemann-pick disease, type c1; npc1 O15118
#601665 Obesity P32245
P37231
#164230 Obsessive-compulsive disorder; ocd P31645
#604715 Orthostatic intolerance P23975
#259730 Osteopetrosis, autosomal recessive 3; optb3 P00918
#167000 Ovarian cancer P04626
#260500 Papilloma of choroid plexus; cpp P04637
#168601 Parkinson disease 1, autosomal dominant; park1 P37840
#605543 Parkinson disease 4, autosomal dominant; park4 P37840
#168600 Parkinson disease, late-onset; pd P37840
#260540 Parkinson-dementia syndrome P10636
#613135 Parkinsonism-dystonia, infantile; pkdys Q01959
#172700 Pick disease of brain P10636
#610031 Polymicrogyria, symmetric or asymmetric; pmgysa Q9BVA1
#607276 Resting heart rate, variation in P08588
#275210 Restrictive dermopathy, lethal P02545
#604906 Schizophrenia 9; sczd9 P49798
#181500 Schizophrenia; sczd P49798
#608971 Severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-positive, nk cell-positive P08575
#609620 Short qt syndrome 1; sqt1 Q12809
#313200 Spinal and bulbar muscular atrophy, x-linked 1; smax1 P10275
#253300 Spinal muscular atrophy, type i; sma1 Q16637
#253550 Spinal muscular atrophy, type ii; sma2 Q16637
#253400 Spinal muscular atrophy, type iii; sma3 Q16637
#271150 Spinal muscular atrophy, type iv; sma4 Q16637
#183090 Spinocerebellar ataxia 2; sca2 Q99700
#607250 Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy; scan1 Q9NUW8
#275355 Squamous cell carcinoma, head and neck; hnscc P04637
#601104 Supranuclear palsy, progressive, 1; psnp1 P10636
#187950 Thrombocythemia 1; thcyt1 P40225
#188570 Thyroid hormone resistance, generalized, autosomal dominant; grth P10828
#274300 Thyroid hormone resistance, generalized, autosomal recessive; grth P10828
#145650 Thyroid hormone resistance, selective pituitary; prth P10828
#190300 Tremor, hereditary essential, 1; etm1 P35462
#277440 Vitamin d-dependent rickets, type 2a; vddr2a P11473
#610379 West nile virus, susceptibility to P51681
#112100 Yt blood group antigen P22303

KEGG DISEASE (100)

KEGG disease name UniProt
H00033 Adrenal carcinoma O00255 (related)
P04637 (related)
H00034 Carcinoid O00255 (related)
H00045 Malignant islet cell carcinoma O00255 (related)
H00246 Primary hyperparathyroidism O00255 (related)
H01102 Pituitary adenomas O00255 (related)
H00136 Niemann-Pick disease type C (NPC) O15118 (related)
H00624 Familial cholestasis O95342 (related)
P21439 (related)
H00016 Oral cancer P00533 (related)
P00533 (marker)
P04637 (related)
P04637 (marker)
H00017 Esophageal cancer P00533 (related)
P04637 (related)
P04637 (marker)
P35354 (related)
H00018 Gastric cancer P00533 (related)
P04626 (related)
P04637 (related)
P10415 (related)
H00022 Bladder cancer P00533 (related)
P04626 (related)
P04637 (related)
H00028 Choriocarcinoma P00533 (related)
P03956 (related)
P04626 (related)
P04637 (related)
P10415 (related)
H00030 Cervical cancer P00533 (related)
P04626 (related)
P10415 (related)
H00042 Glioma P00533 (related)
P00533 (marker)
P04637 (related)
P04637 (marker)
H00055 Laryngeal cancer P00533 (related)
P00533 (marker)
P04637 (related)
P04637 (marker)
H00241 Combined proximal and distal renal tubular acidosis (RTA type 3) P00918 (related)
H00436 Osteopetrosis P00918 (related)
H00264 Charcot-Marie-Tooth disease (CMT) P02545 (related)
Q01453 (related)
H00294 Dilated cardiomyopathy (DCM) P02545 (related)
H00420 Familial partial lipodystrophy (FPL) P02545 (related)
P37231 (related)
H00563 Emery-Dreifuss muscular dystrophy P02545 (related)
H00590 Congenital muscular dystrophies (CMD/MDC) P02545 (related)
H00593 Limb-girdle muscular dystrophy (LGMD) P02545 (related)
H00601 Hutchinson-Gilford progeria syndrome P02545 (related)
H00663 Restrictive dermopathy P02545 (related)
H00665 Mandibuloacral dysplasia P02545 (related)
H01216 Left ventricular noncompaction (LVNC) P02545 (related)
H00026 Endometrial Cancer P03372 (marker)
P04626 (related)
P04637 (related)
Q92731 (marker)
H00599 46,XX disorders of sex development (Disorders related to androgen excess) P04150 (related)
H00005 Chronic lymphocytic leukemia (CLL) P04183 (marker)
P04637 (related)
P10415 (related)
H00019 Pancreatic cancer P04626 (related)
P04637 (related)
P04637 (marker)
H00027 Ovarian cancer P04626 (related)
P04637 (related)
H00031 Breast cancer P04626 (related)
P04626 (marker)
P04637 (related)
H00046 Cholangiocarcinoma P04626 (related)
P04637 (related)
P35354 (related)
H00004 Chronic myeloid leukemia (CML) P04637 (related)
H00006 Hairy-cell leukemia P04637 (related)
H00008 Burkitt lymphoma P04637 (related)
H00009 Adult T-cell leukemia P04637 (related)
H00010 Multiple myeloma P04637 (related)
H00013 Small cell lung cancer P04637 (related)
P10415 (related)
H00014 Non-small cell lung cancer P04637 (related)
H00015 Malignant pleural mesothelioma P04637 (related)
H00020 Colorectal cancer P04637 (related)
P04637 (marker)
H00025 Penile cancer P04637 (related)
P04637 (marker)
P14780 (related)
P35354 (related)
H00029 Vulvar cancer P04637 (related)
H00032 Thyroid cancer P04637 (related)
P37231 (related)
H00036 Osteosarcoma P04637 (related)
P08684 (marker)
H00038 Malignant melanoma P04637 (related)
H00039 Basal cell carcinoma P04637 (related)
H00040 Squamous cell carcinoma P04637 (related)
H00041 Kaposi's sarcoma P04637 (related)
P10415 (related)
H00044 Cancer of the anal canal P04637 (related)
H00047 Gallbladder cancer P04637 (related)
H00048 Hepatocellular carcinoma P04637 (related)
H00881 Li-Fraumeni syndrome P04637 (related)
H01007 Choroid plexus papilloma P04637 (related)
H00021 Renal cell carcinoma P04637 (marker)
H00083 Allograft rejection P05106 (related)
H00226 Glanzmann thrombasthenia P05106 (related)
H00093 Combined immunodeficiencies (CIDs) P06239 (related)
H00079 Asthma P07550 (related)
H00100 Neutropenic disorders P08246 (related)
H00091 T-B+Severe combined immunodeficiencies (SCIDs) P08575 (related)
H00024 Prostate cancer P10275 (related)
H00062 Spinal and bulbar muscular atrophy (SBMA) P10275 (related)
H00608 46,XY disorders of sex development (Disorders in androgen synthesis or action) P10275 (related)
H00609 46,XY disorders of sex development (Other) P10275 (related)
H00054 Nasopharyngeal cancer P10415 (related)
H00058 Amyotrophic lateral sclerosis (ALS) P10636 (related)
H00077 Progressive supranuclear palsy (PSP) P10636 (related)
H00078 Frontotemporal lobar degeneration (FTLD) P10636 (related)
H00249 Thyroid hormone resistance syndrome P10828 (related)
H00342 Tuberculosis P11473 (related)
H00784 Localized autosomal recessive hypotrichosis P11473 (related)
H01143 Vitamin D-dependent rickets P11473 (related)
H01205 Coumarin resistance P11712 (related)
H00479 Metaphyseal dysplasias P14780 (related)
H00548 Brunner syndrome P21397 (related)
H01213 Gallbladder disease P21439 (related)
H01031 Orthostatic intolerance (OI) P23975 (related)
H00490 Diaphyseal dysplasia with anemia (Ghosal) P24557 (related)
H01171 Poor drug metabolism (PM) P33261 (related)
H00409 Type II diabetes mellitus P37231 (related)
H00057 Parkinson's disease (PD) P37840 (related)
H00066 Lewy body dementia (LBD) P37840 (related)
H00227 Congenital amegakaryocytic thrombocytopenia (CAMT) P40225 (marker)
H00480 Non-syndromic X-linked mental retardation P50052 (related)
Q99714 (related)
H00094 DNA repair defects P54132 (related)
H00296 Defects in RecQ helicases P54132 (related)
H01296 Hereditary neuropathy with liability to pressure palsies (HNPP) Q01453 (related)
H00001 Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia) Q03164 (related)
Q03164 (marker)
H00002 Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia) Q03164 (related)
H00720 Long QT syndrome Q12809 (related)
H00725 Short QT syndrome Q12809 (related)
H00838 Congenital fibrosis of the extraocular muscles (CFEOM) Q13509 (related)
H00455 Spinal muscular atrophy (SMA) Q16637 (related)
Q16637 (related)
H00268 Lissencephaly (LIS) Q71U36 (related)
H00063 Spinocerebellar ataxia (SCA) Q99700 (related)
Q9NUW8 (related)
H00658 Syndromic X-linked mental retardation Q99714 (related)
H00925 2-Methyl-3-hydroxybutyryl-CoA dehydrogenase (MHBD) deficiency Q99714 (related)

Diseases related to CTD interactions

231 disease from interactions of metabolites

MeSH disease OMIM compound disease name evidence type reference
pmid
D015746 D017239 Abdominal Pain marker/mechanism
8708721
D000230 D017239 Adenocarcinoma therapeutic
8552128
C538231 D017239 Adenocarcinoma of lung therapeutic
8643967
16604029
19027286
D000380 D017239 Agranulocytosis marker/mechanism
7525883
7543559
8636011
8643973
9007119
9007120
9440750
10362115
10800167
C554498 D017239 AIDS-related Kaposi sarcoma therapeutic
10861090
18521433
D000435 D017239 Alcoholic Intoxication marker/mechanism
16402636
D000505 D017239 Alopecia marker/mechanism
7884419
8636602
8643971
8708721
8751544
8893892
8893895
9007121
9007123
9007126
9149030
9346219
9374088
9774950
11104554
11147586
12442916
15923795
15961435
16354605
20025538
D000707 D017239 Anaphylaxis marker/mechanism
7509380
7524159
D000740 D017239 Anemia marker/mechanism
therapeutic
7525883
7543559
7644923
8610231
10800167
11147586
11230474
11371143
12208573
12367796
12601542
14760117
15493352
15493357
15581045
15923795
15961435
16100454
16332718
16612156
16763792
16914900
17974278
19396017
19812061
20051288
D000755 D017239 Anemia, Sickle Cell marker/mechanism
18593679
D000783 D017239 Aneurysm marker/mechanism
15804801
D017541 D017239 Aneurysm, False marker/mechanism
16892440
D000855 D017239 Anorexia marker/mechanism
8708721
D018771 D017239 Arthralgia marker/mechanism
7509380
7524159
7543559
7543699
7644931
7884419
8558189
8643966
8643968
8643971
8893894
9007120
9007126
9007130
9149030
9635850
9850043
9889038
10483822
11147586
11230474
11706781
11977541
12442916
14698135
15118009
15334869
16766103
18839222
D001247 D017239 Asthenia marker/mechanism
10928183
15493358
D001259 D017239 Ataxia marker/mechanism
8649555
10483822
20389300
D050197 D017239 Atherosclerosis therapeutic
17449502
D001281 D017239 Atrial Fibrillation marker/mechanism
9676843
10052252
D054537 D017239 Atrioventricular Block marker/mechanism
8102012
17223814
D001416 D017239 Back Pain marker/mechanism
18593679
D001855 D017239 Bone Marrow Diseases marker/mechanism
9346219
9346226
15790438
D001859 D017239 Bone Neoplasms therapeutic
15867366
D001919 D017239 Bradycardia marker/mechanism
8102012
14514973
16354605
D001927 D017239 Brain Diseases marker/mechanism
8649555
12056715
16604029
16991134
D001929 D017239 Brain Edema marker/mechanism
16132524
D020520 D017239 Brain Infarction marker/mechanism
10100699
D001932 D017239 Brain Neoplasms therapeutic
7481858
D001943 D017239 Breast Neoplasms therapeutic
7541186
7543699
7595726
7638640
7669713
7692001
7912737
8625200
8629032
8893892
8893894
8893895
8893896
9018096
9071336
9106649
9149085
9296218
9374088
9553960
9676843
9766754
10458265
10472783
10577856
10586344
10767372
11325840
11335791
11552226
11726273
12189532
14698135
15136595
15170980
15325671
15493352
15581045
15668279
15865068
15907983
16115903
16244791
16273361
16354605
16580691
16739356
17223814
17348454
17611715
18026678
18223236
18234424
18323546
19027286
19544276
20813818
21321953
21346553
21781528
D001986 D017239 Bronchial Spasm marker/mechanism
11455223
D002037 D017239 Bundle-Branch Block marker/mechanism
8102012
D002277 D017239 Carcinoma therapeutic
9018096
10458265
10569619
11487721
15907983
15923795
18418024
D018270 D017239 Carcinoma, Ductal, Breast therapeutic
11020424
16414547
18593679
D018269 D017239 Carcinoma, Endometrioid therapeutic
21151415
D006528 D017239 Carcinoma, Hepatocellular therapeutic
9858906
10964328
16027087
16313753
17399942
D018287 D017239 Carcinoma, Large Cell therapeutic
8643967
D018827 D017239 Carcinoma, Lewis Lung therapeutic
19027286
D002289 D017239 Carcinoma, Non-Small-Cell Lung therapeutic
7543559
7644931
7692001
8094467
8558189
8610231
8643966
8643967
8643968
8797774
9007119
9007120
9007121
9007122
9007123
9007126
9007130
9007133
9007139
9440737
10777471
10928183
11135224
11679185
11800032
12216094
14514973
14769840
16612156
17166623
17974278
18839222
D002294 D017239 Carcinoma, Squamous Cell therapeutic
8643967
C535575 D017239 Carcinoma, squamous cell of head and neck therapeutic
19484992
D002295 D017239 Carcinoma, Transitional Cell therapeutic
7525883
9346226
11104554
11113764
D009202 D017239 Cardiomyopathies marker/mechanism
11552226
D002493 D017239 Central Nervous System Diseases marker/mechanism
10483822
D002637 D017239 Chest Pain marker/mechanism
8893117
19382279
20052472
D015209 D017239 Cholangitis, Sclerosing marker/mechanism
19544276
D002779 D017239 Cholestasis therapeutic
8895755
9794924
D015834 D017239 Cochlear Diseases marker/mechanism
16406077
D003072 D017239 Cognition Disorders marker/mechanism
16490239
D017091 D017239 Colitis, Ischemic marker/mechanism
11468447
D015179 D017239 Colorectal Neoplasms therapeutic
18802399
D003128 D017239 COMA marker/mechanism
10100699
D003221 D017239 Confusion marker/mechanism
8649555
10100699
16604029
16991134
D003244 D017239 Consciousness Disorders marker/mechanism
18418024
D003248 D017239 Constipation marker/mechanism
11104554
D003251 D017239 Constriction, Pathologic marker/mechanism
therapeutic
17328975
19815708
D054059 D017239 Coronary Occlusion marker/mechanism
15657205
D003329 D017239 Coronary Vasospasm marker/mechanism
12677287
D003638 D017239 Deafness marker/mechanism
11205470
D003711 D017239 Demyelinating Diseases marker/mechanism
9149085
D003866 D017239 Depressive Disorder marker/mechanism
9018096
D003967 D017239 Diarrhea marker/mechanism
therapeutic
7525883
7543699
8708721
9164208
9774950
10955861
11104554
12110496
15131032
15493358
15923795
16332718
19812061
D004172 D017239 Diplopia marker/mechanism
15566651
D004244 D017239 Dizziness marker/mechanism
7909329
18418024
D003875 D017239 Drug Eruptions marker/mechanism
20598060
D004342 D017239 Drug Hypersensitivity marker/mechanism
7909329
8636602
8751544
9346218
12442916
21233199
D056486 D017239 Drug-Induced Liver Injury marker/mechanism
therapeutic
9676843
16332718
D064420 D017239 Drug-Related Side Effects and Adverse Reactions marker/mechanism
7669713
7904060
8554453
8626111
8649555
9057954
9239526
9635850
9879778
10483822
11205470
11455223
12110496
12207621
12442916
12618886
14615449
15923795
16991134
18990504
19704064
D004408 D017239 Dysgeusia marker/mechanism
18378545
D004417 D017239 Dyspnea marker/mechanism
18593679
D053159 D017239 Dysuria marker/mechanism
8708721
D004487 D017239 Edema marker/mechanism
11731066
12859102
19260244
D016889 D017239 Endometrial Neoplasms therapeutic
9346228
12601542
20863554
D004751 D017239 Enteritis marker/mechanism
12759687
D044504 D017239 Enterocolitis, Neutropenic marker/mechanism
12110496
D004761 D017239 Enterocolitis, Pseudomembranous marker/mechanism
11468447
D004890 D017239 Erythema marker/mechanism
7644923
D004892 D017239 Erythema Multiforme marker/mechanism
12582404
D004938 D017239 Esophageal Neoplasms therapeutic
7692001
10362115
12110496
16100454
16481741
20389300
D004941 D017239 Esophagitis marker/mechanism
9007133
9007139
14760117
D005076 D017239 Exanthema marker/mechanism
8708721
9007123
9774950
10955861
D005119 D017239 Extravasation of Diagnostic and Therapeutic Materials marker/mechanism
8797774
D005155 D017239 Facial Nerve Diseases marker/mechanism
10586344
D005158 D017239 Facial Paralysis marker/mechanism
10586344
D005185 D017239 Fallopian Tube Neoplasms therapeutic
18554701
D005221 D017239 Fatigue marker/mechanism
8708721
10483822
14698135
14760117
16100454
17974278
18593679
D005334 D017239 Fever marker/mechanism
7884419
8643967
8893894
9149030
9346218
9346219
9676843
9740541
9849468
10362115
12367796
14760117
D005483 D017239 Flushing marker/mechanism
7509380
7909329
15026476
D005549 D017239 Foreign-Body Reaction marker/mechanism
19564562
D020233 D017239 Gait Disorders, Neurologic marker/mechanism
8625200
9149085
11350883
20813818
D005767 D017239 Gastrointestinal Diseases marker/mechanism
8751544
15923795
20052472
D005833 D017239 Genital Neoplasms, Female therapeutic
8751544
D005909 D017239 Glioblastoma therapeutic
7481858
17701358
18098270
D005910 D017239 Glioma therapeutic
12874004
15201989
D006212 D017239 Hallucinations marker/mechanism
16604029
D006261 D017239 Headache marker/mechanism
7509380
7904060
8649555
D006258 D017239 Head and Neck Neoplasms therapeutic
7692001
8643971
9149030
19396017
D006311 D017239 Hearing Disorders marker/mechanism
8626111
10483822
12911718
D006312 D017239 Hearing Loss, Bilateral marker/mechanism
9849468
D006319 D017239 Hearing Loss, Sensorineural marker/mechanism
9849468
16406077
D006323 D017239 Heart Arrest marker/mechanism
15657205
16632443
D006327 D017239 Heart Block marker/mechanism
7578376
16354605
D006331 D017239 Heart Diseases marker/mechanism
7904060
8554453
8677355
10037178
15668279
D006333 D017239 Heart Failure marker/mechanism
7595726
8629032
8893895
10550159
10577856
10828864
11296620
11583187
15173858
15865068
16354605
16739356
D006394 D017239 Hemangiosarcoma therapeutic
9774950
D006402 D017239 Hematologic Diseases marker/mechanism
7644931
9346228
D006501 D017239 Hepatic Encephalopathy marker/mechanism
9106649
10100699
D006685 D017239 Hoarseness marker/mechanism
8683640
D006930 D017239 Hyperalgesia marker/mechanism
7509380
11134612
11731066
11738263
14984413
15041441
15082137
15875786
16213089
16361064
16406309
16414547
16480831
16530964
16632831
16687474
16854522
17005179
17174526
18037242
18234883
18472288
18664590
18777607
18846037
19027286
19276613
19336915
19833436
20068451
20184918
21050491
21118710
21233199
D006932 D017239 Hyperbilirubinemia marker/mechanism
15131032
D006943 D017239 Hyperglycemia marker/mechanism
8626111
15493358
D006967 D017239 Hypersensitivity marker/mechanism
9817264
11455223
11800032
15033348
15668279
D006973 D017239 Hypertension marker/mechanism
20389300
D006976 D017239 Hypertension, Pulmonary marker/mechanism
11422257
D006987 D017239 Hypesthesia marker/mechanism
7509380
7904620
7909329
8625200
9149085
11350883
15997923
16414547
D007022 D017239 Hypotension marker/mechanism
8636011
11455223
11800032
14760117
D007024 D017239 Hypotension, Orthostatic marker/mechanism
9849495
D045823 D017239 Ileus marker/mechanism
8683640
D058922 D017239 Inflammatory Breast Neoplasms therapeutic
11401310
D007674 D017239 Kidney Diseases marker/mechanism
8751544
9057954
9164208
D007806 D017239 Language Disorders marker/mechanism
8649555
D007822 D017239 Laryngeal Neoplasms therapeutic
8917408
D007890 D017239 Leiomyosarcoma therapeutic
9774950
D053609 D017239 Lethargy marker/mechanism
8636602
D007938 D017239 Leukemia therapeutic
7904060
D007945 D017239 Leukemia, Lymphoid therapeutic
17059768
D015470 D017239 Leukemia, Myeloid, Acute therapeutic
9766754
D056784 D017239 Leukoencephalopathies marker/mechanism
10100699
D007970 D017239 Leukopenia marker/mechanism
7543699
8094467
8643973
12601542
15493352
15493358
15566651
15923795
17593098
17637549
20025538
D008080 D017239 Liposarcoma therapeutic
17353645
D008113 D017239 Liver Neoplasms therapeutic
9018096
9849468
11468447
D008114 D017239 Liver Neoplasms, Experimental therapeutic
18058816
D008171 D017239 Lung Diseases marker/mechanism
9007123
D017563 D017239 Lung Diseases, Interstitial marker/mechanism
16612156
D008175 D017239 Lung Neoplasms marker/mechanism
therapeutic
8683640
9722903
15907983
18455578
21975929
D020522 D017239 Lymphoma, Mantle-Cell therapeutic
7884419
D008228 D017239 Lymphoma, Non-Hodgkin therapeutic
10800167
14749477
D008231 D017239 Lymphopenia marker/mechanism
7644923
D008325 D017239 Mammary Neoplasms, Experimental therapeutic
9231689
20838997
D008545 D017239 Melanoma therapeutic
12025231
12040289
16342250
19826135
20389300
D008546 D017239 Melanoma, Experimental therapeutic
1359143
D008654 D017239 Mesothelioma therapeutic
21645609
D051346 D017239 Mobility Limitation marker/mechanism
17005179
D019957 D017239 Motor Skills Disorders marker/mechanism
19027286
D009062 D017239 Mouth Neoplasms therapeutic
12912971
D052016 D017239 Mucositis marker/mechanism
7525883
7543699
7595726
7644923
9374088
9676843
9849468
11147586
D009101 D017239 Multiple Myeloma therapeutic
14749477
15728126
16969509
D009120 D017239 Muscle Cramp marker/mechanism
8708721
9149085
10483822
D018908 D017239 Muscle Weakness marker/mechanism
7904620
8710063
9149085
11350883
15997923
17611715
D009135 D017239 Muscular Diseases marker/mechanism
7509380
7524159
7543699
7884419
8558189
8636602
8643966
8643971
8667418
9007120
9007123
9007126
9007130
9635850
9676843
9850043
9889038
10458265
11104554
11679185
11706781
12442916
15118009
15334869
16766103
18839222
D009203 D017239 Myocardial Infarction marker/mechanism
8893117
9135899
12677287
14682199
16354605
19702043
D017202 D017239 Myocardial Ischemia marker/mechanism
7578376
8102012
8569460
8629032
D009260 D017239 Nail Diseases marker/mechanism
12442916
D009325 D017239 Nausea marker/mechanism
8610231
8643966
8708721
8893895
9007120
9007121
9149030
9346219
10955861
11800032
12442916
15170980
15493358
15923795
15961435
17974278
20025538
D009336 D017239 Necrosis marker/mechanism
11468447
15680171
16027087
D009362 D017239 Neoplasm Metastasis marker/mechanism
therapeutic
7543699
7638640
8552128
8893892
8913442
9018096
9676843
9849468
10458265
11401310
15170980
15867366
17637549
18058816
19826135
21975929
D009364 D017239 Neoplasm Recurrence, Local therapeutic
11706781
18455578
D009369 D017239 Neoplasms therapeutic
16334120
16763792
20433922
D009374 D017239 Neoplasms, Experimental therapeutic
17701358
18098270
22233293
D009373 D017239 Neoplasms, Germ Cell and Embryonal therapeutic
17593098
D009382 D017239 Neoplasms, Unknown Primary therapeutic
11468447
D009410 D017239 Nerve Degeneration marker/mechanism
7837287
7912506
9149085
9553960
11022860
11134612
12859102
16797537
17010629
18809400
19027286
19260244
21050491
D009422 D017239 Nervous System Diseases marker/mechanism
7525883
7595726
7638640
7669713
8097161
8636602
8643973
8893894
9007120
9007123
9007126
9007139
9149030
9164208
9239526
9346226
9346228
9374088
9440737
9440750
9676843
9774950
10362115
10777471
11147586
11205470
11221961
12110496
12216094
12442916
12552058
14615449
14758127
15252139
15493357
15493358
16039110
18042835
19704064
19727778
20547415
21321953
D009437 D017239 Neuralgia marker/mechanism
11134612
11731066
15082135
16213089
16406309
16414547
16687474
18037242
18472288
18664590
18777607
19595634
19833436
20068451
D009443 D017239 Neuritis marker/mechanism
8893892
D018358 D017239 Neuroendocrine Tumors therapeutic
11468447
D009468 D017239 Neuromuscular Diseases marker/mechanism
7692001
8708721
D020258 D017239 Neurotoxicity Syndromes marker/mechanism
9149085
10553948
11022860
12187335
15330181
D009503 D017239 Neutropenia marker/mechanism
therapeutic
7524159
7543559
7543699
7595726
7638640
7692001
7884419
8558189
8610231
8629032
8643966
8643967
8751544
8893894
8893895
8893896
9007121
9007123
9007126
9071336
9164208
9296218
9346218
9346219
9346221
9346223
9374088
9440737
9676843
9740541
9774950
9849468
9879778
10472783
10928183
10955861
11104554
11135224
11147586
11221961
11230474
11679185
11800032
12110496
12367796
12442916
12601542
12847320
14514973
14760117
14769840
15131032
15493357
15493358
15566651
15581045
15668279
15865068
15961435
16100454
16293865
16332718
16612156
16763792
16950614
17974278
18042835
19396017
19812061
20389300
20406837
20547415
C537844 D017239 Nonseminomatous germ cell tumor therapeutic
8913442
D054039 D017239 Onycholysis marker/mechanism
12582404
D009901 D017239 Optic Nerve Diseases marker/mechanism
7912737
D010014 D017239 Osteolysis therapeutic
15867366
D012516 D017239 Osteosarcoma therapeutic
16140185
C538090 D017239 Ovarian epithelial cancer therapeutic
8626111
9346221
11205470
11268500
12442916
19704064
D010051 D017239 Ovarian Neoplasms therapeutic
7669713
8643973
8683640
9041188
9106649
9346218
9346219
9346222
9346223
9766754
11161223
11206272
11299847
11330975
11487721
11528251
11706781
12476280
14758127
15370618
15907983
16354605
16490239
16766103
17404021
18418024
18594523
20389300
20538177
20547415
20798562
D010146 D017239 Pain marker/mechanism
7909329
8893895
10483822
11104554
11113764
11330975
11487721
16766103
17659836
20389300
D010259 D017239 Paranoid Disorders marker/mechanism
10100699
D010292 D017239 Paresthesia marker/mechanism
7509380
7904620
7909329
8625200
8643971
8708721
8797774
8893895
9007130
9149085
9266440
9849468
10483822
10955861
11104554
11113764
11230474
11350883
11401310
12187335
14514973
14760066
15923795
16414547
17611715
D010300 D017239 Parkinson Disease marker/mechanism
8552128
D010523 D017239 Peripheral Nervous System Diseases marker/mechanism
therapeutic
7481858
7509380
7524159
7543559
7601264
7692001
7850713
7884419
7904620
7907208
7912506
8610231
8625200
8643967
8667418
8683640
8710063
8751544
8797774
8866126
8893892
9007119
9007121
9007122
9007133
9266440
9337680
9346218
9346219
9346221
9346223
9635850
9740541
9748043
9849468
10586344
10928183
11104554
11113764
11206272
11268500
11330975
11350883
11679185
11706781
11731066
11738263
12601542
12825825
12831778
12859102
12911718
14597872
14599877
14654561
14760066
14769840
15170980
15319252
15566651
15642899
15756015
15913989
15948540
15958131
15997923
16000582
16021477
16193394
16284715
16332718
16406309
16414547
16442593
16530964
16612156
16797537
16854522
16939848
16950614
17005179
17508942
17509163
17611715
17637549
17659836
17686523
17974278
18270703
18472288
18664590
18754875
18777607
18809400
19027286
19091544
19151569
19260244
19396017
19429028
19473225
19576881
19595634
19755835
19812061
20184918
20486471
20578381
20813818
20863554
20932997
21118710
21233199
21865574
22079976
D011014 D017239 Pneumonia marker/mechanism
12367796
16612156
D011115 D017239 Polyneuropathies marker/mechanism
7850713
8643966
8677355
11022860
16354605
19358999
D054038 D017239 Posterior Leukoencephalopathy Syndrome marker/mechanism
18554701
D054198 D017239 Precursor Cell Lymphoblastic Leukemia-Lymphoma therapeutic
9766754
19781537
D011471 D017239 Prostatic Neoplasms therapeutic
10881025
15492279
16356831
16442593
16729912
17136230
17172428
20052472
D011537 D017239 Pruritus marker/mechanism
9149030
9774950
D011655 D017239 Pulmonary Embolism marker/mechanism
20052472
D011658 D017239 Pulmonary Fibrosis marker/mechanism
20025538
D012008 D017239 Recurrence therapeutic
7884419
D012021 D017239 Reflex, Abnormal marker/mechanism
7904620
9149085
10483822
14760066
17611715
D051437 D017239 Renal Insufficiency marker/mechanism
11104554
D012509 D017239 Sarcoma therapeutic
18074150
20406837
D020426 D017239 Sciatic Neuropathy marker/mechanism
11022860
11134612
D045743 D017239 Scleroderma, Diffuse marker/mechanism
12605319
D012594 D017239 Scleroderma, Localized marker/mechanism
20598060
D012598 D017239 Sclerosis marker/mechanism
12582404
D012607 D017239 Scotoma marker/mechanism
7912737
D012640 D017239 Seizures marker/mechanism
15026476
19637953
D012678 D017239 Sensation Disorders marker/mechanism
7644931
8643968
12189532
12911718
15082135
D018805 D017239 Sepsis marker/mechanism
9346218
9346226
9879778
12110496
15493357
D012817 D017239 Signs and Symptoms, Digestive marker/mechanism
9346223
D012871 D017239 Skin Diseases marker/mechanism
12207621
20446892
D012878 D017239 Skin Neoplasms therapeutic
9774950
D012893 D017239 Sleep Disorders marker/mechanism
12911718
D055752 D017239 Small Cell Lung Carcinoma therapeutic
9818034
11230474
14760117
20389300
D012983 D017239 Soft Tissue Neoplasms therapeutic
7543699
D020886 D017239 Somatosensory Disorders marker/mechanism
7543699
9553960
11487721
19260244
D013118 D017239 Spinal Cord Diseases marker/mechanism
11022860
11134612
D013274 D017239 Stomach Neoplasms therapeutic
9858922
15923795
15961435
16332718
17637549
18396642
18506536
19755835
19812061
21289336
21586171
D013280 D017239 Stomatitis marker/mechanism
14760117
D013610 D017239 Tachycardia marker/mechanism
9311449
D013617 D017239 Tachycardia, Supraventricular marker/mechanism
11455223
20547415
D017180 D017239 Tachycardia, Ventricular marker/mechanism
7578376
8102012
D013651 D017239 Taste Disorders marker/mechanism
7904060
D024801 D017239 Tauopathies therapeutic
16930453
D013736 D017239 Testicular Neoplasms therapeutic
17593098
D013921 D017239 Thrombocytopenia marker/mechanism
therapeutic
7543559
7543699
8643968
8643973
9007119
9007120
9007121
9007126
9149030
9296218
9346218
9346219
10037178
10800167
11135224
11147586
11230474
12367796
14760117
15493352
15581045
15961435
16332718
16612156
16763792
17974278
19396017
20389300
20547415
D013923 D017239 Thromboembolism marker/mechanism
15493358
D013927 D017239 Thrombosis marker/mechanism
7907689
7907690
17145250
C536910 D017239 Thyroid cancer, anaplastic therapeutic
20025538
D014012 D017239 Tinnitus marker/mechanism
9849468
D014067 D017239 Tonsillar Neoplasms therapeutic
8683640
D001749 D017239 Urinary Bladder Neoplasms therapeutic
7525883
9241080
10569619
10704734
11113764
14981929
D014571 D017239 Urologic Neoplasms therapeutic
9440750
15493358
D002583 D017239 Uterine Cervical Neoplasms therapeutic
15493357
15907983
D014594 D017239 Uterine Neoplasms therapeutic
9774950
D018487 D017239 Ventricular Dysfunction, Left marker/mechanism
8893117
8893894
8893896
9374088
10472783
10577856
10828864
11147586
11583187
15865068
D018879 D017239 Ventricular Premature Complexes marker/mechanism
14514973
D014717 D017239 Vertigo marker/mechanism
10483822
D014786 D017239 Vision Disorders marker/mechanism
7913722
9722903
10483822
D014826 D017239 Vocal Cord Paralysis marker/mechanism
18026678
D014839 D017239 Vomiting marker/mechanism
therapeutic
8610231
8643966
8893895
9007120
9007121
9149030
9346219
10955861
11800032
12110496
12442916
15170980
15493358
15923795
16332718
17974278